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Introduction
The incidence of carcinoma of the uterine cervix in The Netherlands is 9/100.000 which means that 
every year 650 women are treated for the disease (1). World-wide, cervical cancer is the second most 
common type of female cancer, accounting for 10% of all newly diagnosed cancers in women (1;2). 
The treatment of choice depends on the stage of the disease and can either be surgery or radiotherapy. 
Especi al ly in young women the surgical approach has the great advan ta ge over radiotherapy of pre-
serving the ovaries, keeping a more functio nal vagina and obtains more detailed information about 
the nature and pattern of spread of the tumour at hand. The state of the art treatment for women 
with early stage cervical cancer (I-IIa) is a radical hysterectomy with pelvic lymphadenectomy (RHL) 
with or without adjuvant (chemo) radiation (3;4). Operati on consists of extirpation of the uterus, the 
paracervical and paravaginal tissue, plus a portion of the upper vagina and the perivascular fatty and 
connective lymph-bearing tissues on the lateral pelvic wall. Patients with unfavourable prognostic fac-
tors, such as lymph node metastases, tumour growth into the parametria or irradical surgical resection 
margins and tumours with a combination of large diameter, deep infi ltration or vaso-invasion may 
receive postoperative radiotherapy.
The results of treatment for low stage carcinoma of the uterine cervix have improved tremendously 
over the past century. Today, the prognosis of early stage cervical carcinoma after RHL is good in most 
cases, with 5-year survival rates of 80-90% (5-11). Furthermore, the mortality rates of surgi cal treat ment 
have dropped from 50% to almost zero and the morbi dity fi gures are accepta bly low. However, cervical 
cancer still affl icts a lot of women and, therefore, improvement of the quality of treatment procedures 
remains an important issue. The good results of the treatment for early stage cervical cancer in terms of 
survival, have their price: loss of fertility, bladder dysfunction, colorectal motility disorders and sexual 
dysfunction (12-20). A better control of the quality of surgical procedures in oncology, for example, is 
possible and may have a major impact on outcomes of cancer patients (21).
It is time to improve the balance between cure and quality of life. This thesis describes the results 
of studies concerning the sequelae of the treatment and the treatment-related information acquired 
by registries of women with early stage cervical cancer in order to improve the quality of treatment 
procedures and the quality of life.
Quality control of treatment procedure
In recent years increasing attention has been paid to the quality of cancer care. In surgery, little or no 
quality assurance guidelines are yet available. One of the reasons for this is the scarcity of quantifi able 
parameters in surgery. Moreover, the impact of primary surgical treatment is often underestimated 
especially when postoperative adjuvant treatments are evaluated (22).
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For many years, most treatment failures were considered to be caused by the biological behaviour of 
the tumour rather than by inadequate local therapy (22). However, several studies have shown that 
an improvement in surgical procedures had much more infl uence on local recurrence rates than the 
use of adjuvant radiotherapy (23-27). In order to monitor the quality of treatment the registration 
of all aspects of cancer care is essential. Concerning surgery, the most important items should be 
the operation-related morbidity, mortality, adequacy of resection or radicality, local recurrences and 
overall survival. Registries would probably be the most relevant means to acquire all this information. 
A regular audit of the data could achieve more awareness of existing differences in outcome, gain 
more insight into the existence of other risk factors or morbidity and could lead to other treatment 
modalities. This would probably have a major impact on the quality of treatment and quality of life.
Quality of life
Treatment for cervical cancer by RHL has an adverse effect on bladder, colorectal and sexual function-
ing (12-20). When diagnosing a woman with a life-threatening disease and treating her with a RHL or 
with radiotherapy, it may not seem a priority to discuss micturial, colorectal and especially not sexual 
issues. However, urinary incontinence restricts patients’ activity, affects the quality of her live and is a 
cause of patient discomfort. Furthermore, sexual function is an essential component of many people’s 
lives and the diagnosis of a gynaecological cancer can affect many aspects of sexual function and sat-
isfaction, and therefore is an issue that should not be ignored. It has been shown that for women with 
gynaecological cancer, the maintance of a positive self-image and feelings of sexuality is an issue of 
central importance in the provision of quality of their daily living (28). Moreover, sexuality is important 
during illness and in particular following a diagnosis of gynaecological cancer. Intimate contact can 
be a form of support during the distressing time after the diagnosis. Because sexual function and 
satisfaction are based on both physical and psychological components, the treatment for gynaecologi-
cal cancer can affect both of these aspects, particularly because of the anatomical nature of the cancer 
(29). The impact of morbidity after the treatment for gynaecological cancer should therefore never be
underestimated.
Research has shown that in gynaecological cancer, levels of communication between doctors and 
the women with cancer are still low (30). In a study of Stead et al. it was shown that reasons for not 
discussing sexual issues included ‘it is not my responsibility’, ‘embarrassment’, ‘lack of knowledge 
and experience’ and ‘lack of resources to provide support if needed’. While some of these reasons were 
also viewed as barriers by the women involved in the study, the results showed that there is a need from 
the women’s perspective to improve communication about sexual issues (30).
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A further reason for lack of communication about sexual issues is a lack of research evidence to sup-
port the discussions. Fortunately, this evidence is gradually building, with a range of research being 
carried out in the different types of gynaecological cancer (31).
Postoperative morbidity following radical hysterectomy
Urologic dysfunction
It is well known that RHL can lead to postoperative urinary dysfunc tion such as urinary retention and 
straining or inability to void, and, to a lesser extent, urge and stress incontinence (14;15;17;20;32). Re-
sults of urodynamic studies evaluating urinary dysfunction in patients after RHL are suggestive for dis-
ruption of the autonomic nerve supply to the bladder and urethra: the rest-tone and the fi lling pressure 
of the bladder increase, whereas pressure in and along the length of the urethra decreases (17;20;33). 
Loss of compliance of the bladder is thought to be caused by neural denervation of the bladder and 
urethra in combination with direct surgical injury to the bladder wall, lymph stasis, interruption of the 
blood supply, and fi brosis of the urethra (17;33;34). Furthermore, a substantial number of patients ap-
pear to suffer from impaired bladder sensation, which is an additional indication for disruption of the 
nerve supply (35;36). The inferior hypogastric plexus is the pathway for the autonomic nerve supply 
of the internal genitals and the lower urinary tract, and is topographically closely related to its target 
organs. It is therefore conceivable that damage to this plexus during surgery plays an important role in 
the etiology of the observed urologic morbidity. This theory is further strengthened by the observation 
of various authors that the extent of dysfunction is related to the radicality of the surgical procedure in 
the pelvis (14;34-38). The precise effect of disruption of the autonomic nerve system in the function of 
the pelvic muscles is not known.
Long-term bladder dysfunctions after RHL occur in about 8-80% of patients (14;37;39;40). This 
discrepancy refl ects the varying degrees of surgical radicality, the diverse follow-up intervals and the 
various instrumental methods used in literature. However, up to one half of patients undergoing RHL 
experience at least one lower urinary tract symptom that develops after surgery and at a variable period 
of time (14;32;34;36;41-43).
Radiotherapy is described as a cause of hydronephrosis due to distal ureteric stricture, urge and stress 
incontinence and changes observed in the bladder such as mural thickening, mucosal irregularity, 
focal ulceration, reduction in size, and vesicovaginal fi stula. Furthermore, some authors have reported 
that about 10% of patients treated with radiotherapy experience radiation-induced urologic complica-
tions (44-50). Unfortunately, most of these studies offer retrospective data collected from the medical 




Colorectal dysfunction after RHL has been described in 5-58% (51-55) and in the form of severe con-
stipation in 5-10% (14;19;32). The pelvic autonomic nerves play an equally important role in colorectal 
motility as in bladder function. The neural control of the coordinated contractions of the smooth 
muscle of the bowel as well as the sensory innervation of the bowel runs through the inferior hypo-
gastric plexus. Several studies have shown colorectal motility disorders after hysterectomy for benign 
as well as for malignant conditions (19;54;55). Anorectal manometry revealed signifi cant changes in 
colorectal function after RHL, showing a pattern which correlates to a partial denervation of the bowel 
(55-57).
Radiotherapy causes strictures of the recto-sigmoid which showed a smooth mucosa, fi ne surface ul-
ceration, focal ulceration or a ‘cobble-stone’ appearance. Furthermore, patients who receive radiation 
may also experience early or late large bowel complications such as bleeding, fi stulae and perforations. 
Lesions observed in the small bowel included fi xity of bowel loops, thickening of the wall, coarsen-
ing of the mucosal pattern and strictures. All these changes could also cause colorectal dysfunction 
(44;47;50;58). The incidence of colorectal complications of postoperative radiotherapy varies in the 
literature from 3% to 30% (59-61). The reasons for such a disparity are multiple and include different 
systems to classify the late radiation side-effects and differences in the reporting of complications.
Lymphedema
RHL results in long-term lymphedema that gives rize to moderate or much symptom induced distress 
in about half of the affected women (32). During the past decade lymphedema has been reported to 
occur in 3-23% after RHL (14;32;40;62). However, the assessed prevalence of the disorder varies with 
the defi nition. Bergmark et al. found that 19% of the women reported constantly swollen legs or lower 
abdomen, while 12% reported constantly heavy legs or lower abdomen. Furthermore, there are limited 
data on long-term lymphedema in women treated for cervical cancer, and most studies only report the 
physician’s documentation of grade 3-4 edema (63) in the medical records, with prevalence ranging 
from 0-5% (11;40;64).
It is reasonable to assume that the incidence of lymphedema will depend on the surgical technique 
used during the RHL and the extent of the lympadenectomy (65). However, the mechanism behind 
lymphedema and the prevention of it needs further research. Modifi cations of surgical techniques 
and intense rehabilitation programs for lymphedema might reduce the occurrence of this treatment-
induced symptom and the subsequent distress.
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Sexual dysfunction
Women who have been treated for cervical cancer by RHL have persistent vaginal changes that compro-
mise sexual activity and result in considerable distress. Changes or problems that have been described 
are diminished lubrication, a narrow and short vagina, dyspareunia and sexual dissatisfaction. Sexual 
dysfunction after RHL occurs in about 25% of the patients (12;13;18;66-71). Radiotherapy also causes 
sexual dysfunction and vaginal changes by chronic fi brotic changes in pelvic tissue (44;72;73). After 
surgery, alone or in combination with radiotherapy, several symptoms related to sexual dysfunction 
appeared to be the primary sources of symptom-induced distress. It is concluded that sexual function 
is important to women with a history of cervical cancer (66).
The autonomic nerves are essential for a normal sexual function. They supply the blood vessels of 
the internal genitalia and are involved in the neural control of vasocongesti on and, consequently, the 
lubrication-swelling response (74;75). It is assumed that orgasm is the sensory consequence of the 
contraction of the internal genitalia, media ted by sympathetic fi bres of the autonomic nervous system 
of which the superior and inferior hypogastric plexus are the pathway from the spinal cord (76).
Measuring instruments of morbidity
The Gynaecologic Leiden Questionnaire; a subjective measuring instrument of urological, colorectal and sexual morbidity.
To obtain an impression of the impact of a given treatment on a patient’s quality of life and to un-
derstand the patient’s perception of symptom severity, self-report questionnaires may give more 
informative answers (77;78). Over the last decades several questionnaires have been developed to 
diagnose dimensions of female sexual dysfunction (79;80). Lately, Jensen et al. showed the results 
of the validation of the Sexual function-Vaginal changes Questionnaire (SVQ), that was to investigate 
sexual and vaginal problems in gynaecological cancer patients (81).
For the Dutch language area however, until recently (82) no questionnaire was available that focuses on 
sexual and vaginal problems due to disease and treatment specifi c for gynaecological cancer patients. 
We developed a Dutch self-report questionnaire, the Gynaecologic Leiden Questionnaire (LQ), which 
is the fi rst Dutch questionnaire that includes items for sexual function, voiding- and bowel problems 
for women with cancer. The Gynaecologic LQ has 1 item for weariness, 1 item for lymphedema, 11 
items for sexual functioning, 6 items for voiding and 2 items for bowel problems.
Vaginal photoplethysmography; an objective measuring instrument of sexual morbidity.
Sexual arousal in women is characterized by the appearance of vaginal lubrication, which is produced 
by an increase of the arterial fl ow to the vaginal wall, leading to the transudation of fl uid (83). This 
vaginal response to erotic stimulation in women is the most comparable response to erection in men. 
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The most reliable method of measuring vaginal blood fl ow is vaginal photoplethysmography (84;85). 
The vaginal photoplethysmograph is a menstrual tampon-sized device, easy to insert and sterilize, 
containing an infrared  light-emitting diode as a light source and a photo transistor as a light detector. 
The light source illuminates the vaginal tissues, and the phototransistor responds to the incident light 
that is backscattered from the vaginal wall and the blood circulating within it. Because the opacity of 
the tissue, and hence the amount of light backscattered, is largely dependent upon the volume of blood 
within it, the vaginal photoplethysmograph provides a measure of vasocongestion. The increased 
vaginal blood fl ow during sexual arousal refl ects a highly automated genital response mechanism, oc-
curring irrespectively of subjective appreciation of the sexual stimulus (86;87). The genital physiologi-
cal response is an involuntary refl ex mediated by the (unconscious) autonomic nervous system (88). 
Assessment of vaginal vasocongestion through vaginal photoplethysmography during visual sexual 
stimulation can be an impor tant tool in the attempt to measure physiological aspects of sexual arousal 
in women after hysterectomy. Pras et al. determined the feasibility of vaginal photoplethysmography 
in order to measure physical late effects of radiotherapy on sexual function. Patients (n=9) treated with 
radiotherapy for cervical, endometrial or ovarian cancer, who were in complete remission for over 1 
year, underwent vaginal photoplethysmography to measure changes in vaginal vasocongestion, while 
watching erotic video fragments. The results were compared with those of healthy women (n=8). No 
signifi cant difference was seen in vaginal vasocongestion during the various video fragments between 
the two groups, probably because the group of patients was small and heterogeneous. The authors 
concluded that vaginal photoplethysmography can be used to measure vaginal vasocongestion in 
patients treated with radiotherapy to the proximal vagina (89).
Theoretically, one would expect disruption of the inferior hypogastric  plexus to result in decreased 
vaginal vasocongestion at vaginal photoplethysmography after RHL. At the Leiden University Medical 
Centre we performed a study on the changes in vaginal blood fl ow in women with a history of RHL. 
Vaginal pulse amplitude during sexual stimulation by erotic fi lms was assessed in twelve women with 
a history of RHL, in twelve women with a history of simple abdominal hysterectomy and in seventeen 
age-matched controls. Self-reported ratings of subjective sexual arousal were collected after each 
erotic stimulus condition. The maximum vaginal pulse amplitude differed between the three groups 
(p=0.043) (90). Women with a history of RHL had a signifi cantly lower maximum response than 
controls (p=0.015). Women in the RHL group and controls reported an equally strong subjective 
arousal after the erotic stimulus condition. Women with a history of simple hysterectomy showed an 
intermediate maximum vaginal pulse amplitude, but differences with the other two groups were not 
signifi cant. Despite the limits of the study design and its size, the study indicates that RHL seems to be 
associated with a disturbed vaginal blood fl ow response during sexual arousal. The disturbed response 
could not be explained solely by uterine extirpation, since it was not observed to the same extent after 
simple hysterectomy. The difference in outcome might be related to a more extended denervation of 
the vagina with increasing radicality of surgery (91-97).
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The pelvic autonomic nerves in radical hysterectomy
Radical hysterectomies on the pelvis of female cadavers have been performed, the course of the sym-
pathetic and parasympathetic nerves in the small pelvis have been studied and the autonomic nerves 
have been found to be closely related to tissues that are routinely damaged during RHL (97-99). By 
performing RHL on cadaver pelves fi rst and dissecting the nerves later, it became evident that the hypo-
gastric nerves and the proximal and distal part of the inferior hypogastric plexus are routinely damaged 
during this surgical procedure. Therfore, it is conceivable that surgical damage to the pelvic autonomic 
nerves is responsible for a considerable part of postoperative morbidity following RHL (93). Others 
have quantifi ed nerve disruption after RHL. Immunohistochemical staining of nerve tissue in biopsies 
from surgical margins after simple hysterectomy and RHL has shown that both hysterectomies are 
associated with disruption of nerves. Quantitative analysis of these biopsies showed that the nerve 
disruption was signifi cantly greater in RHL than in simple hysterectomy (94).
A study from our institution showed that preservation of the autonomic nerves in rectal cancer surgery 
was feasible, and yielded very good functional results concerning micturition and sexual function 
(100). Preservation of the autonomic nerves during RHL would be expected to result in comparable 
improvements in voiding and bowel function and sexuali ty for cervical cancer patients.
Outline of this thesis
Since January 1984, the Leiden University Medical Centre (LUMC) prospectively collects more than 
200 relevant clinical and pathological parameters of women with cervical cancer treated in the LUMC. 
From January 1984 untill April 2005 this database consists of 985 patients. Of these 985 patients, 643 
underwent a RHL. The purpose of this thesis was to use the treatment-related information of this 
database to get inside information and to become aware of the possibilities for improvement in the 
current treatment procedures, in order to monitor the quality of treatment.
Furthermore, when the results of cancer treatment in terms of survival are good it is also important to 
focus on the sequelae of the treatment. The incidence of lymphedema, urinary and colorectal dysfunc-
tion has been reported with variable rates (14;19;32;34;36;37;41;54;55) and sexual dysfunction after 
RHL has been shown to occur in about 25% of the patients (12;13;18;66-71). Furthermore, a study as-
sessed by vaginal plethysmography, showed that RHL seems to be associated with a disturbed vaginal 
blood fl ow response during sexual arousal (90). The second purpose of this thesis was to monitor 
the sequelae of the treatment of women with a history of early stage cervical cancer in order to have 
measures in attempts to improve the quality of life.




This study was designed to evaluate the role of postoperative radiotherapy for patients with early stage 
cervical carcinoma with tumour related risk factors, other than positive nodes, parametrial invasion or 
non-radical margins. Furthermore, the prognosis of patients using the criteria of the LUMC for giving 
adjuvant radiotherapy was compared with that of the Gynecologic Oncology Group.
Chapter 3
A systemic lymphadenectomy can reliably establish the presence or absence of lymph node involve-
ment, with the attendant consequences for prognosis and treatment. Yet, it has never been proven that 
the removal of nodes itself leads to better survival fi gures (101). This is the fi rst study that has evaluated 
the number of removed lymph nodes in the quality control of the surgical treatment of early stage 
cervical cancer and the possible association of patient, tumour and treatment factors with the number 
of lymph nodes examined in node-negative early stage cervical cancer patients.
Chapter 4
The possibility to give an accurate individual prediction of the future (disease free) survival of patients 
with a history of early stage cervical cancer was evaluated, given the fact that a patient has been disease 
free for a specifi c period after treatment. Statistical analysis was done on the existing database with 
multi-state risk models specifi cally designed for this purpose.
Chapter 5
The LUMC developed a Dutch self-report questionnaire, the Gynaecologic Leiden Questionnaire (LQ), 
which is the fi rst Dutch list consisting of the items for sexual function, voiding- and bowel problems 
for women with cancer. In this study, we investigated the psychometric properties of the items con-
cerning sexual functioning of the Gynaecologic LQ.
Chapter 6
The prevalence of lymphedema, bladder dysfunction, colorectal motility disorders and sexual dysfunc-
tion among women who had been treated for cervical cancer by a RHL was determined in this study. 
We provide the results of the fi rst longitudinal study of self-reported bladder, defecation, sexual and 
vaginal problems with a baseline score before the RHL. We compared this group of patients with a 
group of age-matched controlled women from the general population. Because the effect of adjuvant 
radiotherapy on late side effects is still unclear, we also compared patients who underwent adjuvant 
radiotherapy to those who did not.
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Chapter 7
RHL for cervical cancer causes surgical damage to the autonomic nerves which are responsible for the 
increased vaginal blood fl ow during sexual arousal. The aim of the current study, of which we report 
preliminary data in this thesis, was to determine whether the nerve-sparing technique indeed leads to 
an objectively less disturbed vaginal blood fl ow response during sexual stimulation. The mean vaginal 
pulse amplitude during sexual stimulation by erotic fi lm was assessed in women with a history of a 
conventional RHL, in women with a history of a nerve-sparing RHL and in healthy controls.
Chapter 8
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Abstract
Objective: To assess the role of postoperative radiotherapy for early stage cervical carcinoma with risk 
factors other than positive nodes, parametrial invasion or positive margins, and to compare outcomes 
using the Leiden University Medical Centre (LUMC) modifi cation of the Gynecologic Oncology Group 
(GOG) system with the GOG prognostic scoring system itself.
Methods: Between January 1984 and April 2005, 402 patients with early stage cervical cancer under-
went radical hysterectomy. Fifty-one patients (13%) had 2 of the 3 risk factors; pathological tumour 
size (≥40mm), invasion (≥ 15 mm) and capillary lymphatic space involvement and were identifi ed as 
the so-called High Risk group (HR group).We compared 34 patients who received radiotherapy based 
on the LUMC risk profi le (67%) with 17 who did not (33%). The GOG score was calculated as well. We 
compared the GOG scores within the LUMC risk groups: HR+ (2 out of 3 risk-factors) and HR- (less 
than 2 out of 3 risk-factors).
Results: Differences in 5- year Cancer Specifi c Survival (CSS) and 5-year Disease Free Survival (DFS) 
between the HR group treated with (86%; 85%) and without radiotherapy (57%; 43%) were statisti-
cally signifi cant. The LUMC criteria did not signifi cantly differ from the GOG risk profi le, concerning 
recurrence, CSS and DFS.
Conclusions: High-risk patients benefi t from adjuvant radiotherapy. The LUMC modifi cation of the 
GOG system seems to be simpler, has a slightly higher threshold for the indication for radiotherapy, 
but without a difference in outcome.
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Introduction
The treatment for women with early stage cervical cancer (FIGO I-IIa) (1) can either be a radical hyster-
ectomy with pelvic lymphadenectomy (RHL) or radiotherapy. When RHL is performed and adverse risk 
factors are present, such as lymph node involvement, parametrial invasion and positive surgical mar-
gins, postoperative radiotherapy is indicated (2-12). However, within the group of recurrences, 50% of 
these patients are without these risk factors (13-16). Several studies have suggested that patients with 
disease confi ned to the cervix but with certain other primary tumour related risk factors might also 
benefi t from postoperative radiotherapy (3;17-20). In a study performed by the Gynecologic Oncology 
Group (GOG), Delgado et al. identifi ed capillary lymphatic space involvement (CLS), clinical tumour 
size and depth of tumour invasion into the cervical stroma (DI) as independent prognostic variables. A 
GOG score >120 was correlated with a 41% recurrence rate (3). In a randomised GOG trial, Sedlis et al. 
used the GOG scoring system and combined the risk factors large tumour size, deep (greater than one 
third) stromal invasion and the presence of CLS. The authors reported a 44% reduction of the risk of 
recurrence after adjuvant radiotherapy when a combination of these risk factors was present compared 
without radiotherapy (12).
Before 1997, patients in our centre received adjuvant radiotherapy if lymph node involvement, 
parametrial invasion or positive surgical margins were found. In 1997 we extended the indication for 
postoperative radiotherapy, using a modifi cation of the GOG scoring system. Patients with at least 2 of 
the following 3 risk factors received postoperative radiotherapy: pathological tumour size (≥40mm), 
depth of invasion (≥ 15 mm) and CLS. The choice for the defi nition of these risk factors was based on 
the results from the literature (3;21;22) and on a retrospective analysis of our own treatment results, 
indicating that depth of invasion ≥ 15mm was an independent prognostic risk factor (23). The aim 
of the present study was to assess treatment outcome of patients with early stage cervical carcinoma 
(FIGO I-IIa) (1) without lymph node involvement, parametrial invasion or positive surgical margins, 
but with the presence of these adverse risk factors. We compared the outcome of patients who received 
adjuvant radiotherapy on the basis of adverse tumour factors mentioned above with patients with a 
similar risk profi le treated before 1997 who did not receive radiotherapy. Finally, we compared prog-
nosis of patients using our criteria for giving adjuvant radiotherapy (Leiden University Medical Centre 
(LUMC) risk profi le) with those of the GOG prognostic scoring system (GOG risk score (RS)) (3).
Material and Methods
Study group
Between January 1984 and April 2005, 643 patients with stage I-IIa cervical carcinoma were treated 
in our centre (LUMC) with a RHL. Relevant clinical and pathological parameters of this group of pa-
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tients were prospectively collected in a database. Patients with lymph node involvement, parametrial 
invasion or positive surgical margins were excluded from this study (n=232). One patient received 
preoperative radiotherapy, 5 patients received preoperative chemotherapy and 3 patients postoperative 
chemotherapy; they were also excluded from the study.
LUMC risk profi le
For the fi rst analysis we selected from the remaining 402 patients the women with at least 2 of the 3 
following risk factors; pathological tumour size ≥40mm, depth of invasion ≥ 15 mm and CLS. Fifty-one 
(13%) patients met these criteria and were identifi ed as the so-called High Risk group (HR group). 
Among these 51 patients we compared the prognosis of those patients who received adjuvant radio-
therapy (after 1997) with those who did not (before 1997 or protocol violation after 1997). Reasons 
for protocol violation for not receiving radiotherapy after 1997 were refusal of the patient (n=3) or 
complicating comorbidity (n=3).
GOG risk score
For the second analysis we used the GOG risk score (RS) (3). A GOG score was calculated for each of the 
402 patients by multiplying the 3 relative risk scores (RR) associated with clinical tumour size, depth 
of tumour penetration and presence or absence of CLS. The GOG used the cervical tumour regression 
coeffi cient for the superfi cial, middle and deep penetration of the tumour (3). Because we used the 
infi ltration depth in millimetres, we took the mean RR of the superfi cial, middle and deep penetration 
to calculate the RR for depth of tumour penetration. Furthermore we used the pathological tumour 
size instead of the clinical tumour size. We could not calculate the RS for 41(10%) patients because of 
missing data such as exact depth of invasion or tumour size or information from referring hospitals 
(conisation and colposcopy). Fourteen patients would receive radiotherapy according to the LUMC 
RS as well as according to the GOG score, but did not. Nine patients would not receive radiotherapy 
according to both scorings systems, but they did. These 23 patients were excluded from the analysis, 
because we were interested in the differences between the 2 scorings systems. A total of 338 patients 
was left. We divided the patients into 2 groups: RS≤120 and RS>120 and compared the prognosis of 
these patients with the prognosis of the patients stratifi ed according to our own risk system (LUMC 
risk profi le): the group with 2 out of 3 risk factors present who received adjuvant radiotherapy (HR+) 
and the group without 2 out of 3 risk factors present who did not receive adjuvant radiotherapy (HR-).
Staging and pathology
Preoperative staging was performed according to the guidelines of the International Federation of 
Gynaecology and Obstetrics (FIGO) (1). The following characteristics from the pathology slides were 
documented: tumour size, histologic tumour type and depth of invasion. When no residual tumour 
was found in the radical hysterectomy specimen, presurgical data from conization or biopsies were 
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used. The depth of invasion was measured from the most superfi cial epithelial-stromal interface of the 
adjacent intra-epithelial process to the lower limits of invasion (24). Capillary lymphatic space involve-
ment (CLS) was considered positive when neoplastic cells were seen within endothelium-lined spaces. 
Central recurrences were defi ned as those involving vagina, bladder or rectum. Regional recurrences 
were those involving the pelvic sidewall but remained confi ned to the pelvis and distant recurrences 
were those with disease outside the pelvis with or without pelvic involvement.
Radiotherapy
External beam radiotherapy was administered to the pelvis using a four-fi eld box technique. Patients 
were treated with 10 MV photons from a linear accelerator to a total dose of 46 Gy in 2 Gy fractions, 
specifi ed at the isocentre. A brachytherapy boost was given to the vaginal vault in case of extensive CLS 
(68% of the patients), using vaginal colpostats, 15 Gy low dose rate or equivalent dose, prescribed at 5 
mm from the vaginal mucosa.
Survival analysis
The follow-up was closed on April 2005 and ranged for the 402 patients from 0 to 223 months. The 
mean duration of follow-up was 60 months. The mean and median duration of follow-up for the 51 
HR patients was 54 and 40 months, respectively; with adjuvant radiotherapy 50 and 38 months and 
without radiotherapy 59 and 58 months, respectively. The disease free survival (DFS) was defi ned as the 
time from RHL to cytologically or histologically proven evidence of recurrent disease or date last seen. 
Cancer specifi c survival (CSS) was defi ned as the time from date of operation to death by tumour or 
date last seen. Survival curves were made using the Kaplan-Meier method (25). The difference in DFS 
and CSS by treatment regimen was evaluated using the log-rank test (25;26). The chi-square test was 
used to calculate the relative risk and a p-value <0.05 was considered as statistically signifi cant.
Results
High-risk patients according to LUMC risk profi le
Fifty-one (13%) patients met the LUMC criteria for postoperative radiotherapy. The clinical and histo-
logical characteristics of the HR patients who were treated with (n=34, 67%; after 1997) and without 
postoperative radiotherapy (n=17, 33%; before 1997 or protocol violation after 1997) are listed in Table 
1. Median age was 44 and 42 years for the patients with and without radiotherapy respectively. Apart 
from the number of deep infi ltrating tumours (more frequent in the irradiated group), the various 
characteristics of the 2 groups were similar.
Recurrence of disease was diagnosed in 11 of these 51 (22%) patients. Of these 11 patients, 8 died 
of disease (Table 2 and 3). A signifi cantly larger percentage of the HR patients who did not receive 
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adjuvant radiotherapy had recurrence of disease, with a RR of 0.29 (95% confi dence interval 0.1-0.8, 
p=0.02) (Table 2). Central recurrences were only diagnosed in patients who did not receive adjuvant 
radiotherapy (Table 3). The median time from surgery to recurrence and from recurrence to death 
was 15 and 12 months respectively for the total group. Two of the 51 patients died because of other 
reasons: one because of a psoasabces and diverticulitis and the other because of cardiac failure. The 
5-year CSS and DFS of the entire HR group of 51 patients was 74 % and 69%, respectively. The 5-year 
CSS and DFS were 86% and 85% respectively, among the patients treated with adjuvant radiotherapy 
(n=34) in contrast to the patients without adjuvant radiotherapy (n=17), who had a 5-year CSS and DFS 
Characteristics 
of the HR patients
Patients treated 
with RT n (34)
n (%)
Patients treated 
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Table 1. Clinical and histological characteristics of the HR patients who were treated with (n=34) and without (n=17) 
postoperative radiotherapy (RT).
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of 57% and 43%, respectively (Fig.1 A, B). The differences in CSS and DFS between the 2 groups were 
statistically signifi cant (p=0.013 and p=0.006, respectively).
Comparison of the GOG risk score and LUMC risk profi le
Table 4 shows the comparison of the GOG and LUMC risk assessment in the total of 338 patients. In 
322 of 338 patients (95%) there was agreement in allocated high-risk profi le in the LUMC and the GOG 
system. In 16 patients (5%) there was no agreement and in all these cases the patients had a high RS ac-
cording to the GOG system, but not according to the LUMC assessment. Because the threshold to give 
Recurrence HR group Radiotherapy n(%) No radiotherapy n(%) Total
Yes 4(12) 7(41) 11(22)
No 30(88) 10(59) 40(78)
Total 34(67) 17(33) 51(100)
Table 2. Number and percentage of recurrence of disease in the HR group with and without radiotherapy.
Radiotherapy Months to 
recurrence
Site of recurrence    Survival after 
     recurrence
      (months)
Status
Yes 5 distant            7 DOD
Yes 14 regional           14 NED
Yes 20 regional            0 ALD
Yes 31 distant           34 DOD
No 7 central            8 DOD
No 7 central+regional          213 NED
No 10 central           10 DOD
No 15 regional           14 DOD
No 25 central+regional           32 DOD
No 37 central+regional           32 DOD
No 51 distant            9 DOD








RS<120 (GOG) (n) 288 0 0
RS>120 (GOG) (n) 16 34 50
Total (n) 304 34 338
Table 4. Table of the number of patients; GOG prognostic scoring system versus LUMC system. HR: high risk group, 
RS: GOG risk score. 
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adjuvant radiotherapy was lower using the GOG prognostic scoring system, we determined if there 
would be a difference in CCS and DFS when the GOG RS was used instead of the LUMC risk profi le. To 
answer this question the HR + group (high risk group, n=34) was compared with the HR- group (no 
high risk group, n=16). The 2 groups were treated according to the LUMC system; the HR+ group did 
receive radiotherapy and the HR- group did not. Both groups had a RS>120 (GOG system).
Eight of the 50 patients (16%) had recurrence of the disease, four patients in each group
(HR+: 12%, HR-: 25%). There was no statistically signifi cant difference in recurrence between these 2 
groups (RR 0.5, 95% confi dence interval 0.13-1.7, p=0.23).
For the 34 high-risk patients (HR+; RS>120) who received radiotherapy the median time from therapy 
to recurrence was 18 months, from recurrence to death 20 months. For the 16 patients (HR-; RS>120) 
treated without radiotherapy time to recurrence was 20 months, from recurrence to death 39 months. 
One of the 50 patients died because of a psoasabces and diverticulitis.
The 5-year CSS and DFS of the entire group of 50 patients (HR+ and HR- groups with a RS>120) were 
88 and 79%, respectively. The 5-year CSS and DFS were 86% and 85% among the HR + group (n=34), 
in contrast to 92% and 62% for the HR- group (n=16) (Fig. 2 A, B). These differences were however, not 
statistically signifi cant (p=0.444 and p=0.212, respectively).






























Figure 1. Survival (A) and disease free survival (B) of the HR group with adjuvant radiotherapy (n=34) and the HR group without 
radiotherapy (n=17). 
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Discussion
The role of postoperative radiotherapy was evaluated for patients with early stage cervical carcinoma 
with tumour related risk factors, other than positive nodes, parametrial invasion or positive margins.
The current study indicated that the high risk group according to the LUMC risk profi le, characterized 
by at least 2 of the 3 risk factors, signifi cantly benefi ted from postoperative radiotherapy. We found that 
a signifi cantly larger percentage (41 vs 12%, p=0.02) of the HR group who did not receive radiotherapy, 
had recurrence of disease. Central recurrence only appeared in the latter group. The differences in 
CSS and DFS between the HR group with adjuvant radiotherapy (86%; 85%) and HR group without 
adjuvant radiotherapy (57%; 43%) were statistically signifi cant. The fact that the patients who did 
receive postoperative radiotherapy might represent a higher risk group as far as the percentage of deep 
infi ltrating tumours is concerned, underlines this conclusion. Furthermore, this study showed that the 
LUMC modifi cation of the GOG prognostic scoring system did not signifi cantly differ from the GOG 
prognostic scoring system itself, with regard to risk of recurrence, CSS and DFS.
The strength of the current study is the fact that a prospective database and a consecutive series of 
patients were used. However, the observations are based on limited numbers of patients.
Our results concerning the benefi t of radiotherapy for the HR group are according to the literature. 
Delgado et al. found CLS, clinical tumour size and DI to be the parameters best predicting prognosis in 
patients with early stage cervical cancer with negative lymph nodes. Using the GOG prognostic scoring 
system, they found that in patients with a combination of these risk factors, but with negative nodes, 
the 3-year risk of recurrence could be as high as 41% (3). In a randomised study, Sedlis et al. used 
































Figure 2. Survival (A) and disease free survival (B) of the HR+ and HR- group and both with a RS>120.
(HR-, RS>120, RT-: Less than 2 of the 3 risk factors positive, a GOG risk score>120 and no adjuvant radiotherapy (RT)) 
(HR+, RS>120, RT+: At least 2 of the 3 risk factors positive, GOG risk score >120 and adjuvant radiotherapy (RT))
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a modifi cation of the GOG scoring system and included 277 patients with stage Ib cervical carcinoma 
with at least 2 out of 3 risk factors: CLS, large tumour size and DI (greater than one third). The results 
of this study showed that the risk of recurrence was signifi cantly reduced by 44% (p=0.02) in patients 
treated with postoperative radiotherapy (12). Furthermore, a recent study by Rushdan et al. reported that 
postoperative radiotherapy given in patients with a high risk score, signifi cantly improved their 5-year 
recurrence rate and disease-free survival (27). Similar results were also reported by other investigators 
(7;13).
However, in the retrospective analysis by Van der Velden et al. no survival benefi t was found using adjuvant 
radiotherapy for risk factors other than positive nodes, parametrial extension and positive margins. They 
reported that the variant of RHL could be an explanation for the observed difference between this study 
and literature data. Van der Velden et al. used the Wertheim/Okabayashi variant of the RHL, with a more 
radical removal especially of the lower parametrial and paracolpal tissues compared to Wertheim/Meigs 
procedure (28). Because of the expected higher morbidity rate of the Wertheim/Okabayashi procedure, 
we perform the Wertheim/Meigs variant (29).
The cited studies used the GOG prognostic scoring system or a modifi cation of it to decide on the indica-
tion for radiotherapy. To calculate a GOG score for an individual patient, one has to multiply 3 relative 
risk scores associated with exact tumour size, DI related to the specifi c part of the uterine wall, and the 
presence or absence of CLS. This requires various pathology details. All 3 details were not always avail-
able in our group of patients and therefore we could not calculate the GOG risk score in 10% of the cases. 
Furthermore, the LUMC risk profi le is simpler and more straightforward than the GOG prognostic scor-
ing system and even simpler than the modifi cation of Sedlis et al.(12). In the current study, there was 95% 
(n=322) agreement in allocation of a high-risk profi le to the patients for the LUMC and the GOG system. 
According to the GOG system, 5% (n=16) of the LUMC low risk patients would have had an indication for 
radiotherapy. This difference did not affect the prognosis of these patients in any detectable way; there 
was no signifi cant difference in recurrence of disease, CSS and DFS, although statistical signifi cance 
might not have been reached because of the small number of patients.
The risk of late side effects after adjuvant radiotherapy could be an argument against adjuvant radio-
therapy in absence of the major risk factors lymph node metastases, positive margins or parametrial 
involvement. However, in a recent study of our own data we found that adjuvant radiotherapy did not 
signifi cantly increase the risk of bladder dysfunction, bowel symptoms, lymphedema and sexual function 
after 2 years follow-up (30).
It is concluded that, despite the relatively limited numbers of patients analyzed, the current study 
confi rms that high-risk patients signifi cantly benefi t from adjuvant radiotherapy. Moreover, this study 
compared in a prospective way a modifi cation of the GOG RS to the GOG prognostic scoring system 
itself. Furthermore, we found that the LUMC risk profi le is simpler and more straightforward in use, has 
a slightly higher threshold to defi ne patients as high risk who need adjuvant radiotherapy as compared 
to the GOG prognostic scoring system, but without compromising their prognosis.
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Abstract
Objective: To determine if the number of removed lymph nodes in radical hysterectomy with lymph-
adenectomy (RHL) infl uences survival of patients with early stage cervical cancer and to analyze the 
relation of different factors like patient age, tumour size and infi ltration depth with the number of 
nodes examined in node-negative early stage cervical cancer patients.
Methods: Of consecutive patients, who underwent RHL between January 1984 and April 2005, 331 
had negative nodes (group A) without adjuvant therapy and 136 had positive nodes (group B). The 
Kaplan-Meier method and Cox regression model were used to detect statistical signifi cance. Factors 
associated with excision of nodes were confi rmed with linear regression models.
Results: The median number of removed nodes was 19 and 18 for group A and group B, respectively. 
There was no signifi cant relationship between the number of removed nodes and the cancer specifi c 
survival (CSS) or disease free survival (DFS) for patients of group A (p=0.625 and p=0.877, respectively). 
The number of removed nodes in group B was not signifi cantly associated with the CSS (p=0.084) but 
it was for the DFS (p=0.014). Factors like patient age, tumour size and infi ltration depth were not 
associated with the number of nodes. 
Conclusions: No relation was found between the number of negative nodes examined after RHL for the 
treatment of early stage cervical cancer and CSS or DFS. However, a higher amount of removed lymph 
nodes leaded to a better DFS for patients with positive nodes. It is suggested that patients with positive 
nodes benefi t from a complete pelvic lymphadenectomy and a suffi cient yield of removed nodes.
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Introduction
Pelvic lymphadenectomy is widely performed as part of the treatment of patients with cervical cancer 
stage I-IIa (1-6). Spread of the disease outside the cervix, especially in the pelvic nodes, has the stron-
gest effect on prognosis (5-8). The goal of lymphadenectomy is to remove and diagnose cancer cells 
that have been transported to the lymphatic tissue draining the uterine cervix and the upper vagina. A 
systemic lymphadenectomy can reliably establish the presence or absence of lymph node involvement, 
with the attendant consequences for prognosis and treatment (5).
In other cancers such as breast cancer, it has been suggested that removal of the axillary regional 
nodes in patients with breast cancer is important for long-term survival, even when such nodes are 
interpreted as pathologically negative (9-15).
In endometrial carcinoma the role of lymphadenectomy remains a topic of continuing debate. Litera-
ture data document the possible therapeutic benefi t of selective lymphadenectomy in the management 
of patients with early stage endometrial cancer. However, it remains an unresolved issue whether a 
minimum number of nodes should be required to consider the lymphadenectomy as adequate, since 
data from randomized studies are lacking (16-19). Benedetti-Panici et al. reported in their random-
ized clinical trial that systematic lymphadenectomy improves the progression-free survival in women 
with optimally debulked advanced ovarian carcinoma (20). They supported the concept of therapeutic 
lymphadenectomy.
For the treatment of early stage cervical cancer, the therapeutic value of lymphadenectomy is also still 
a matter of debate. Other authors emphasized the possible benefi cial effect of removing metastatic 
lymph nodes, especially when they are bulky (21-27). The aim to remove all accessible lymphatic tissue 
in the pelvis might also include micrometastases which have a high rate by false-negatives on CT and 
MRI, and the inaccuracy of intraoperative lymph node palpation (34). Furthermore, the number of 
removed nodes is underlined by some authors as a matter of quality of the surgery (5;21). Yet, it has 
never been proven that the removal of nodes itself leads to better survival fi gures (26).
The aim of the present study is to determine if the number of removed pelvic lymph nodes in radi-
cal hysterectomy with pelvic lymphadenectomy (RHL) infl uences survival of patients with early stage 
cervical cancer. As it is a clinical impression that the number of reported lymph nodes can depend 
on several factors, including anatomic differences between patients, variations in local infl ammatory 
parameters, variations in surgical techniques, processing of the specimen and its examination by the 
pathologist, the second purpose of this study is to examine the association of patient, tumour and 
treatment characteristics with the number of lymph nodes examined in early stage cervical cancer 
patients.
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Material and Methods
Patient characteristics and study design
Between January 1984 and April 2005, 643 patients with stage I-IIa cervical carcinoma were treated in 
our centre with RHL. Relevant clinical and pathological parameters of this group were prospectively 
collected in a database. For the fi rst purpose of this study we used 2 groups: a group with negative 
nodes (n=503) and a group with positive nodes (n=140).
Patients in our centre received adjuvant radiotherapy if lymph node involvement, parametrial invasion 
or positive surgical margins were found. Since 1997, patients with at least 2 of the following 3 risk 
factors also received postoperative radiotherapy: pathological tumour size (≥40mm), depth of invasion 
(≥ 15 mm) and capillary lymphatic space involvement.
From the group with negative nodes, 143 patients received adjuvant radiotherapy and 5 patients re-
ceived chemotherapy. These 148 patients were excluded. Twenty patients were excluded because data 
of the total number of examined lymph nodes were missing, and 4 patients were excluded because 
an incomplete lymphadenectomy was performed due to various reasons. For the further analysis 331 
patients remained (group A).
Para aortic lymph nodes were removed in 4 patients with positive nodes. These patients were excluded 
from the study, because it has been reported that para aortic node dissection could infl uence the survival 
(27;28). For the further analysis 136 patients with positive nodes remained (group B). Hundred thirty 
one patients received adjuvant radiotherapy and 14 received chemotherapy. In this group 10 patients 
did not have a complete lymphadenectomy.
To investigate the relationship between patient, tumour and treatment characteristics and the number 
of removed nodes, we only studied the group of patients with negative lymph nodes (group A), since it 
has been a former policy to abandon a complete lymphadenectomy when lymph node metastases were 
found during surgery.
All patients in the study were treated by the same four gynaecologic oncologists (GGK, AAWP, JBT, 
KNG) during this period. Fifteen percent of the patients in group A and 24% of the patients in group 
B were referred from Suriname (South America) for their treatment. In all cases a RHL type III was 
performed (29).
Lymphadenectomy consisted of removal of all the fatty tissue from 6 different stations: along the 
common iliac vessels until halfway the aortic bifurcation, the external and internal iliac vessels, and 
the obturator fossa, at both sides. Parametrial nodes were not included in the counting of number of 
nodes. Para aortic nodes were only removed in case of palpable enlarged nodes or confi rmed positive 
common iliac nodes at frozen section. In the current study there were no para aortic lymph nodes 
removed in patients of group A and B. The follow-up was closed on April 2005 and ranged from 0 to 
223 months for the group with negative nodes and 0 to 220 months for the group with positive nodes. 
The mean and median duration of follow-up for the group with negative nodes was 57 months and 53 
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months, respectively; for the group with positive nodes 37 months and 18 months, respectively. The 
disease free survival (DFS) was defi ned as the time from RHL to cytologically or histologically proven 
evidence of recurrent disease or date last seen. Cancer specifi c survival (CSS) was defi ned as the time 
from date of operation to death by tumour or date last seen.
Pathologic examination
Radical hysterectomy specimens were routinely examined. Four μm thick tumour sections of formalin-
fi xed, paraffi n embedded material were stained with haematoxylin and eosin (H&E). The following 
tumour characteristics were documented: tumour size, histological tumour type, capillary lymphatic 
space involvement (CLS) and depth of invasion. CLS was considered positive when neoplastic cells 
were seen within endothelium-lined spaces. The depth of invasion was measured from the most 
superfi cial epithelial-stromal interface of the adjacent intra-epithelial process to the lower limits of 
invasion (30).
At pelvic lymph node dissection the lymph nodes were labeled according to site. After arriving at the 
department of pathology, the specimens were formalin fi xed. The next day, conventional lymph node 
retrieval technique was performed for each specimen separately, i.e. inspection, palpation, and/or se-
rial sectioning of the resected tissue. Certain (often larger) lymph nodes were measured and sectioned 
in multiple slides of 2 to 3 mm after which representative samples were embedded. Smaller (possible) 
lymph nodes were totally embedded. The 4 μm thick sections of formalin-fi xed, paraffi n embedded 
material were stained with haematoxylin and eosin (H&E).
Data analysis
The relationship between the number of removed nodes and the survival of patients was examined 
graphically with the Kaplan-Meier method. The number of nodes was categorized as <10, 10-15, 16-20, 
21-25, 26-30 and >30 nodes. We also analyzed the number of lymph nodes examined with a cut-off 
based on the median number of nodes in the cohort. The Cox regression model was used to determine 
statistical signifi cance (31;32). Furthermore, the relationship between the following variables; patient 
age, referral from Surinam, postmenopausal status, conisation before surgery, tumour size, infi ltra-
tion depth, CLS and the number of removed lymph nodes was investigated by using univariate and 
multivariate linear regression models. The parameter of Surinam origin of the patients was included 
because historically patients with cervical cancer from Surinam (SA) are referred to the Leiden Uni-
versity Medical Centre for treatment. These patients have a different ethical origin as compared to the 
Dutch patients. The number of removed nodes was regarded as a normally distributed continuous 
variable in the linear regression models, because a histogram showed an almost normal distribution. 
Statistical signifi cance was assigned at a level of p<0.05.
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Results
Number of lymph nodes
The mean age at the time of the operation among the patients with negative lymph nodes (group A) 
was 43.3 years (SD 11.5) (Range 21-82 years) in contrast to the patients with positive lymph nodes 
(group B) who had a mean age of 47.0 years (SD 13.6) (Range 25-80 years). The clinical and histologi-
cal characteristics of the 2 groups of patients with early stage cervical cancer are listed in Table 1. In 
group A the median number of lymph nodes examined was 19 (mean, 19.90; SD, 8.16) with a range of 
Characteristics Group A (n=331)
n



























































































Table 1. Clinical and histological characteristics of the patients with early stage cervical cancer, node negative (group 
A) and node positive (group B).
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4-53. The median number of lymph nodes examined in group B was 18 (mean, 17.47; SD, 7.91) with a 
range of 1-38. The number of examined lymph nodes in both groups followed a normal distribution. 
Table 2 shows the number of examined nodes in both groups categorized into 6 groups.
Negative lymph nodes and prognosis
Overall, the CSS and DFS of the patients with negative nodes did not differ between the 6 analysis 
groups. Also there was no difference in the CSS and the DFS between the group with less than 19 
removed lymph nodes and the group with 19 or more removed lymph nodes. The Cox regression model 
did not show a signifi cant relationship between the number of removed lymph nodes and the CSS or 
DFS (p=0.625 and p=0.877, respectively).
Positive lymph nodes and prognosis
The number of removed lymph nodes in patients with positive nodes was positively correlated with a 
better DFS (p=0.014). Figure 1 shows the DFS curves for the 6 analysis groups of patients with positive 
nodes. The DFS curves of the group less than 18 removed lymph nodes and the group with 18 or more 
removed lymph nodes are shown in Figure 2. The Cox regression model did not show a signifi cant re-
lationship between the number of examined lymph nodes and CSS (p=0.084). The number of removed 
positive nodes for these patients is listed in Table 3. The number of positive nodes was positively cor-
related with a better CSS (p=0.017) and DFS (p=0.048).






<10 22    23    
10-15 85    35     
16-20 83    30     
21-25 73    26     
26-30 33    17     
>30 35    5       
Table 2. Number of removed nodes in patients with negative lymph nodes (group A) and positive lymph nodes (group 
B), categorized into 6 analysis groups.








Table 3. Number of removed positive nodes in patients with positive lymph nodes (group B).
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Relationship between several factors and the number of lymph nodes examined
To evaluate a possible relationship between several patient and tumour characteristics and the number 
of examined lymph nodes, we used the patients of group A, with negative lymph nodes (n=331). The 
univariate and multivariate linear regression models using the variables patient age, referral from 
Surinam, postmenopausal status, conisation before surgery, tumour size, infi ltration depth and CLS, 
did not show that any of these factors were associated with the number of examined lymph nodes.
Discussion
The role of the number of removed pelvic lymph nodes after RHL for the treatment of early stage 
cervical cancer was evaluated for patients with negative and positive lymph nodes. Furthermore, the 
association of different factors with the number of lymph nodes was examined.
The strength of the current study is the fact that a prospective database and a consecutive series of 
patients were used. Furthermore, all patients were treated by the same group of gynaecologic oncolo-
gists.
The therapeutic value of removing lymph nodes, especially when they are bulky, has been reported by 
different authors (21-27;33). However, the number of removed lymph nodes in the quality control of 
the surgical treatment of early stage cervical cancer has never been evaluated before. The hypothesis 
that removal of a larger number of regional nodes in patients with breast cancer improves survival is 
nowadays strongly supported by both prospective randomized trials and multiple retrospective stud-














































Figure 1. Disease free survival of the categorized 
6 analysis groups, of patients with positive lymph 
nodes (Group B). 





























Figure 2. Disease free survival of the 2 groups with a 
cut-off based on the median number of removed nodes, in 
patients with positive lymph nodes (Group B).
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ies of large groups of women (9-15). This may be explained as being due to understaging caused by 
examination of too few lymph nodes (more likely for node-negative patients) or as a real association 
between the extent of the dissection and improved disease control (more likely for node-positive 
patients) (34).
From the present study of patients with negative as well as positive nodes, it can be concluded that a 
large variability in the number of lymph nodes exists. Despite this fi nding, there was no evidence that 
a higher number of examined lymph nodes lead to better survival fi gures for patients with negative 
lymph nodes. Thus the explanation of a possible relation between the number of examined nodes 
and survival caused by examination of too few lymph nodes (understaging) could not be confi rmed 
for these patients. In contrast, the current study did show an association between the extent of the 
dissection and a better disease control, as a larger number of removed lymph nodes prolonged the DFS 
for patients with positive lymph nodes. However, the improvement in DFS was not translated into an 
improvement in CSS. One possible explanation for this might be that the follow-up has been too short 
and a longer period might be needed before long-term survival values are defi nitive.
The large variability in the number of examined lymph nodes is diffi cult to explain. The stable group 
of surgeons does not seem to have impact on the extent of the surgery, which might lead to variable 
numbers of removed nodes. One explanation could be the fact that the number of reported nodes may 
not refl ect the number of removed nodes. Total node count is not only a refl ection of completeness 
of lymphadenectomy, but is also dependent on the pathologist’s evaluation of the surgical specimen. 
Total node count and thorough evaluation of all lymph nodes in the specimen are depending on the 
pathologist’s macroscopic evaluation, and are therefore subject to bias. In our centre, the conventional 
lymph node retrieval technique was used embedding all large and easily recognized lymph nodes. If a 
structure was not a lymph node by inspection or palpation, it was embedded completely, reducing the 
risk to leave any lymph node in the fatty tissue. Hereby the pathologist’s bias was reduced to a minimal. 
Compared with other studies, the median number of removed nodes in the current study is somewhat 
lower (1;2;28;35;36). The reason for this difference might be that in our study parametrial nodes were 
not included in the number of nodes and para aortic nodes were not removed in the patients of this 
study. Furthermore, 10 patients of the group with positive nodes did not undergo a complete lymph-
adenectomy, as the procedure was aborted in view of subsequent radiation.
Surgery is still the most important treatment variable in most solid cancers and its impact has been 
emphasized in past decades. A better control of the quality of surgical procedures in oncology is pos-
sible and may have a major impact on outcomes of cancer patients (37).
This is the fi rst study that has evaluated the number of removed lymph nodes in the quality control 
of the surgical treatment of early stage cervical cancer and the possible association of different fac-
tors with the number of lymph nodes examined. In a previous analysis we reported on the effect on 
survival of pelvic lymphadenectomy of 294 patients with early stage cervical cancer treated by RHL 
(26). Patients with positive nodes and with complete lymphadenectomy (n=23) had signifi cantly less 
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recurrences compared to patients with positive nodes with incomplete lymphadenectomy (n=40). The 
complete lymphadenectomy showed an independent benefi cial effect on the DFS. The fi ndings of the 
current study are in line with the results of this previous analysis (26).
Until the results of other trials are known, the outcome of the present study suggests that there is no 
relation between the number of tumour negative nodes examined after a RHL for the treatment of 
early stage cervical cancer and CSS or DFS. However, the number of examined lymph nodes leads to 
better DFS fi gures for patients with positive lymph nodes. This suggests that patients with early stage 
cervical cancer with positive lymph nodes benefi t from a suffi cient number of removed lymph nodes. 
And because on forehand, one does not know whether the removed pelvic lymph nodes will be positive 
or negative, the most important clinical consequence of the present study is that one should complete 
the lymphadenectomy when frozen section reveals lymph node involvement during RHL.
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Abstract
Objective: To evaluate the possibility to give a prediction of the future (disease free) survival, given the 
fact that a patient with a history of early stage cervical cancer has been disease free for a specifi c period 
after treatment.
Methods: Between January 1984 and April 2005, 615 patients with cervical cancer stage I-IIa underwent 
radical hysterectomy with or without adjuvant radiotherapy. The Kaplan-Meier method was used to 
detect statistical signifi cance and multi-state risk models to estimate the infl uence of covariates and 
to generate predicted survival curves by simulation. Simulations were done for patients with positive 
lymph nodes (n=123), patients with negative lymph nodes (n=492) and four hypothetical patients.
Results: The 5-year cancer specifi c survival and disease free survival of the entire group was 84% and 
76%, respectively. The probability of death of the two lymph node groups and the four hypothetical 
patients were demonstrated in predicted cumulative probability plots.
Conclusions: It is possible with multi-state risk models to give a detailed prediction of the future 
(disease free) survival, given the fact that a patient has been disease free for a specifi c period after 
treatment. This possibility is an important step forward to improve the quality of cancer care.
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Introduction
The prognosis of early stage cervical carcinoma after radical hysterectomy is excellent in most cases, 
with 5-year survival rates of 80-90% (1-4). However, recurrences confront the physician and the patient 
with a rather dismal prognosis, leading to the death in more than 85% of cases (5;6) and this ‘sword 
of Damocles’ is often present in the patient’s mind. When a patient confronts the physician with ques-
tions about the exact risk of recurrence or death in their individual case by time, it can be diffi cult 
and sometimes even impossible to answer this adequately. An adequate answer could also provide 
information to individualise the treatment management and the (length of ) programs of surveillance. 
Furthermore, it could provide psychological support.
Standard survival data measure the time span from some time origin until the occurrence of one type of 
event. If several types of events (like recurrence or death) occur, a model describing progression to each 
of these competing risks is needed. For a cervical cancer patient, if the event of interest is death, then 
recurrence becomes an intermediate event worth modelling. These intermediate event types provide 
more detailed information on the disease/recovery process and allow for more precision in predicting 
the prognosis of patients.
Multi-state models may be considered as a generalization of the basic framework for dealing with 
survival data to the case where several (possibly competing) events occur successively over time. The 
occurrence of successive events constitutes the transitions from an initial state to a fi nal state. Here, 
the states of these cervical cancer patients are recurrence and death. Furthermore, these models allow 
the incorporation of prognostic factors in order to study the infl uence of these factors on each of the 
transition rates. Multi-state models can be used to predict the likelihood to reach a specifi c future state 
(e.g. recurrence) on the basis of their present state at various time intervals following initial treat-
ment.
The aim of this study is to give a prediction of the future (disease free) survival, given the fact that 
a patient has been disease free for a specifi c period after treatment. For this means a database was 
used in which all clinical and pathological parameters of patients with cervical cancer treated in our 
institute were prospectively collected since January 1984. Statistical analysis was done with multi-state 
risk models specifi cally designed for this purpose.
Patients and Methods
Study group
Between January 1984 and April 2005, 643 patients with stage I-IIa cervical carcinoma were treated at 
the department of gynaecology of the Leiden University Medical Centre (LUMC) with a radical hyster-
ectomy and pelvic lymphadenectomy (RHL) with or without adjuvant radiotherapy. All patients in the 
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study were treated by the same four gynaecologic oncologists. Clinical and pathological parameters 
were prospectively collected in a database. Two patients were excluded from this analysis because 
they received both pre- and postoperative radiotherapy, nine because of preoperative chemotherapy 
and 17 because they received postoperative chemotherapy. Of the remaining 615 patients, 536 (87%) 
underwent a radical hysterectomy according to Rutledge type III (7) and pelvic lymphadenectomy, and 
79 (13%) patients a class II (Te Linde) extended hysterectomy, all in combination with pelvic lymph-
adenectomy.
Staging and pathology
Preoperative staging was performed according to the guidelines of the International Federation of 
Gynaecology and Obstetrics (FIGO) (8). The following characteristics from the pathology slides were 
documented: tumour size, histologic tumour type, depth of invasion, parametrial involvement and 
capillary lymphatic space status (CLS). When no tumour was found in the material from the radical 
hysterectomy specimen, presurgical data from conisation or biopsies were used. The depth of invasion 
was measured from the most superfi cial epithelial-stromal interface of the adjacent intra-epithelial 
process to the lower limits of invasion (9). CLS was regarded positive when neoplastic cells were seen 
within endothelium lined spaces.
Radiotherapy
The indications for postoperative radiotherapy were (1) node positivity, (2) parametrial infi ltration, 
(3) positive or non radically free (less than 5 mm) surgical margins, (4) the combination of at least 2 
of the following 3 risk factors: pathological tumour size (≥40mm), depth of invasion (≥ 15 mm) and 
CLS involvement. Seven patients had individual reasons for postoperative radiation, such as surgical 
or medical diffi culties to complete the operation as planned or tumour spill during surgery. External 
beam radiotherapy was administered to the pelvis using a four-fi eld box technique. Patients were 
treated with 10 MV photons from a linear accelerator to a total dose of 46 Gy in 2 Gy fractions, specifi ed 
at the isocentre. A brachytherapy boost was given to the vaginal vault in case of extensive CLS (68% 
of the patients), using vaginal colpostats, 15 Gy low dose rate or equivalent dose, prescribed at 5 mm 
from the vaginal mucosa.
Data analysis
The follow-up was closed on April 2005 and ranged from 0 to 223 months with a mean duration of 53 
months. The disease free survival (DFS) was defi ned as the time from RHL to cytologically or histologi-
cally proven evidence of recurrent disease or date last seen. Cancer specifi c survival (CSS) was defi ned 
as the time from date of operation to death by tumour or date last seen. Survival after recurrence was 
defi ned as the time from cytologically or histologically proven evidence of recurrent disease to death 
by tumour or date last seen. Survival curves were made using the Kaplan-Meier method (10). The dif-
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ference in DFS and CSS by treatment regimen was evaluated using the log-rank test (10;11). A p-value 
<0.05 was considered statistically signifi cant. The variables that have been taken into consideration in 
the analysis of individual patient survival are; lymph nodes involvement, tumour size, depth of inva-
sion, CLS, parametrial invasion, adenosquamous carcinoma and positive surgical margins.
Multi-state modeling
After therapy, only a fraction of patients encounters a relapse. After relapse, the probability of dy-
ing (within fi ve years) is high. So we are dealing with a survival process with three states: the initial 
state directly after therapy, the relapse state and death. Every patient starts in the initial state and may 
undergo a transition to the second state (relapse) or (from the second state) to the third state (death). 
The proper way to model such a process, on the basis of observed data, is multi-state survival analysis. 
The dependence of the hazard of each possible transition as a function of time and covariates (like 
for example lymph node status and tumour size) is modelled by the proportional hazard approach, 
commonly known as the Cox model.
The fi rst phase of multi-state modelling is the estimation of coeffi cient values for the covariates and the 
baseline hazard curves. In a second stage these results are used to predict individual survival curves, 
given the values of the covariates for a (virtual or real) patient.
The occurrence of relapse strongly increases the probability of a fatal outcome. Conversely, the longer 
a patient stays relapse-free, the better her chances for survival. The methodology allows the compu-
tation of conditional survival curves, given the length of the relapse-free period. Such curves allow 
doctors and patients to get a better estimate of future prospects.
The multi-state analysis was performed with a library of statistical functions for the R system, an 
open-source statistical system (12). The library was developed at the Department of Medical Statistics 
and Bioinformatics of the LUMC (13). It uses established routines for estimation of the proportional 
hazards sub-models. To construct compound survival curves (in the present case for the path from 
disease-free to recurrence to death), a simulation approach is used, generating event histories for a 
large number of pseudo-patients with given values of their covariates (14).
The multi-state model makes the usual assumptions of the Cox model: the effect of covariates can be 
modelled as a change in hazards of events (recurrence or death) which is constant over time. Another 
important assumption that we make is that of “clock reset”: at the moment of relapse, time starts 
running in this state, independent of the length of the spell in the disease-free state. Thus, the clock is 
reset every time the patient enters a new state.
The predicted (conditional) survival functions are based on the non-parametric estimate of baseline 
hazard that results from the Cox model. This means that the simulation uses the observed time points 
in the data, because the Cox model by construction “knows nothing” about intervals between events. 
As a result a simulated survival curve looks like a staircase with unequal steps. We apply P-splines to 
produce smooth curves which allow easy interpolation (15).
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Characteristics Patients (n=615)  








































































































Table 1. The clinical and histological characteristics of the 615 patients.
* Capillary lymphatic space involvement.
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Results
The age of the patients ranged from 21 to 88 years, with a mean of 45. Forty one percent received 
adjuvant radiotherapy. The clinical and histological characteristics of the patients are listed in Table 1.
Of the 615 patients in the study population, 116 (19%) developed recurrence of disease and 80 (13%) 
died of the disease. The interval from RHL to recurrence ranged from 2-134 months, with a median of 
26. The interval from recurrence to death ranged from 1-47 months with a median of 15. Sixty-three 
percent of the recurrences occurred in the fi rst 2 years after the therapy. Only 8 % of the relapses oc-
curred after 5 years. The 5-year CSS (Fig. 1) and DFS of the entire group was 84% and 76%, respectively. 
The 5-year CSS (Fig.1) and DFS were 56% and 43% respectively, among the patients with positive lymph 
nodes (n=123) in contrast to the patients with negative lymph nodes (n=492), who had a 5-year CSS 
(Fig.1) and DFS of 90% and 84%, respectively. The differences in CSS and DFS between the 2 groups 
were statistically signifi cant (p<0.001 and p<0.001, respectively). Table 2 shows the risk factors and 
their estimator of coeffi cient in the two stages.
































Figure 1. Cancer specifi c survival of the entire group 
(n=615), the patients with positive lymph nodes (n=123) 
and the patients with negative lymph nodes (n=492). 
Legend: Total, entire group; LN+, positive lymph nodes; 
LN-, negative lymph nodes. See colour fi gure page 151. 
Risk factors Disease free-recurrence
        Coeffi cient             SE
    Recurrence-death
    Coeffi cient              SE
Lymph node involvement 0.737 0.270 0.891 0.345
Tumour size 0.032 0.007 0.013 0.010
Depth of invasion -0.003 0.017 0.000 0.025
CLS* 0.648 0.278 -0.828 0.389
Parametrial invasion 0.761 0.281 -0.486 0.427
Adenosquamous carcinoma 0.907 0.353 0.011 0.454
Non-radical surgical margins 0.391 0.286 0.851 0.383
Table 2. Risk factors and their estimator of coeffi cient and Standard error (SE) in the two stages, disease free to 
recurrence and recurrence to death. * Capillary lymphatic space involvement.
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The predicted probability of death of patients with and without positive lymph nodes is shown in Figure 2. 
If a patient with negative nodes survives 60 months since therapy without recurrence (T60), she will have a 
probability of only 1.4% (0.014) that she will be death after another 100 months (160 months since therapy). 
On the other hand, if a patient with positive lymph nodes has no recurrence at 60 months since therapy 
(T60), she will have a probability of 73.3% (probability of death 0.267) that she is still alive after another 
100 months.
To demonstrate the results of an individual prediction of the future survival we defi ned four hypothetical 
patients (A, B, C and D) for simulation. The different risk factors that were used for simulation in these 
four hypothetical patients are shown in Table 3. Figure 3 shows the predicted cumulative probability plots 































Figure 2. Predicted cumulative probability plots of patients with early stage cervical cancer with negative lymph nodes 
(LN negative) and with positive lymph nodes (LN positive).
Legend: T0=0 months, T12= 12 months, T24=24 months, T36=36 months, T48=48 months and T60=60 months. See 
colour fi gure page 151.































Risk factors Patient  A Patient B Patient C Patient D
Lymph node involvement + - - +
Tumour size 45 mm 18 mm 50 mm 30 mm
Depth of invasion 18 mm 7 mm 20 mm 10 mm
CLS* + - + -
Parametrial invasion + - - -
Adenosquamous carcinoma + - - -
Non-radical surgical margins + - - -
Table 3. The values of the different risk factors of four hypothetical patients used for simulation. * Capillary lymphatic 
space involvement.
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of patient A, B, C and D. When patient C survives 12 months without recurrence (T12) she has a 
probability of 21.5 % to be death after 60 months since surgery. But when there is still no sign of the 
disease after 24 months (T24) the probability that she will be death after 60 months since surgery 
will be reduced to 12.7 % (Fig.3). When patient A, B, C and D all experience no recurrence after 12 
months, the probability to death after 24 months since treatment is 95.9%, 1.9%, 9.2% and 25.1%, 
respectively (Fig.3).






















































































































Figure 3. Predicted cumulative probability plots of patient A, B, C and D (Table 3).  Legend: T0=0 months, T12= 12 
months, T24=24 months, T36=36 months, T48=48 months and T60=60 months. See colour fi gure page 152.
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Discussion
The possibility to give a detailed prediction of the future (disease free) survival was evaluated, given 
the fact that a patient has been disease free for a specifi c period after treatment. The characteristics 
of our patients in terms of CSS, DFS and the time of recurrence are in accordance with the literature 
(1-6;16-20), defi ning our study group as a standard population of patients with early stage cervical 
cancer. Finally, the current study indicated that with the use of multi-state risk models a prediction of 
the future (disease free) survival could be calculated.
The strength of the current study is the fact that a prospective database and a consecutive series of 
patients were used. Besides, all patients were treated by the same group of gynaecologic oncologists. 
Furthermore, multi-state risk models were used. In complex survival data such as data of patients 
after a RHL for the treatment of early stage cervical cancer, a number of important (time-) dependent 
variables (positive lymph nodes, metastases, recurrence) must be taken into consideration in the 
analysis of patient survival. Multi-state modelling is proposed, analyzing each state separately using 
e.g. Cox regression models. This enabled us to evaluate which risk factors infl uence the prognosis of 
a patient and the complete model could hereafter be used to synthesize patient survival. On the other 
hand, uncertainties can occur at several levels. Given the model output, there is simulation uncertainty, 
which can be reduced by simulating enough pseudo-patients. Because the model is based on limited 
data (615 patients), there are uncertainties in the parameter estimates; no amount of simulation can 
reduce these. Next, there is a third source of uncertainty. While the moment of death is known with 
great precision, the relapse state of a patient is often determined at follow-up visits. So the exact date 
of transition—if such a concept is meaningful at all—cannot be known. In survival analysis parlance 
this is known as interval censoring. Commonly the date of the follow-up visit at which relapse is 
ascertained is taken as the moment of its occurrence. We have followed that convention too. Finally, 
since multi-state survival analysis is a recently developed analysis method it is yet not easy to provide 
confi dence intervals for the probabilities. This will be a future development.
Various types of multi-state models have previously analysed other types of treatment and disorders, 
including bone marrow transplantations (21), liver transplantations (22), diabetes (23), quality of life 
in cancer (24), malaria (25) and nosocomial infections in intensive care unit patients (26). The current 
study is the fi rst study that used multi-state risk models to evaluate the future (disease free) survival of 
patients treated for cervical cancer stage I-IIa.
Almost all studies evaluating the follow-up, use a minimum follow-up period of 5 years (1-4). However, 
the majority (70-90%) of recurrences are diagnosed within the fi rst 2 years of initial treatment (5;6;18-
20). Besides, there seems to be no consensus in policy as post treatment surveillance programs differ 
widely among institutions (27) and numerous reports in the literature have shown that routine clinical 
follow-up surveillance is ineffective in detecting recurrent disease or in achieving a more favourable 
outcome (20;28-31). When a prediction of the future (disease free) survival could be calculated for 
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an individual patient, it could provide information to individualise the treatment management and 
the (length of ) programs of surveillance and this obviously will benefi t cost and time implications. 
Furthermore, improving the quality of cancer care will undoubtedly lead to a better quality of life for 
cancer patients.
As the experience with this new statistical approach will increase, it can only be a matter of time before 
gynaecologic oncologists will have a program, based on multi-state modelling, on their computer. 
By this program they will be able to fi ll in all the individual adverse risk factors, which will lead to the 
prediction of the future (disease free) survival for that individual patient.
Until the results of other trials are known, the outcome of the present study shows the possibility to 
give a prediction of the future (disease free) survival, given the fact that a patient has been disease 
free for a specifi c period after treatment. It can be concluded that this possibility is an important step 
forward to improve the quality of cancer care.
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Abstract
Objective: The aim of this study was to investigate the psychometric properties of the items concern-
ing sexual functioning of the Gynaecologic Leiden Questionnaire (LQ), which consists of items for 
postoperative morbidity for women with cancer.
Methods: The total study sample consisted of 198 subjects: 66 patients treated for cervical cancer, 66 
patients with sexual complaints and 66 subjects from the general population.
Results: By means of factor analysis three subscales were derived: Female Sexual Complaints (FSC), 
Female Sexual Function (FSF) and Female Orgasm (FO). The reliability of the subscales appeared to be 
satisfactory. The scores on the three subscales differentiated well between the patients treated for cervi-
cal cancer, patients with sexual complaints and the subjects from the general population. Furthermore, 
the subscales were sensitive to change within the patients treated for cervical cancer. The convergent 
and divergent construct validity of the Gynaecologic LQ was investigated using other validated instru-
ments measuring sexual functioning, sexual dissatisfaction, marital distress, general life distress and 
psychological distress. The Gynaecologic LQ subscales were found to represent relatively independent 
constructs.
Conclusions: The results support the reliability and psychometric validity of the Gynaecologic LQ in 
the assessment of sexual functioning and vaginal changes in gynaecological cancer patients.
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Introduction
Diagnosis and treatment of gynaecological cancer are very likely to have a negative impact on the 
sexual function of the patient (1-6). It is known that women who have been treated for cervical cancer 
by radical hysterectomy with pelvic lymphadenectomy (RHL) have persistent vaginal changes that 
compromise sexual activity and result in considerable distress. Changes or problems that have been 
described are diminished lubrication, a narrow and short vagina, dyspareunia and sexual dissatisfac-
tion (1-7). Therefore, the treatment of cancer should not only be evaluated with regard to survival. The 
complications and personal implications of the disease and treatment should also be assessed. To 
obtain an impression of the impact of a given treatment on a patient’s quality of life and to understand 
the patient’s perception of symptom severity, self-report questionnaires may give more informative 
answers (8). Over the last decades several questionnaires have been developed to diagnose dimensions 
of female sexual dysfunction (9;10). Lately, Jensen et al. showed the results of the validation of the 
Sexual function-Vaginal changes Questionnaire (SVQ), that was developed to investigate sexual and 
vaginal problems in gynaecological cancer patients (11).
For the Dutch language area however, until recently (12) no questionnaire was available that focuses on 
sexual and vaginal problems due to disease and treatment specifi c for gynaecological cancer patients. 
We developed a 21-items Dutch self-report questionnaire, the Gynaecologic Leiden Questionnaire 
(LQ), which is the fi rst Dutch list consisting of items for sexual function, voiding- and bowel problems 
for women with gynaecological cancer. The items of the Gynaecologic LQ were based on the items to 
assess sexual function, voiding- and bowel problems of a non-validated questionnaire which has been 
successfully used in rectal cancer studies (13). Clarity of formulation was assessed by presenting the 
scale items to patients treated for early stage cervical cancer. The fi nal version of the Gynaecologic LQ 
consists of one item for weariness, one item for lymph edema, 11 items for sexual functioning, 6 items 
for voiding and 2 items for bowel problems. The aim of this study is to investigate the psychometric 
properties of the items concerning sexual functioning of the Gynaecologic LQ.
Methods
Study population
The study involved three subject groups: 1) patients with a history of a RHL for the treatment of cervical 
cancer stage I-IIa, (oncology group (ONCO)); 2) patients of an out-patient clinic of sexology (female sexual 
dysfunction group (FSD)); 3) subjects from the general population (control group (CONTROL)).
The data from the prospective study of Pieterse et al.(7) were used for the ONCO group. This group 
consisted of consecutive patients who stayed at the department of gynaecology to undergo a RHL 
for early stage cervical cancer at the Leiden University Medical Centre (LUMC). They were asked to 
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complete the Gynaecologic LQ before, 3, 12 and 24 months after the operation (7). For the validation of 
the Gynaecologic LQ we used the Gynaecologic LQ that was completed 12 months after the operation. 
Sixty-six women who completed the Gynaecologic LQ after 12 months of follow-up were included.
The FSD group consisted of women with a sexual problem who solicited for therapy at an out-patient 
clinic for sexology of a university medical hospital. The women completed the questionnaires at the 
end of the fi rst visit. Sixty-six consecutive women with sexual complaints, matched for age with the 
ONCO group, were included. All the women had a heterosexual relationship.
For the CONTROL group the data from the prospective study of Pieterse et al. (7) were used. This group 
consisted of employees from the hospitals and relatives and friends of these employees. Sixty-six 
women were selected. The CONTROL group was matched for age and marital status with the ONCO 
group (χ2=0.04, p=.849). Demographic data of the three groups are given in Table 1.
The Gynaecologic LQ
The current study investigated only the psychometric properties of the items concerning sexual 
functioning of the Gynaecologic LQ. The 11 items cover aspects of sexual satisfaction, sexual desire, 
orgasm, lubrication and pain (see attachment). Items covering treatment specifi c problems e.g. short 
or narrow vagina and dry vagina were also included. An inherent problem in the development of ques-
tionnaires on sexuality is that not all participants had a partner and that not all the participants were 
sexually active. For the analysis two questions were excluded because they were not answered on a 5 
point Likert scale (item 1 “sexual active lately?”, yes/no and item 10 “numbness labia or thigh?”, yes/
no). A higher score on a particular item indicates higher endorsement of the dysfunction or problem 








































Table 1. Demographic characteristics of ONCO group (patients treated for cervical cancer), FSD group (out-patients 
with sexual complaints) and CONTROL group (subjects from the general population). 1Observed two-tailed 
signifi cance. Statistical signifi cance at a level of p<0.05. 
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The Dutch version of the Gynaecologic LQ was translated into English by three independent persons. 
A consensus translation of each was translated into Dutch by a native Dutch speaker. On the basis 
of differences between the original and retranslated versions of the questionnaires, some additional 
changes were made in the English translation (see attachment).
Measures used for construct for validation
Only in the FSD group, data for the divergent and convergent construct validity were collected. The 
following measures were used:
The Female Sexual Function Index (FSFI) (10). The FSFI is a multidimensional self-report questionnaire 
for assessing sexual function in women (10). The FSFI consists of 19 items that assess sexual desire, 
arousal, lubrication, orgasm, satisfaction and pain. The psychometric qualities of original FSFI 
(10;14;15) and the Dutch FSFI translation (16) were found satisfactory to good. A higher score means 
a better sexual function.
The Female Sexual Distress Scale (FSDS) (17). The FSDS is a 12-items self-report questionnaire that is devel-
oped to assess sexuality related personal distress. Overall the FSDS seems a valid and reliable measure 
for assessing sexuality related personal distress in women (17). The reliabilility and psychometric 
validity of the Dutch FSDS is excellent (16). Higher scores indicate more sexual dissatisfaction.
The Golombok Rust Inventory of Sexual Satisfaction (GRISS) contains 28 items and covers the most frequently 
occurring sexual complaints of heterosexual persons with a steady partner. Seven subscale scores can 
be derived: anorgasmia, vaginismus, (in)frequency of sexual contact, sexual non-communication, dis-
satisfaction, non-sensuality, and avoidance of sex. For the current study we only used the anorgasmia 
and vaginismus subscales of the GRISS. The psychometric qualities of original GRISS (18;19) and the 
Dutch version were found to be satisfactory (20;21). Higher scores indicate more problems.
The Maudsley Marital Questionnaire (MMQ) is a 20-items self-report instrument measuring dissatisfaction 
with the general relationship, with the sexual relationship, and dissatisfaction with life in general. 
For the current study we only used the subscales general relationship and dissatisfaction with life 
in general. The MMQ has shown good reliability and validity (22). The psychometric qualities of the 
Dutch version of the MMQ were also found to be satisfactory (23). Higher scores represent larger dis-
satisfaction.
To measure psychological distress, the Symptom Checklist-90 (SCL-90) (24) was used. The Dutch version 
of the SCL-90 (25;26) was used as an index of psychological distress. The psychometric qualities of the 
Dutch version were found to be satisfactory. Higher scores represent greater psychological distress.
Statistical analysis
Exploratory principle component analysis was conducted on the items of the Gynaecologic LQ in the 
ONCO and FSD groups. The Kaiser criterion (27) was used to determine the number of components. 
According to the Kaiser criterion, only components whose eigenvalues are larger than 1 are considered 
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as being of interest. Where a multi-componential solution resulted, simultaneous components analysis 
(28) was used to identify the optimal dimensional structure in the different subgroups. This analysis 
tries to establish component weights such that the components optimally summarize the variables 
in each group. Based on the components, subscales were constructed1. The internal consistency was 
calculated using Cronbach’s alpha in the ONCO group, the FSD group and the CONTROL group. The 
stability of the Gynaecologic LQ was assessed by calculating the test-retest reliability in CONTROL 
group. To test the discriminant validity of the Gynaecologic LQ-subscales between the three subject 
groups, univariate comparisons were made by means of one-way analysis. The sensitivity to change 
was assessed by a repeated analysis of variance in the ONCO group.
The divergent and convergent construct validity were studied using a higher order principal compo-
nents analysis with varimax rotation of the scores on the Gynaecologic LQ subscales together with 
the scores on (subscales of ) standardized psychometric instruments measuring theoretically related 
constructs (complaints): sexual functioning (FSFI), sexual dissatisfaction (FSDS), marital and general 
life maladjustment (MMQ), and psychological distress (SCL-90).
Results
Preliminary analysis
Prior to analysis, all variables were examined for missing values and fi t between their distributions and 
the assumptions of multivariate analyses. The majority of the item score of the Gynaecologic LQ in the 
CONTROL group was very low, resulting in positively skewed distributions. For seven out of 9 items 
the median was category one, indicating that on these seven items at least 50% of the subjects in the 
CONTROL group only used the fi rst of the fi ve available response categories. This can be explained by 
the fact that these subjects in the CONTROL group did not have any complaints. Therefore, we decided 
to exclude the CONTROL group from the factor structure analysis.
Since item 4 (orgasm during masturbation) did not correlate with any of the other Gynaecologic LQ 
items (<.35) (29), item 4 was also excluded from the further analysis.
1 The original version of the Dutch Gynaecologic LQ consisted of one item with a 6-point Likert scale 
(item 5) and one item with a 4-point Likert scale (item 2). To obtain uniform weights of the individual 
items on a subscale, we recoded the answering formats of item 2 and 5. For item 5, two answer formats 
“Less than once a month” and “Approximately once a month” were added together and the score of 
item 2 was multiplied with 5/4. In the fi nal version of the Gynaecologic LQ, the answer format “always” 
was added to item 2. 
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Factor structure
Explorative principal component analysis was conducted on the 8 items of the Gynaecologic LQ in 
the ONCO and FSD groups. On the basis of the Kaiser criterion (30), a three-component solution was 
obtained in both groups. A three-component simultaneous components analysis (28) was conducted 
to fi nd the components weights with which the components optimally summarized the variables in 
the two subject groups. The total amount of variance explained by component 1 was 43% in the ONCO 
group and 30% in the FSD group. For component 2 the total amount of variance was 17% in the ONCO 
group and 23 % in the FSD group. The total amount of variance explained by the third component was 
in both subject groups 13%. The total amount of variance explained by the components resulting from 
the simultaneous components analysis was 71% for the ONCO group and 65% for the FSD group. These 
percentages differed not more than 1.0 % from the variance accounted for by the separate principal 
component analyses in the two subject groups. Thus it may be concluded that the same combinations 
of variables can be used in both subject groups to describe the data adequately. The loading of the 
individual items on the three common components in the ONCO and FSD group are shown in Table 
2. Items with a loading on one component exceeding 0.55 and a difference between loadings on the 
three components of at least >0.10 in the two subject groups were considered to belong to a subscale. 
The fi rst subscale consisted of item 7 (Do you experience vaginal dryness during sexual intercourse?), 
8 (Do you experience your vagina as too tight or too short during sexual intercourse?) and 9 (Is sexual 
intercourse painful to you?). This was interpreted as refl ecting Female Sexual Complaints (FSC). The 
Gynaecologic Leiden Questionnaire( LQ) items ONCO FSD
Component 1: Female Sexual Complaints (FSC)
7   Do you experience vaginal dryness during sexual 
     intercourse?
8   Do you experience your vagina as too tight or too 
     short during sexual intercourse? 







Component 2: Female Sexual Function (FSF)
2   Do you feel sexual desire?
3   Do you notice that your vagina becomes lubricated 
     (“wet”) during sexual arousal?
5   Do you have sexual contact with a partner?









Component 3: Female Orgasm (FO)     
6   Do you reach orgasm during sexual intercourse? 0.703 0.720
Table 2. Component loadings of the individual items of the Gynaecologic Leiden Questionnaire on the three 
components resulting from the simultaneous components analysis in the ONCO group (patients treated for cervical 
cancer) and FSD group (out-patients with sexual complaints). 
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second subscale included item 2 (Do you feel sexual desire?), 3 (Do you notice that your vagina 
becomes lubricated (“wet”) during sexual arousal?), 5 (Do you have sexual contact with a partner?) 
and 11 (How satisfi ed are you with your present sexual life?), and was considered to represent Female 
Sexual Function (FSF). The third subscale only consisted of item 6 (Do you reach orgasm during sexual 
intercourse?) and represent Female Orgasm (FO).
Reliability
For the internal consistency the ONCO group, the FSD group and the CONTROL group were used. 
Since subscale FO consists of only one item, only the consistency of subscales FSC and FSF were as-
sessed. The Cronbach’s alpha values (Table 3) of the subscales FSC and FSF were suffi cient in our 
ONCO group (>0.70) (31). The correlation-coeffi cients between test and re-test, ranging from 0.78 to 
0.93, were never more than 0.20 lower than Cronbach’s Alpha of a subscale (31). These results indicate 
that the Gynaecologic LQ subscales have appropriate levels of stability over a period of 2.8 weeks of 
time (SD= 1.7; range: 1 - 8 weeks).
As an internal criterion for the validity of the three subscales, interscale correlations were computed 
in the three groups and ranged from 0-0.53. For the purpose of interpretation|0.10|< r < |0.30| is 
considered as small, |0.30| < r < |0.50| as medium and r > |0.50| as large (32) . These results indicate 
that the Gynaecologic LQ subscales do not measure totally independent constructs.
No signifi cant associations were found between the Gynaecologic LQ subscales on the one hand and 
age or ‘living with a partner’ on the other. Therefore, it can be concluded that the Gynaecologic LQ 
subscales scores are independent of biographic variables.
Discriminant validity
The power of the Gynaecologic LQ subscales to discriminate between different groups of subjects was 
investigated within the three study groups. As can be seen in Table 4, the Gynaecologic LQ subscales 
proved to differentiate between the three groups. The women treated for cervical cancer (ONCO) 
scored signifi cantly higher on the FSF, FSC and FO subscales than women from the general population 
Subscale ONCO FSD CONTROL
FSC
Chronbach’s alpha 0.80 0.65 0.68
FSF
Chronbach’s alpha 0.73 0.72 0.68
Table 3. Crohnbach’s alpha of the subscale Female Sexual Complaints (FSC) and the subscale Female Sexual Function 
(FSF) of the Gynaecologic Leiden Questionnaire of ONCO group(patients treated for cervical cancer), FSD group (out-
patients with sexual complaints) and CONTROL group (subjects from the general population).
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(CONTROL) and signifi cantly lower on FSF, FSC and FO subscales than women who request therapeu-
tic assistance for sexual problems (FSD).
Sensitivity to change
To test if the Gynaecologic LQ subscales change in the theoretically proposed direction following an 
intervention the data from the prospective study of Pieterse et al. (7) were used. Sixty-two of the 66 
patients of the ONCO group completed the 24 months follow-up and were included in the analysis. 
The differences in the subscale scores were analysed at three time moments: before the RHL and 12 
months and 24 months after the RHL.
Before the RHL all three subscales score signifi cantly lower than 12 months (p<0.01) and 24 months 
after the treatment (FSC, p<0.01; FSF, p<0.01; FO, p=0.037). The scores of the three subscales did 
not signifi cantly differ 12 and 24 months after the treatment (p>0.5). These fi ndings are in line with 
the results of the prospective study of Pieterse et al. (7) in which the patients reported signifi cantly 
less sexual complaints before than after the RHL. Moreover, sexual dysfunction was reported up to 24 
months of follow-up. Only item ‘orgasm during sexual intercourse’ that formed the subscale FO, never 
reached signifi cantly difference over time in that study (7).2
Construct validity
A principal components analysis suggested a four-component solution that accounted for 72% of the 
total variance (Table 5). We found that the fi rst component accounted for 31% of the variance and 
interpreted it as sexual dysfunction. High loadings were found on this component for the FSF and the 
fi ve FSFI subscales arousal, desire, satisfaction, lubrication and orgasm. The second component, 
accounting for 18% of the total variance, is interpreted as sexual pain disorder. High loadings on this 
component were found for the FSC, the GRISS subscale vaginismus and the FSFI subscale pain. The 
third component, accounting for 13% of the total variance, is interpreted as psychological distress. High 
2 Sensitivity to change was also tested for all the 72 patients of the prospective study of Pieterse et al. 


























Table 4. Untransformed mean, standard deviation (SD) and transformed F ratios for the scores on the Female Sexual 
complaints (FSC), the Female Sexual Function (FSF) and Female Orgasm (FO) in ONCO group (patients treated for 
cervical cancer), FSD group (out-patients with sexual complaints) and CONTROL group (subjectsfrom the general 
population).* All p-values were <0.01, statistical signifi cance at a level of p<0.05. 
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loadings on this component were observed for the SCL-90 total score, the MMQ subscale scores for 
general life maladjustment and relationship maladjustment and the FSDS. The fourth component, 
accounting for 11% of the total variance, is interpreted as orgasm disorder. High loadings were found 
on this component for the FO, the FSFI subscale orgasm and the GRISS subscale anorgasmia. These 
results indicate that the Gynaecologic LQ subscales represent relatively independent constructs.
Discussion
The aim of the present study was to investigate the psychometric properties of the items concerning 
sexual functioning of the Gynaecologic LQ.
Component analysis of the Gynaecologic LQ in patients treated for cervical cancer and patients with 
sexual complaints yielded a three-component solution. Three items appeared to contribute to com-
ponent 1, the subscale Female Sexual Complaints (FSC). Four items contribute to component 2, the 
subscale Female Sexual Function (FSF) and only one item formed component 3, the subscale Female 
Orgasm (FO) (Table 2).
The internal consistency was suffi cient. The stability was good for all three subscales. The scores on 
the three subscales were overall not associated with age or ‘living with a partner’. The convergent and 
divergent validity of the Gynaecologic LQ was good, since the 3 subscales corresponded with subscales 
measuring similar complaints and discriminated from subscales measuring other (psychological) 































Table 5. Principal component analysis with varimax rotation of the Gynaecologic LQ subscales and other scales for 
women with sexual complaints (n=66). Rotated factor loadings of >0.35 are reported. FSFI=Female Sexual Function 
Index; FSDS= Female Sexual Distress Scale; GRISS= Golombok Rust Inventory of Sexual  Satisfaction; MMQ= 
Maudsley Marital Questionnaire ; SCL-90= Symptom Checklist-90.
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problems. The scores from the three subscales appeared to differentiate between patients treated for 
cervical cancer, patients with sexual complaints and subjects from the general population. Further-
more, the subscales were sensitive to change within the patients treated for cervical cancer.
To get insight in the morbidity after RHL in our own population, the Gynaecologic LQ was developed 
since no other validated Dutch list existed. We already used the Gynaecologic LQ in a prospective study 
(7) in which it was concluded that women after RHL for early stage cervical carcinoma were associ-
ated with adverse effects mainly on sexual functioning. The fi ndings were in line with the literature 
(2-4;33;34). It is expected that our new developed nerve-sparing modifi cation of the RHL (35) will lead 
to less postoperative morbidity. The validated LQ will be used as a tool to compare the nerve-sparing 
RHL with the conventional RHL.
Since the Gynaecologic LQ is a Dutch self-report questionnaire, an English version would need to be 
tested in English speaking populations to check the reliability and validity.
However, the scoring system of the Gynaecologic LQ is not very easy in use. Our suggestion would be 
to simplify the scoring system of the Gynaecologic LQ by using a uniform Likert scale and that a higher 
score on all items indicates higher endorsement of the dysfunction or problem measured. In this way 
the Gynaecologic LQ will be more comfortable to do measurements with.
In conclusion, the results of the current study support the reliability and psychometric validity of 
the Gynaecologic LQ in the assessment of sexual functioning and vaginal changes in gynaecological 
cancer patients. The validated Gynaecologic LQ is the fi rst developed Dutch questionnaire which can 
be used to assess sexual function for women with gynaecological cancer. In an era where quality of life 
is considered of major importance in the evaluation of cancer treatment, instruments like these are 
essential tools to improve our treatment modalities for cancer patients.
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Attachment
The Gynaecologic Leiden Questionnaire
Sexual activity can include masturbation or sexual contact with a partner. When thinking of sexual 
contact with a partner, please do not only think of sexual intercourse, but also consider other ways of 
making love that you or your partner experience as sexually arousing.
1.  Have you been sexually active lately?
 1.Yes
 2.No






3.  Do you notice that your vagina becomes lubricated (“wet”) during sexual arousal?






4.  Are you able to reach an orgasm during masturbation?






The Gynaecologic Leiden Questionnaire: psychometric properties
82 
5.  Do you have sexual contact with a partner?
 1. No
 2. Approximately once a month
 3. A few times a month
 4. Approximately once a week
 5. A few times a week
The following questions ask about sexual intercourse. If you never engage in sexual intercourse, please 
continue with question number 10.
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11.  How satisfi ed are you with your present sexual life?
 1. Very satisfi ed
 2. Satisfi ed
 3. Not satisfi ed/ not dissatisfi ed
 4. Dissatisfi ed
 5. Very dissatisfi ed.
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Abstract
Objective: To evaluate the problems with voiding, defecation and sexuality after a radical hysterectomy 
with or without adjuvant radiotherapy for the treatment of cervical cancer stage I-IIa.
Methods: An observational longitudinal study of self-reported bladder, defecation, sexual problems 
with a baseline score.
Results: Ninety-four women were included in the study. An age matched control group existed of 224 
women. The patients showed signifi cant more negative effects on sexual function compared both with 
the controls as well as compared with their situation before the treatment throughout 24 months of 
follow-up. The problems included less lubrication, a narrow and short vagina, numb areas around the 
labia, dyspareunia, and sexual dissatisfaction. Up to 12 months after the treatment the patients com-
plained signifi cantly more of little or no urge to urinate and diarrhoea as compared with the controls. 
Adjuvant radiotherapy did not increase the risk of bladder dysfunction, colorectal motility disorders 
and sexual functions.
Conclusions: We conclude that a radical hysterectomy for the treatment of early stage cervical carci-
noma is associated with adverse effects mainly on sexual functioning.
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Introduction
State of the art treatment for women with early stage cervical cancer (I-IIa) is a radical hysterectomy 
with pelvic lymphadenectomy (RHL) with or without adjuvant (chemo) radiation (1). Although RHL 
has good result in terms of survival, it also has its price: loss of fertility, bladder dysfunction, colorectal 
motility disorders, lymphedema and sexual dysfunction (2-10).
Autonomic nerve damage during surgery plays a crucial role in the aetiology of this morbidity (11). The 
effects of the treatment for cervical carcinoma on the women’s sexuality and the resulting distress, 
have recently received some attention (4;12-19). In 1999 Bergmark et al. contacted 256 women with a 
history of early-stage cervical cancer who had been treated 5 years before and asked them to answer 
a questionnaire about vaginal changes and sexual function. In this retrospective study they reported 
vaginal changes, like decreased lubrication and a short vagina, after RHL in 25% of cases (3). Weimar 
Schultz et al. showed in a comparative and longitudinal study that the sexual response of women 
treated for cervical carcinoma, was signifi cantly disturbed although current sexual behaviour and 
motivation for sexual interaction were within the normal range (4). Recently, Jensen et al. published 
the fi rst longitudinal study, which was partly prospective. It comprised 173 patients with early-stage 
cervical cancer after RHL, who received questionnaires up to 2 years after the operation. Information 
about the sexual function before the diagnosis of cancer was obtained retrospectively, one year after 
the operation. The authors reported that RHL had a persistent and negative impact on patients’ sexual 
interest and vaginal lubrication and that the majority of other sexual and vaginal problems disappeared 
over a two years period (5).
Furthermore, it is well known that RHL can lead to postoperative urinary dysfunction such as urinary 
retention, straining or inability to void, and, to a lesser extent, to urge and stress incontinence (6;8). 
Severe constipation has also been described in 5-10% (6;10).
Finally, it remains controversial whether RHL with or without adjuvant radiotherapy or radiation alone 
has a more adverse impact on the sexual function of patients (3;20-25). Jensen et al., reported persis-
tent and severe sexual problems throughout the 2 years after radiotherapy with only small changes over 
time (20). On the other hand the results of Bergmark et al. showed that surgery alone had more adverse 
effects on sexual function than combined treatment modalities, including surgery and radiotherapy or 
radiotherapy alone (3). The authors did not comment on this.
To evaluate the symptoms that arise following RHL with or without adjuvant radiotherapy for the treat-
ment of cervical cancer, we performed a prospective study in 2 Dutch university centres. The aim of 
this study was to determine the prevalence of lymphedema, bladder dysfunction, colorectal motility 
disorders and sexual dysfunction among women who had been treated for cervical cancer by a RHL.
We compared this group of patients with a group of age-matched controlled women from the general 
population. Because the effect of adjuvant radiotherapy on late side effects is still unclear, we also 
compared patients who underwent adjuvant radiotherapy to those who did not.




From May 1998 until January 2003 women with early stage cervical cancer who had to undergo RHL 
were enrolled in the study. These women were treated in the Leiden University Medical Centre or the 
University Medical Centre Utrecht. In all cases, a RHL type III was performed through a midline inci-
sion. Nerve-sparing surgery was not yet routine practice during the time of the study. Patients with 
lymph node metastasis, parametrial infi ltration, tumour growth in the vaginal surgical margins or a 
combination of unfavourable tumour size, deep infi ltration and lympho-vascular space involvement 
received adjuvant radiotherapy. Radiotherapy included external pelvic irradiation, brachytherapy or 
both. Ovaries were not routinely transposed before potential radiotherapy. Data on the treatment 
results were obtained from the prospective databank. Exclusion criteria were: unable to understand 
the Dutch language and no follow-up due to living outside the Netherlands. The Medical Ethics Com-
mittee of both centres approved the study and all women gave their written informed consent.
The control group consisted of women without cervical cancer and who had not undergone a hysterec-
tomy in the past and were matched for age. They were employees from the hospitals and relatives and 
friends of these employees. The control group was asked to complete the questionnaire once.
Questionnaire
For this study 14 items of the 21 items self-report Gynaecologic Leiden questionnaire (LQ) were used31. 
The 14 items used in the current study were related to lymphedema (1), sexual function (9), voiding (2) 
and bowel problems (2). The Gynaecologic LQ was completed before the operation and at 3, 12, and 24 
months after the operation. Eight questions (sexual function (7), bowel problems (1)) were answered 
on a 4 or 5-point Likert-scale ranging from ‘never’ to ‘always’. Four questions (bowel problems (1), 
voiding problems (2), lymphedema (1)) were answered on a 3-point ordinal scale (yes/sometimes/
no). Two questions (sexual function) were answered on a dichotome scale (yes/no). In order to obtain 
an uniform answering format for all the 14 items, the 3, 4 and 5-point scales were dichotomized. 
Dichotome answer categories were obtained by adding up the answer categories. Since the score on 
each item did not indicate that a higher score means more endorsement it depends on the score how 
the dichotome answer categories were computed: 3-point scale: ‘yes and sometimes’ versus ‘no’ or ‘no 
and sometimes’ versus ‘yes’; 4/5-point scale: ‘sometimes, often and always’ versus ‘seldom and never’ 
or ‘often and always’ versus ’sometimes, seldom and never’.
1 At the time of the current study the Gynaecologic LQ was not yet validated. Recently, the validation of 
the psychometric properties of the items concerning sexual functioning of the Gynaecologic LQ was 
performed (Chapter 5). The results of that study support the reliability and psychometric validity of 
the Gynaecologic LQ in the assessment of sexual functioning and vaginal changes in gynaecological 
cancer patients (Chapter 5).
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Data analyses
Sexual function, voiding and bowel dysfunction were analyzed in four ways: before versus after the op-
eration, changes since the operation, premenopausal versus postmenopausal, patient versus control, 
and radiotherapy versus no radiotherapy.
The responses to the questionnaires were dichotomized and the results are presented as relative risks 
(RR) and corresponding 95% confi dence intervals (CI). RR was calculated as the proportion of women 
with cervical cancer before the treatment reporting the particular problem divided by the proportion of 
these women after the surgery. The same was done for the patients versus the controls, radiotherapy 
versus no radiotherapy and pre menopausal versus postmenopausal. In some cases, the relative risk 
could not be computed, because of zero counts. When this occurred, we added 1 to each cell of the two 
by two table (an application of Laplace’s rule of succession).
We used the scores from all the sexual function items in the 24 months questionnaire to compare 
the sexual situation at 24 months after the surgery with the situation before treatment. The possible 
options were better, no change or worse. The Chi square test was used to test whether the score dis-




A total of 94 consecutive women were included in the study. Analysis was performed 2 years after 
involvement of the last patient. Seventy-three women fi lled in all the questionnaires, in 21 cases data 
were not available. Nine women did not return all the questionnaires for unknown reasons, they all 
had a complete remission and are still alive. Two women moved to another city or country. Ten women 
died. Of these last women, 9 died as a result of the cervical carcinoma and 1 woman due to a cerebral 
tumour. The mean age at the time of the operation was 43.3 years (SD 11.0) (Range 21-72 years). The 
characteristics and distribution of treatment of the patients are shown in Tables 1 and 2. The control 
group consisted of 224 women. All characteristics of the control group are shown in Table 1. Thirty-one 
women became postmenopausal because they received radiotherapy or their ovaries were removed. 
Eleven of them used hormonal replacement therapy (HRT) after the treatment.
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Characteristics before operation Women with Cancer 
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   9(10)
   36(39)
   27(29)
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   65(70)
   13(14)
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Table 1. Characteristics of patients and controls.
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Table 2. Treatment characteristics of the cervical cancer patients. * Total number varies between 91-94, because of 
missing data.
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Patient before surgery versus patient after surgery
The absolute numbers, RR and corresponding 95% CI for all items are shown in Table 3.
Patients had signifi cantly more lymphedema 3 months after the treatment up to 24 months follow-up. 
At the 3 months follow-up, a signifi cantly larger percentage of the patients complained of little or no 
urge to urinate. After 12 months follow-up a signifi cantly larger percentage of the patients reported 
moderate urine incontinence. Only after 24 months follow-up a signifi cantly larger percentage of the 
patients complained of “little or no lubrication” during sexual arousal compared to the pre-surgery 
levels. Compared to the situation before the operation, throughout the fi rst 24 months a signifi cantly 
larger percentage of the patients reported complaints of pain during coitus, a short vagina, numb areas 
around the labia, dry vagina during coitus and dissatisfaction with sexual relationship.
No/total no.responding (%)
Before 3 Months 12 Months 24 Months 
surgery
Characteristics Patient Patient RR(95%CI) Patient RR(95%CI) Patient RR(95%CI)
Often diarrhoea 1/94(1) 5/93(5) 5.1(0.6-42) 4/77(5) 4.9(0.6-43) 2/73(3) 2.6(0.2-28)
Often constipation 3/94(3) 3/93(3) 1.0(0.2-4.9) 4/77(5) 1.6(0.4-7.1) 3/73(4) 1.3(0.3-6.2)
Little/no urge 0/93(0) 10/93(11) 11(1.5-84)* 5/77(7) 7.2(0.9-59)* 4/73(6) 6.4(0.8-53)*
Severe incontinence 0/94(0) 1/93(1) 2.0(0.2-22)* 1/76(1) 2.5(0.2-27)* 1/73(1) 2.6(0.2-28)*
Moderate incontinence 24/94(26) 30/93(32) 1.3(0.8-2.0) 34/76(45) 1.7(1.1-2.6) 30/73(41) 1.5(0.97-2.3)
Lymphedema 0/94(0) 8/92(9) 9.2(1.2-71)* 11/78(14) 14(1.9-109)* 14/73(19) 19(2.6-142)*
Numbness thigh/labia 3/90(3) 69/90(77) 23(7.5-70) 59/78(76) 25(8.1-76) 52/73(71) 22(7.0-66)
Not sexual active lately 41/91(45) 37/89(42) 0.9(0.7-1.3) 21/78(27) 0.6(0.4-0.9) 21/73(29) 0.6(0.4-1.0)
Little or no interest in sex 16/90(18) 25/90(28) 1.6(0.9-2.7) 20/78(26) 1.3(0.8-2.4) 18/73(25) 1.4(0.8-2.5)
Little or no lubrication 3/80(4) 7/69(10) 2.7(0.7-10) 4/65(6) 2.0(0.5-8.2) 9/64(14) 3.8(1.1-13)
during sexual arousal
Dry vagina during coitusª 5/78(6) 9/55(16) 2.6(0.9-7.2) 10/60(17) 3.1(1.1-8.2) 13/55(24) 4.6(1.7-12)
Narrow or short vaginaª 2/77(3) 10/55(18) 7.0(1.6-31) 9/59(15) 5.9(1.3-26) 14/55(25) 9.9(2.4-42)
Pain during coitusª 5/78(6) 8/55(15) 2.3(0.8-6.6) 11/59(19) 3.1(1.2-8.4) 10/55(18) 2.9(1.0-9.7)
No orgasm during coitusª 16/79(20) 18/58(31) 1.5(0.9-2.7) 18/60(30) 1.4(0.8-2.5) 18/55(33) 1.6(0.9-2.9)
No satisfaction with 4/76(5) 8/66(12) 2.3(0.7-7.3) 11/62(18) 3.3(1.1-10) 13/58(22) 4.3(1.5-12)
sex life
Table 3. Prevalence and relative risk of micturation, defecation, lymphedema and sexual complaints after a radical  
hysterectomy with or without radiotherapy in a group of patients (n=94) before surgery compared to 3, 12 and  
24 months after surgery. RR: relative risk; 95% CI:95% confi dence interval. Bold numbers indicate signifi cance   
at the 5% level. * Laplace succession rule. ª This question was not answered when the women never had coitus. 
Bladder, colorectal and sexual function after radical hysterectomy
92 
Changes since the operation
We also calculated the change of all the sexual function items 24 months after the treatment (Table 4). 
Only the sexual activity had increased two years after the operation. All the other items deteriorated 
within 24 months of follow-up.
Premenopausal versus postmenopausal
The ovaries were removed in 26 patients and 36 received radiotherapy. Analysis comparing premeno-
pausal (i.e. women who stayed premenopausal and women who received HRT) versus postmenopausal 
women or women who became postmenopausal after the treatment, did show some differences. The 
absolute numbers, RR and corresponding 95% CI for all items are shown in Table 5. A signifi cantly 
larger percentage of the patients who were postmenopausal before the treatment reported to be less 
sexually active lately and were less interested in sex compared to the women who were premenopausal. 
After the treatment a signifi cantly larger percentage of the patients who were already postmenopausal 
before the treatment and the patients who became postmenopausal after the treatment, complained 
of no or less sexual activity and no or less interest in sex, up to 24 months follow-up. After 2 years 
follow-up only a signifi cantly larger percentage of the patients who were postmenopausal after the 
treatment complained of a narrow or short vagina compared to the women who were premenopausal 
after the treatment. No other differences after 2 years follow-up were found.
Patient versus control
The absolute numbers, RR and corresponding 95% CI for all items are shown in Table 6.
After 3 and 12 months follow-up, a signifi cantly larger percentage of patients reported diarrhoea 
and more problems with urge to urinate compared to women in the control group. After 2 years, the 
differences between the patients and controls concerning bladder dysfunction and colorectal motil-
ity disorders, were no longer statistically signifi cant. Up to 2 years follow-up a signifi cantly larger 
percentage of the patient group reported lymphedema than the control group.
Change since operation
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 Table 4. Change of all the sexual function items 24 months after the  treatment (n=73). 
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  Before surgery 3 Months 12 Months  24 Months 
Characteristics pre  post pre post pre post pre post
Often diarrhoea       
no./total no.(%)  1/77(1) 0/16(0) 1/57(2) 4/35(11) 2/49(4) 2/27(7) 1/47(2) 1/25(4) 
RR pre- vs 
postmenopausal(95%CI) 1.0 2.3(0.2-24)* 1.0 
6.5(0.8-
56) 1.0 1.8(0.3-12) 1.0 1.9(0.1-29) 
Often constipation          
no./total no.(%)  2/77(3) 1/16(6) 2/57(4) 1/35(3) 2/49(4) 1/27(4) 1/47(2) 1/25(4) 
RR pre- vs 
postmenopausal(95%CI) 1.0 2.4(0.2-25) 1.0 
0.8(0.1-
8.7) 1.0 0.9(0.1-9.6) 1.0 1.9(0.1-29) 
Little/no urge         
no./total no.(%)  0/77(0) 0/16(0) 6/57(11) 4/35(11) 3/49(6) 2/27(7) 3/47(6) 1/25(4) 
RR pre- vs 
postmenopausal(95%CI) 1.0 4.6(0.3-70)* 1.0 
1.1(0.3-
3.6) 1.0 1.2(0.2-6.8) 1.0 0.6(0.1-5.7) 
Severe  incontinence         
no./total no.(%)  0/77(0) 0/16(0) 0/57(0) 1/35(3) 0/48(0) 1/27(4) 1/47(2) 0/25(0) 
RR pre- vs 







Moderate incontinence         
no./total no.(%)  18/77(23) 5/16(31) 20/57(35) 9/35(26) 20/48(42) 13/27(48) 18/47(38) 12/25(48) 
RR pre- vs 
postmenopausal(95%CI) 1.0 1.3(0.6-3.1) 1.0 
0.7(0.4-
1.4) 1.0 1.2(0.7-1.9) 1.0 1.3(0.7-2.2) 
Lymphedema          
no./total no.(%)  0/77(0) 0/16(0) 5/56(9) 3/35(9) 6/49(12) 5/28(18) 11/47(23) 3/25(12) 
RR pre- vs 
postmenopausal(95%CI) 1.0 4.6(0.3-70)* 1.0 
1.0(0.2-
3.8) 1.0 1.5(0.5-4.4) 1.0 0.5(0.2-1.7) 
Numbness thigh/labia         
no./total no.(%)  2/75(3) 1/14(7) 43/56(77) 26/33(79) 39/49(80) 20/28(71) 33/47(70) 18/25(72) 
RR pre- vs 
postmenopausal(95%CI) 1.0 2.7(0.3-28) 1.0 
1.0(0.8-
1.3) 1.0 0.9(0.7-1.2) 1.0 1.0(0.8-1.4) 
Not sexual active lately      
no./total no.(%)  29/74(40) 12/16(75) 14/56(25) 23/32(72) 7/49(14) 14/28(50) 8/47(17) 12/25(48) 
RR pre- vs 
postmenopausal(95%CI) 1.0 1.9(1.3-2.9) 1.0
2.9(1.7-
4.8) 1.0 3.5(1.6-7.6) 1.0 2.8(1.3-6.0) 
Little or no interest in sex         
no./total no.(%)  7/74(10) 9/15(20) 10/56(18) 15/33(45) 5/49(10) 15/29(54) 7/47(15) 11/25(44) 
RR pre- vs 
postmenopausal(95%CI) 1.0 6.3(2.8-14) 1.0
2.6(1.3-
5.0) 1.0 5.3(2.1-13) 1.0 3.0(1.3-6.7) 
Little or no lubriaction during         
sexual arousal          
no./total no.(%)  1/68(2) 2/11(2) 5/51(10) 2/17(12) 2/47(4) 2/17(12) 6/46(13) 3/17(18) 
RR pre- vs 
postmenopausal(95%CI) 1.0 12(1.2-125) 1.0
1.2(0.3-
5.6) 1.0 2.8(0.4-18) 1.0 1.4(0.4-4.8) 
Dry vagina during coitusª         
no./total no.(%)  2/68(3) 3/9(33) 8/43(19) 1/11(9) 8/43(19) 2/16(13) 11/41(27) 2/13(8) 
RR pre- vs 
postmenopausal(95%CI) 1.0 11(2.2-59) 1.0
0.5(0.1-
3.5) 1.0 0.7(0.2-2.8) 1.0 0.6(0.2-2.3) 
Narrow or short vaginaª         
no./total no.(%)  1/68(2) 1/8(13) 7/43(16) 3/11(27) 6/43(14) 3/15(20) 6/41(15) 7/13(54) 





5.5) 1.0 1.4(0.4-5.0) 1.0 3.4(1.4-8.5) 
Pain during coitusª          
no./total no.(%)  4/68(6) 1/9(11) 6/43(14) 2/11(18) 7/43(16) 4/15(27) 7/41(17) 3/13(23) 
RR pre- vs 
postmenopausal(95%CI) 1.0 1.9(0.2-15) 1.0 
1.3(0.3-
5.6) 1.0 1.6(0.6-4.8) 1.0 1.4(0.4-4.5) 
No orgasm during coitusª         
no./total no.(%)  11/68(16) 5/10(50) 13/44(30) 5/13(39) 9/43(21) 8/16(50) 11/41(27) 6/13(46) 
RR pre- vs 
postmenopausal(95%CI) 1.0 3.1(1.4-7.0) 1.0
1.3(0.6-
3.0) 1.0 2.4(1.1-5.1) 1.0 1.7(0.8-3.7) 
Not content with sex life         
no./total no.(%) 2/68(3) 2/7(29) 3/48(6) 5/17(29) 7/46(15) 4/15(27) 10/43(23) 3/14(21) 
RR pre- vs 
postmenopausal(95%CI) 1.0 9.7(1.6-58) 1.0
4.7(1.3-
18) 1.0 1.8(0.6-5.2) 1.0 0.9(0.3-2.9) 
Table 5. Age adjusted relative risks of colorectal motility disorders, bladder dysfunction, lymphedema and sexual 
dysfunction. Premenopausal (n=77) versus postmenopausal (n=16). RR: relative risk; 95% CI:95% confi dence interval. 
Bold numbers indicate signifi cance at the 5% level. * Laplace succession rule. ª This question was not answered when 
the women never had coitus. Pre, premenopausal; post, postmenopausal.
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Before the operation, a signifi cantly larger percentage of the patients reported to be not sexually active 
lately, to have little or no interest in sex, and having more pain during coitus compared to the control 
group. Throughout the 2 years follow-up, this statistical signifi cance persisted. Little or no lubrication 
during sexual arousal was reported by a signifi cantly larger percentage of the patients after 3 and 24 
months. A dry vagina during coitus, a narrow or short vagina and numb areas around the labia all 
signifi cantly increased throughout the fi rst 2 years after the treatment. The percentage of patients 
who complained of no orgasm during coitus was never statistically signifi cant. A signifi cantly larger 
percentage of the patients reported dissatisfaction with their sex life compared to the controls up to 2 
years of follow-up.
Radiotherapy versus no radiotherapy
We compared the patients with adjuvant pelvic radiotherapy to the patients without adjuvant pelvic 
radiotherapy. Thirty-six of the 94 patients received adjuvant radiotherapy after surgery. The absolute 
numbers, RR and corresponding 95% CI for all items are shown in Table 7.
When compared to surgery alone, the patients with adjuvant pelvic radiotherapy were not more often 
signifi cantly associated with bladder dysfunction, colorectal motility dysfunction or lymphedema. Only 
No/total no.responding (%)
Before surgery 3 Months 12 Months 24 Months 
Characteristics Control Patient RR(95%CI) Patient RR(95%CI) Patient RR(95%CI) Patient RR(95%CI)
Often diarrhoea 2/223(1) 1/94(1) 1.2(0.1-13) 5/93(5) 6.0(1.2-30) 4/77(5) 5.8(1.1-31) 2/73(3) 3.1(0.4-21)
Often constipation 5/223(2) 3/94(3) 1.4(0.4-5.8) 3/93(3) 1.4(0.4-5.9) 4/77(5) 2.3(0.6-84) 3/73(4) 1.8(0.5-7.5)
Little/no urge 4/223(2) 0/93(0) 0.5(0.1-4.0)* 10/93(11) 6.0(1.9-19) 5/77(7) 3.6(1.0-13) 4/73(6) 3.1(0.8-12)
Severe incontinence 0/224(0) 0/94(0) 2.4(0.2-37)* 1/93(1) 4.8(0.4-52)* 1/76(1) 5.8(0.5-64)* 1/73(1) 6.2(0.6-67)*
Moderate incontinence 75/224(33) 24/94(26) 0.8(0.5-1.1) 30/93(32) 1.0(0.7-1.4) 34/76(45) 1.3(0.98-1.8) 30/73(41) 1.2(0.9-1.7)
Lymphedema 7/224(3) 0/94(0) 0.3(0.0-2.3)* 8/92(9) 2.8(1.0-7.5) 11/78(14) 4.5(1.8-11) 14/73(19) 6.1(2.6-15)
Numbness thigh/labia 2/223(1) 3/90(3) 3.7(0.6-22) 69/90(77) 86(21-341) 59/78(76) 84(21-337) 52/73(71) 79(20-318)
Not sexual active lately 37/224(17) 41/91(45) 2.7(1.9-4.0) 37/89(42) 2.5(1.7-3.7) 21/78(27) 1.6(1.0-2.6) 21/73(29) 1.7(1.1-2.8)
Little or no interest in sex 16/222(7) 16/90(18) 2.5(1.3-4.7) 25/90(28) 3.9(2.2-6.9) 20/78(26) 3.6(1.9-6.5) 18/73(25) 3.4(1.8-6.4)
Little or no lubrication 6/213(3) 3/80(4) 1.3(0.3-5.2) 7/69(10) 3.6(1.3-10) 4/65(6) 2.2(0.6-7.5) 9/64(14) 5.0(1.9-14)
during sexual arousal
Dry vagina during coitusª 8/195(4) 5/78(6) 1.6(0.5-4.6) 9/55(16) 4.0(1.6-10) 10/60(17) 4.1(1.7-9.8) 13/55(24) 5.8(2.5-13)
Narrow or short vaginaª 4/196(2) 2/77(3) 1.3(0.2-6.8) 10/55(18) 8.9(2.9-27) 9/59(15) 7.5(2.4-23) 14/55(25) 13(4.3-36)
Pain during coitusª 3/196(2) 5/78(6) 4.2(1.0-17) 8/55(15) 9.5(2.6-35) 11/59(19) 12(3.5-42) 10/55(18) 12(3.4-42)
No orgasm during coitusª 41/196(21) 16/79(20) 1.0(0.6-1.6) 18/58(31) 1.5(0.9-2.4) 18/60(30) 1.4(0.9-2.3) 18/55(33) 1.6(0.98-2.5)
No satisfaction with 6/202(3) 4/76(5) 1.8(0.5-6.1) 8/66(12) 4.1(1.5-11) 11/62(18) 6.0(2.3-15) 13/58(22) 7.6(3.0-19)
sex life
Table 6. Prevalence and relative risk of micturation, defecation, lymphedema and sexual complaints after a RHL with 
or without radiotherapy in a group of patients (n=94) compared to age matched control women from the general 
population (=224), 3, 12 and 24 months after surgery. RR: relative risk; 95% CI:95% confi dence interval. Bold 
numbers indicate signifi cance at the 5% level. * Laplace succession rule. ª This question was not  answered when the 
women never had coitus.
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at 3 months follow-up, a signifi cantly larger percentage of patients with adjuvant pelvic radiotherapy 
experienced more often diarrhoea and at 12 months follow-up moderate urine incontinence (Table 7).
Before surgery 3 Months 12 Months 24 Months 
Characteristics no RT RT no RT  RT no RT  RT no RT  RT
Often diarrhoea
no./total no.(%) 1/58(2) 0/36(0) 0/58(0) 5/35(14) 1/48(2) 3/29(10) 0/47(0) 2/26(8)
RR RT vs surgery alone(95%CI) 1.0 0.8(0.1-8.5)* 1.0 10(1.3-80)* 1.0 5.0(0.5-46) 1.0 5.3(0.6-49)*
Often constipation
no./total no.(%) 0/58(0) 3/36(8) 2/58(3) 1/35(3) 2/48(4) 2/29(7) 3/47(6) 0/26(0)
RR RT vs surgery alone(95%CI) 1.0 6.4(0.7-55)* 1.0 0.8(0.1-8.8) 1.0 1.7(0.3-11) 1.0 0.4(0.1-3.8)*
Little/no urge
no./total no.(%) 0/57(0) 0/36(0) 5/58(9) 5/35(14) 1/49(2) 4/28(14) 1/47(2) 3/26(12)
RR RT vs surgery alone(95%CI) 1.0 1.6(0.1-24)* 1.0 1.7(0.5-5.3) 1.0 7.0(0.8-60) 1.0 5.4(0.6-50)
Severe  incontinence
no./total no.(%) 0/58(0) 0/36(0) 0/58(0) 1/35(3) 0/49(0) 1/27(4) 0/47(0) 1/26(4)
RR RT vs surgery alone(95%CI) 1.0 1.6(0.1-25)* 1.0 2.3(0.3-35)* 1.0 3.6(0.3-38)* 1.0 3.6(0.3-37)*
Moderate incontinence
no./total no.(%) 11/58(19) 13/36(36) 20/58(35) 10/35(29) 18/49(37) 16/27(59) 18/47(38) 12/26(46)
RR RT vs surgery alone(95%CI) 1.0 1.9(0.96-3.8) 1.0 0.8(0.4-1.6) 1.0 1.6(1.0-2.6) 1.0 1.2(0.7-2.1)
Lymphedema
no./total no.(%) 0/58(0) 0/36(0) 4/57(7) 4/35(11) 4/49(8) 7/29(24) 8/47(17) 6/26(23)
RR RT vs surgery alone(95%CI) 1.0 1.6(0.1-25)* 1.0 1.6(0.4-6.1) 1.0 3.0(0.95-9.2) 1.0 1.4(0.5-3.5)
Numbness thigh/labia
no./total no.(%) 1/56(2) 2/34(6) 48/57(84) 21/33(64) 39/49(80) 20/29(69) 36/47(77) 16/26(62)
RR RT vs surgery alone(95%CI) 1.0 3.2(0.3-35) 1.0 0.8(0.6-1.0) 1.0 0.9(0.7-1.2) 1.0 0.8(0.6-1.1)
Not sexual active lately
no./total no.(%) 25/56(45) 16/35(46) 18/57(32) 19/32(59) 11/49(22) 10/29(35) 10/47(21) 11/26(42)
RR RT vs surgery alone(95%CI) 1.0 1.0(0.6-1.6) 1.0 1.9(1.2-3.0) 1.0 1.5(0.8-3.2) 1.0 2.0(0.98-4.0)
Little or no interest in sex
no./total no.(%) 7/56(13) 9/34(27) 14/57(25) 11/33(33) 10/49(20) 10/29(35) 9/47(19) 9/26(35)
RR RT vs surgery alone(95%CI) 1.0 2.1(0.9-5.2) 1.0 1.4(0.7-2.6) 1.0 1.7(0.8-3.6) 1.0 1.8(0.8-4.0)
Little or no lubriaction during
sexual arousal
no./total no.(%) 1/51(2) 2/29(7) 4/48(8) 3/21(14) 2/44(5) 2/21(10) 6/43(14) 3/21(14)
RR RT vs surgery alone(95%CI) 1.0 3.5(0.3-37) 1.0 1.7(0.4-7.0) 1.0 2.1(0.3-14) 1.0 1.0(0.3-3.7)
Dry vagina during coitusª
no./total no.(%) 3/50(6) 2/28(7) 7/41(17) 2/14(14) 5/40(13) 5/20(25) 9/38(24) 4/17(24)
RR RT vs surgery alone(95%CI) 1.0 1.2(0.2-6.7) 1.0 0.8(0.2-3.6) 1.0 2.0(0.7-6.1) 1.0 0.1(0.4-2.8)
Narrow or short vaginaª
no./total no.(%) 2/49(4) 0/28(0) 5/41(12) 5/14(36) 5/40(13) 4/19(21) 7/38(18) 7/17(41)
RR RT vs surgery alone(95%CI) 1.0 0.6(0.1-5.3)* 1.0 2.9(0.99-8.6) 1.0 1.7(0.5-5.6) 1.0 2.2(0.93-5.4)
Pain during coitusª
no./total no.(%) 4/50(8) 1/28(4) 6/41(15) 2/14(14) 6/40(15) 5/19(26) 6/38(16) 4/17(24)
RR RT vs surgery alone(95%CI) 1.0 0.5(0.1-3.8) 1.0 1.0(0.2-4.3) 1.0 1.8(0.7-5.0) 1.0 1.5(0.5-4.6)
No orgasm during coitusª
no./total no.(%) 8/50(16) 8/29(28) 12/42(29) 6/16(38) 11/40(28) 7/20(35) 12/38(32) 6/17(35)
RR RT vs surgery alone(95%CI) 1.0 1.7(0.7-4.1) 1.0 1.3(0.6-2.9) 1.0 1.3(0.6-2.8) 1.0 1.1(0.5-2.5)
Not content with sex life
no./total no.(%) 3/51(6) 1/25(4) 3/44(7) 5/22(23) 8/42(19) 3/20(15) 11/41(27) 2/17(12)
RR RT vs surgery alone(95%CI) 1.0 0.7(0.1-6.2) 1.0 3.3(0.9-13) 1.0 0.8(0.2-2.7) 1.0 0.4(0.1-1.8)
Table 7. Age adjusted relative risks of colorectal motility disorders, bladder dysfunction, lymphedema and sexual 
dysfunction. Radiotherapy (n=36) versus no radiotherapy (n=58). RR: relative risk; 95% CI:95% confi dence interval. 
Bold numbers indicate signifi cance at the 5% level. *Laplace succession rule. ª This question was not answered when 
the women never had coitus. RT, radiotherapy.
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After 3 months a signifi cantly larger percentage of patients with adjuvant pelvic radiotherapy were less 
sexually active lately compared to the patients without adjuvant radiotherapy. No signifi cant differ-
ences in the percentages were found between the two patient groups for numb areas around the labia, 
dry vagina, pain during coitus, narrow vagina, little or no lubrication, sexual activity, interest in sex, 
satisfaction with sex life, and orgasm (Table 7).
Discussion
The current study shows that treatment for cervical cancer stage I-IIa by RHL with or without adjuvant 
pelvic radiotherapy has a negative effect on sexual function. The difference in sexual function was 
not only signifi cant compared to the controls but also compared to the sexual situation before the 
treatment. The changes or problems included less lubrication, a narrow and short vagina, numb areas 
around the labia, dyspareunia and sexual dissatisfaction. Furthermore, in the long term no differences 
were observed for bladder and colorectal dysfunction.
Retrospective studies of frequency of late postoperative micturition and colorectal problems show 
various fi gures: incontinence in 10-12%, urinary retention or inability to void in 2-4% and severe 
constipation in 5-10% (6;10;26;27). After 2 years follow-up, we found no signifi cant difference any-
more concerning bladder dysfunction and colorectal dysfunction compared to the control group and 
compared to the situation before surgery. Contrary to these fi ndings, Sood et al.(31), for example, 
have shown that anorectal manometry revealed signifi cant changes in colorectal function after RHL, 
showing a pattern which correlates to a partial denervation of the bowel (31). Furthermore, results of 
urodynamic studies evaluating urinary dysfunction in patients after RHL are suggestive for disruption 
of the autonomic nerve supply to the bladder and urethra (8;9). The fact that the patients in our study 
did not report a signifi cant difference in bladder and colorectal functions 24 months after the opera-
tion compared with the situation before the operation might be a refl ection of post-surgical recovery or 
an indication that the perception of quality of life may be independent of there objective measures. The 
relief resulting from the completion of this potentially curative treatment may also have contributed to 
the subjective improvement despite changes in bowel and bladder function. And fi nally, most studies 
of colorectal and micturial dysfunction offer data collected from the medical fi les (6;10;26;27). This 
study used questionnaires and has a longitudinal design what makes it more diffi cult to compare with 
the literature.
In the literature, secondary lymphedema after RHL is reported up to 23% (28;29). We found percent-
ages of up to 19%. As well as compared to the control group as compared to the situation before 
the operation, a signifi cantly larger percentage of the patients complained of lymphedema up to 24 
months of follow-up.
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As to the short-term effects of RHL on sexual function, Grumann et al. (21) assessed in a study of 
20 women with early stage cervical carcinoma the effects of RHL on the sexual function up to 8 
months. They found that women with cancer had vaginal dryness 4 and 8 months after the operation 
and reduced sexual activity. Modest but consistent downward trends regarding sexual activity, sexual 
desire, excitement, orgasm, and resolution were found 4 and 8 months after surgery, although these 
last items were not statistically signifi cant (21). Jensen et al. also found short-term adverse effects on 
sexual function: dyspareunia, short vagina and sexual dissatisfaction (5). In line with these results, we 
also found that during the fi rst months after the operation women with early stage cervical cancer have 
sexual dysfunction.
Concerning the long-term effects, Butler-Manual found in a retrospective survey of women who 
had undergone RHL with or without radiotherapy a signifi cant increase of vaginal dryness during 
sexual activity and dissatisfaction with their sexlife (16). In their cross-sectional study, Bergmark et 
al. compared 256 women with a history of early stage cervical cancer with 350 controls using vali-
dated questionnaires. They found that the patients had decreased lubrication, genital swelling during 
arousal, and a short vagina during intercourse (3). The long-term effects that Jensen et al. reported 
were complaints that persisted after 2 years and included less vaginal lubrication and sexual interest 
(5). We also fi nd these long-term effects on sexual function. The short term effects described above by 
Jensen et al., still persisted after 2 years follow-up in the current study. In agreement with these authors 
it can be concluded that up to 2 years after the RHL, women with early stage cervical cancer experience 
negative effects on sexual function.
In the current study, 38% received radiotherapy after the operation. A signifi cantly larger percent-
age of patients with adjuvant radiotherapy were less sexually active and had more diarrhoea after 3 
months follow-up. At 12 months follow-up, a signifi cantly larger percentage of patients with adjuvant 
radiotherapy had moderate incontinence. But adjuvant radiotherapy did not increase the risk of blad-
der dysfunction, colorectal motility disorders, lymphedema and other sexual functions after 2 years 
follow-up.
One would expect that hormonal status particularly infl uences the sexual functioning, because castra-
tion lowers serum testosterone and estrogens concentrations (3). In line with this, the current study 
showed that up to 2 years follow-up women who were postmenopausal or became postmenopausal 
had less libido and were less sexually active compared to the women who were premenopausal. How-
ever, Bergmark et al. suggested that ovarian hormones have minor effects on libido or the frequencies 
of sexual intercourse (3). In the current study, a signifi cantly larger percentage of the patients who 
were postmenopausal after the treatment reported a narrow or short vagina after 2 years follow-up. 
Most patients who became postmenopausal after the treatment had received adjuvant radiotherapy. 
Although adjuvant radiotherapy did not show an increase risk on sexual function, a short or narrow 
vagina is an effect of the adjuvant radiotherapy and not due to hormonal changes directly (20). This 
could explain the difference that a signifi cantly larger percentage of the patients who were postmeno-
Bladder, colorectal and sexual function after radical hysterectomy
98 
pausal after the treatment reported a narrow or short vagina compared to the premenopausal patients. 
Other signifi cant differences were not found. We suggest that the hormonal status has less effect on 
complaints as pain during coitus, less lubrication and orgasm.
Autonomic nerve damage during surgery is thought to play a crucial role in the aetiology of bladder 
dysfunction, colorectal motility disorders and sexual dysfunction that can be seen after RHL. The 
autonomic nerves are essential for a normal physiologic function and neurogenic control of the pelvic 
organs (11;22;26;27;30-32). The autonomic nerves for example, supply the blood vessels of the inter-
nal genitalia and are involved in the neural control of vasocongestion and, consequently, lubrication 
swelling response (32). Evidence from surgical practice has shown that a lesser extent of surgically 
infl icted autonomic nerve injury lowers the incidence of morbidity (33-36).
In our centre, we used photoplethysmographic assessment of vaginal pulse amplitude to measure 
objectively the vaginal blood fl ow during sexual arousal (30;37). Increased vaginal blood fl ow during 
sexual arousal refl ects a highly automatized genital response mechanism, occurring irrespectively of 
subjective appreciation of the sexual stimulus (38;39). From this study, it was concluded that a RHL 
seems to be associated with a disturbed vaginal blood fl ow response during sexual arousal caused by 
denervation of the vagina (40).
The surgical concept of the identifi cation and preservation of the pelvic autonomic nerves was intro-
duced by Japanese gynaecologists in the sixties (36). Recently, the Leiden Medical Centre developed 
a nerve-sparing technique that is described elsewhere (11). This technique was not yet utilized in the 
present study and the benefi t of this procedure will be studied in a multicentre prospective trial in order 
to establish the results of nerve-sparing surgery and the effects on sexual functioning.
The current study did show sexual dysfunction after treatment for low stage cervical carcinoma. It is 
the fi rst longitudinal study of self-reported bladder, defecation, sexual and vaginal problems with a 
baseline score before the RHL. We compared the morbidity after treatment with the situation before 
treatment and the normal population. As could be expected, before the operation a signifi cantly larger 
percentage of the patients reported not to be sexually active, have little or no interest in sex and have 
more pain during coitus, compared to the healthy controls. Probably this has to do with their disease 
status itself or with the psychological impact of the illness. Psychological function and quality of life 
status effect sexual function in women (41). Future research on the effect of RHL should therefore 
include self-report measures of sexual functioning as well as of depression, anxiety and quality of life 
issues including relationship parameters. The control group consisted of employees from the hospi-
tals and relatives and friends of these employees, who had not undergone a hysterectomy in the past. 
Although the control group was not an a-select sample of the Dutch general population, the control 
group was matched for age, as this is related to sexual function (41). We used the Gynaecologic Leiden 
Questionnaire, which is the fi rst developed Dutch questionnaire consisting of the items for sexual 
dysfunction, voiding- and bowel problems for women with cancer.
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This study has an observational design. Despite this, we conclude that RHL for the treatment of early 
stage cervical carcinoma is associated with adverse effects mainly on sexual functioning. Adjuvant 
radiotherapy after RHL seemed not to be a major factor contributing to the complaints, in the present 
study. Whether or not the nerve sparing technique will lead to lower morbidity with comparable treat-
ment results will have to be established.
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Abstract
Objective: Radical hysterectomy with pelvic lymphadenectomy (RHL) for cervical cancer causes dam-
age to the autonomic nerves which are responsible for increased vaginal blood fl ow during sexual 
arousal. The aim of the study of which we now report preliminary data was to determine whether 
a nerve-sparing technique leads to an objectively less disturbed vaginal blood fl ow response during 
sexual stimulation.
Methods: Photoplethysmographic assessment of vaginal pulse amplitude (VPA) during sexual stimula-
tion by erotic fi lms was performed. Subjective sexual arousal was assessed after each stimulus. Thirteen 
women after conventional RHL, 10 women after nerve-sparing RHL and 14 healthy premenopausal 
women participated. Data were collected between January and August 2006. The main outcome mea-
sure was the logarithmically transformed mean VPA. To detect statistically signifi cant differences in 
mean VPA levels between the three groups, a univariate analysis of variance was used.
Results: Mean VPA differed between the three groups (p= 0.014). The conventional group had a lower 
vaginal blood fl ow response than the control group (p = 0.016), which tended also to be lower than 
that of the nerve-sparing group (p= 0.097). These differences were critically dependent on baseline 
vaginal blood fl ow differences between the groups. The conventional group follows a vaginal blood 
fl ow pattern similar to postmenopausal women.
Conclusions: Conventional RHL is associated with an overall disturbed vaginal blood fl ow response 
compared to healthy controls. Since it is not observed to the same extent after nerve-sparing RHL, 
it seems that the nerve-sparing technique leads to a better overall vaginal blood fl ow caused by less 
denervation of the vagina.
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Introduction
Women with a history of radical hysterectomy with pelvic lymphadenectomy for cervical cancer (RHL) 
report a decrease in sexual interest, vaginal lubrication and genital swelling, which compromises 
sexual activity and results in considerable distress (1-4). Surgical damage to the pelvic autonomic 
nerves is responsible for a considerable part of the morbidity following radical hysterectomy (5-7). 
During radical hysterectomy the nerve supply to the blood vessels of the vaginal wall that is responsible 
for the neural control of the lubrication response is disrupted (1;4;5;8).
Psychophysiological assessment using photoplethysmographic vaginal pulse amplitude has been 
proven to be reliable in assessing the increase in vaginal blood fl ow during sexual arousal (9-11). The 
increased vaginal blood fl ow refl ects a highly automated genital response mechanism, occurring irre-
spectively of subjective appreciation of the sexual stimulus (12;13). The genital physiological response 
is an involuntary refl ex mediated by the (unconscious) autonomic nervous system (14;15). Maas et 
al. performed a study in which vaginal pulse amplitude during sexual stimulation by erotic fi lms was 
assessed in women with a history of conventional RHL, women with a history of simple abdominal 
hysterectomy and in age-matched healthy controls. The results of the study indicated that conventional 
RHL is associated with a disturbed vaginal blood fl ow response during sexual arousal. The disturbed 
response could not be explained solely by uterus extirpation, since it was not observed to the same 
extent after simple hysterectomy. The difference in outcome might be related to a more extended 
denervation of the vagina with increasing radicality of surgery (10). A surgical technique in which the 
autonomic nerves are identifi ed and subsequently preserved during surgery was developed at the Leiden 
University Medical Centre (LUMC) (6). The technique involved three steps: fi rst, the identifi cation and 
preservation of the hypogastric nerve in a loose tissue sheath underneath the ureter and lateral to the 
sacrouterine ligaments; second, the inferior hypogastric plexus in the parametrium is lateralized and 
avoided during parametrial transsection; third, the most distal part of the inferior hypogastric plexus 
is preserved during the dissection of the posterior part of the vesico-uterine ligament.
The aim of the study of which we now report preliminary data was to determine whether the nerve-
sparing technique indeed leads to an objectively less disturbed vaginal blood fl ow response during 
sexual stimulation. Genital arousal was assessed by a photoplethysmograph, during sexual stimula-
tion by erotic fi lm in women with a history of a conventional RHL, in women with a history of a nerve-
sparing RHL and in healthy premenopausal women. Subjective sexual arousal was assessed after each 
stimulus and self-report questionnaires were used to assess sexual functioning.




Since 2000 we perform the nerve-sparing modifi cation of the RHL. Patients were recruited by reviewing 
medical fi les, collected prospectively in a database, of 156 women who had consecutively undergone a 
conventional RHL and 70 women who had undergone a nerve-sparing RHL for the treatment of cervical 
cancer stage I-IIa at the LUMC. In all cases a RHL type III was performed (16). None of the patients had 
participated in the study of Maas et al. (10). All patients in the study were treated by the same team of 
gynaecologic oncologists. Surgery had to have been at least one year before entry in the current study. 
Exclusion criteria for the current study were: a history of adjuvant radiotherapy or chemotherapy or 
signs of recurrent or metastatic cervical cancer; a history of bilateral oophorectomy; other perineal or 
abdominal surgery; post- or perimenopausal status. The hormonal status of the patients was assessed 
through history-taking evaluating vasomotor symptoms, hormonal cycles and age. If there was any 
doubt, the patient was classifi ed as postmenopausal. Twenty three out of 156 (15%) patients in the con-
ventional RHL group participated. Ten of these 23 patients were postmenopausal and were excluded 
from the analysis. Participation was refused for various reasons: no interest because of a lack of sexual 
problems (30), lack of time (26), intrusive nature of the experiment (36), or no reason given (41).
In the nerve-sparing RHL group, 11 out of 70 (16%) patients participated. One of the 11 patients was 
postmenopausal and was excluded from the analysis. Participation was refused for similar reasons: no 
interest because of a lack of sexual problems (6), lack of time (10), intrusive nature of the experiment 
(18), or no reason given (25).
Premenopausal women without sexual problems and without a history of abdominal or pelvic surgery 
or radiotherapy/ chemotherapy were recruited from the general population. Women contacted the in-
vestigators after reading an advertisement in a local paper. The exclusion criteria were checked through 
a semi structured clinical interview. None of the 14 recruited healthy controls had ever participated in 
research on sexual arousal.
Material and Response Measurements
All the interviews and experiments were carried out by one female doctor (Q.D.P). The assessor was 
not blinded for patients operation. Informed consent was obtained. All women received travelling 
expenses. The study was approved by the local Medical Ethics Committee.
Stimulus material identical to the study of Maas et al.(10) was used; all the subjects were exposed to 
an experimental session, that contained two 5 minutes neutral stimuli (during which a non-erotic 
documentary fi lm excerpt was shown), and two erotic 5.5 minutes stimuli (erotic fi lms depicting cun-
nilingus and intercourse). The erotic fi lm excerpts were taken from so-called women-made, female-
initiated, and female-centred erotic fi lm (12).
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Genital sexual arousal
The physiological evaluation of the genital response was carried out using vaginal photoplethysmog-
raphy. The plethysmograph is a menstrual tampon-sized device containing a
light-emitting diode and a phototransistor to detect light. The light source illuminates the capillary 
bed of the vaginal wall and the phototransistor responds to light refl ected by the vaginal wall and the 
blood circulating within it. When the signal is connected to an alternating current (AC) amplifi er, 
vaginal pulse amplitude (VPA) is measured, which refl ects the phasic
changes in vaginal engorgement accompanying each heart beat, with larger amplitudes refl ecting 
higher levels of vaginal blood fl ow. Vaginal pulse amplitude (VPA) is currently the most sensitive, 
specifi c, and reliable measure of vaginal vasocongestion (9) and is used in earlier /other studies (17;18) 
on sexual function in women with neurological damage
Subjective sexual arousal
Subjective sexual arousal was assessed through self-reported ratings of sexual arousal that were 
collected after the two neutral stimuli and the two erotic stimuli. Subjects were asked to assess on a 
seven-point Likert scale (19) their feeling of sexual arousal. Each point of the Likert scale was described 
by a verbal label: 1 representing “not sexually aroused at all” to 7 “very strongly sexually aroused”.
Assessment of sexual and psychological functioning
The Gyneacologic Leiden Questionnaire (LQ) is a 21 item measure, which is the fi rst Dutch list consisting of 
items for sexual function, voiding- and bowel problems for women with cancer. This questionnaire is 
currently being validated. This self-report questionnaire is validated in a Dutch population of patients 
with early stage cervical cancer (20).
The Dutch version of the Female Sexual Function Index (FSFI) (21;22) is a 19 items self-report measure of 
female sexual function that assess sexual desire, arousal, lubrication, orgasm, satisfaction and pain. 
The total FSFI score is an indication for sexual function.
The Dutch version of the Hospital Anxiety and Depression Scale (HADS) is a 14 items self-report measure 
to assess anxiety (7 items) and depression (7 items) (23;24), was used to assess the level of anxiety and 
depression.
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-
C30) Dutch version 3.0 (25) is a 30 items self-report measure for assessing health-related quality of 
life of cancer patients. Only the global health status / quality of life scale (two items), was used for the 
current study.
The questionnaires were completed before the experiment.
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Data reduction and analysis
The VPA was continuously recorded. VPA was sampled at 20 Hz across baseline and subsequent trials. 
A two-pass algorithm for automatic artefact removal (Molenkamp Technical Support Group, University 
of Amsterdam) was used to analyse the VPA data. After artefact deletion peak-to-trough amplitude was 
calculated for each remaining pulse and averaged over 60 second epochs.
Statistical calculations were performed with SPSS for Windows version 12. Prior to analysis, all 
dependent variables were examined for fi t between their distributions and the assumptions of uni-
variate analyses. To reduce the positive skew ness of the VPA data, all VPA data were logarithmically 
transformed (log10). For each stimulus (two neutral stimuli and two erotic stimuli), a log10 VPA mean 
score was calculated by averaging all epochs of the specifi c stimulus. To analyse differences in the 
log10 VPA scores between three groups for the four stimuli, the log10 VPA mean scores were submitted 
to 3 (group) x 4 (stimulus) repeated measures ANOVA. Furthermore, to control for baseline differ-
ences, the log10 VPA mean scores were also submitted to 3 (group) x 3(stimulus) repeated measures 
ANCOVA, using each individual’s log10 mean baseline score of the fi rst neutral stimulus as covariate. 
Following signifi cant F ratios for each dependent measure, univariate post hoc analyses (multiple 
comparisons between all pairs of possible means) were performed to test specifi c stimulus effects. To 
analyse differences in the subjective sexual arousal between the three groups for the four stimuli, the 
mean subjective arousal scores were submitted to 3 (group) x 4 (stimulus) repeated measures ANOVA. 
To assess differences in subject’s characteristics and dependent variables between the three groups, 
one-way analyses of variance or chi-square tests were used.
We were interested in a difference between the group of women with a nerve-sparing RHL and the 
group of women with a conventional RHL with a large size effect of at least d=0.8.
With an alpha value of 0.05, a power of 80% and an effect size of d=0.8, a number of minimal 26 
women for each group is needed (26). We did not succeed to recruit this number of subjects for each 
group and it will take at least 3 years to collect enough subjects for this experiment. The results of the 
completed study will be reported later. In this preliminary report, with an alpha value of 0.05 and with 
the smallest number of ten patients in the nerve-sparing group and 13 patients in the conventional 
group, the power was 39 % to detect a difference with a large effect size between the two groups. 
Statistical signifi cance was assigned at a level of p<0.05.
Results
Differences in biographical, medical status and psychological variables
Table 1 shows characteristics and outcome of the questionnaires of the 37 women included. None of 
the women used hormone replacement therapy. The women in the nerve-sparing RHL group were 
younger than the women in the conventional RHL and control group. In the conventional RHL group 
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the time-interval between the operation and the experiment was three times as long as that of the 
nerve-sparing RHL group. Constipation complaints were more frequently reported by the conventional 
RHL and nerve-sparing RHL group compared to the controls. No differences were found for sexual and 
bladder dysfunction.
Differences in genital arousal
Figure 1 shows VPA responses in the three subjects groups throughout the whole experimental session. 
The VPA mean scores differed between the three groups (F (2, 34) = 4.84, p = 0.014); the conventional 
RHL group had overall, signifi cantly lower VPA mean scores than the control group (p=0.016). The 












Age (y) 46.9±5.9      46.7±5.5 40.1±6.3 F=4.78 0.015
Operation-experiment(m)  - 107.7±41.1 25.6±18.4 F=34.28 0.000
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Tabel 1. Patients characteristics and outcome of the questionnaires. SD, standard deviation; RHL, radical hysterectomy 
with pelvic lymphadenectomy; y, years; m, months; LQ, Leiden Questionnaire; FSFI, Female Sexual Function Index (A 
higher score means a better sexual function); HADS, Hospital Anxiety and Depression Scale (A higher score means 
more complaints of anxiety or depression). EORTC QLQ-C30, The European Organisation for Research and Treatment 
of Cancer Quality of Life Questionnaire-C30 (A higher score means a better global health status) *Observed two-tailed 
signifi cance. Statistical signifi cance at a level of p< 0.05. Data are presented as mean ± SD or n (%), unless otherwise 
indicated. 
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the nerve-sparing group (p=0.097). No differences were found between the control group and the 
nerve-sparing group (p=1.000). These results indicate that the VPA responses in the conventional RHL 
group were signifi cantly lower throughout the whole experimental session. Moreover, the two erotic 
fi lms were equally effective in enhancing genital arousal in the three groups which was refl ected by 
signifi cantly higher VPA mean scores of the two erotic stimuli compared to the mean VPA scores of the 
two neutral stimuli (F(3, 102)=66.40, p<0.001). Table 2 shows the untransformed VPA mean scores for 
the three groups and four stimuli.
As the conventional RHL group had signifi cantly lower baseline VPA scores than the controls, we 
repeated the analysis while controlling for individual baseline differences. After controlling, the VPA 
responses in the three subject groups throughout the experimental session were comparable (p=0.140). 
This indicates that the differences in levels throughout the experimental session between the three 
subject groups were critically dependent on the baseline VPA scores (Fig. 1).
Because the women in the nerve-sparing group were signifi cantly younger than the women in the 
other two groups and the time-interval between the operation and the experiment was longer for the 
conventional group, we performed the same analyses for VPA mean scores while controlling for age or 
time-interval between operation and experiment. After controlling for age or time interval the outcome 
did not change. These results indicate that the VPA responses throughout the whole experimental 
session are not affected by age or time-interval.
Figure 1. Change in logarithmically transformed mean vaginal pulse amplitude (log10VPA) during experimental 
session: Neutral stimulus 1 (Baseline assessment) (1-5 min), Erotic stimulus 1 (6-10 min), Neutral stimulus 2 (11-15 
min), Erotic stimulus 2 (16-21 min).
 – –=Conventional RHL (n=13), – –=Nerve-sparing RHL (n=10), – –=Controls (n=14). RHL, radical hysterectomy 
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Differences in subjective arousal
The mean score on subjective arousal was signifi cantly higher during erotic stimulus 1 and 2 compared 
to neutral stimulus 1 and 2 (F (3, 102) = 108.36, p < 0.001). The three subject groups reported the same 
level of subjective sexual arousal. These results indicate that the erotic fi lms were equally effective in 
enhancing subjective sexual arousal in the three groups. Table 2 shows the mean subjective arousal 
scores of the three groups and four stimuli.
Differences in postmenopausal and premenopausal status, post-hoc analyses
Literature data show that postmenopausal women have a signifi cantly lower baseline vaginal blood 
fl ow compared to premenopausal women (10;27;28). To explore the hypothesis that the vaginal blood 
fl ow response of the conventional RHL group follows a pattern comparable with that of postmeno-
pausal women, we used our data of the postmenopausal controls (n=12) and postmenopausal women 
with a history of a conventional RHL (n=10) who were excluded from the earlier main analyses. These 
postmenopausal women met all the other inclusion criteria of our study.
Figure 2 shows the VPA responses in four different groups; post- and premenopausal controls and 
post-and premenopausal patients with a history of conventional RHL. Visual inspection of the data 
indicates that the premenopausal women of the conventional RHL group follow a pattern comparable 
with that of postmenopausal women. We subsequently performed statistical analyses to quantify the 
differences in VPA responses. A two subject groups (conventional vs controls) by hormonal status 
(premenopausal vs postmenopausal) by the four stimuli analysis revealed that the conventional RHL 
groups had overall lower VPA scores (p=0.022). Furthermore a trend for the interaction effect between 
group and hormonal status in VPA responses (F (1, 45) = 2.87, p = 0.097) was found. Post hoc analyses 
showed a signifi cantly higher VPA response for the premenopausal controls compared to the premeno-







Objective report: vaginal pulse amplitude (mV)
Neutral stimulus 1 1.8±1.0 1.2±0.7 1.7±1.0
Erotic stimulus 1 3.8±2.0 2.3±1.7 3.8±2.3
Neutral stimulus 2 3.1±1.6 1.5±0.7                2.9±1.6
Erotic stimulus 2 4.5±2.4 2.5±1.8 4.0±2.5
Subjective report: sexual arousal (Likert scale)
Neutral stimulus 1
Erotic stimulus 1 
Neutral stimulus 2 













Table 2. The mean and SD of the untransformed VPA mean scores in millivolt for the three groups and the mean 
and SD of the mean subjective arousal scores during the four stimuli. SD, standard deviation; VPA, Vaginal Pulse 
Amplitude; mV, millivolt. Data are presented as mean ± SD.
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Discussion
This is the fi rst study in which vaginal photoplethysmography was used to compare the functional results 
of a nerve-sparing modifi cation of the RHL with the conventional RHL. Vaginal blood fl ow response 
during sexual stimulation was evaluated through objective assessment using photoplethysmography 
in women with a history of RHL, in women after nerve-sparing RHL and in healthy controls.
Although we did not yet succeed to recruit the number of subjects which we need according to our 
power calculation we decided to report preliminary data, because we feel that the results raise many 
interesting questions. The previous study from our group showed that damage to the autonomic nerves 
results in disrupted vaginal blood fl ow response during sexual stimulation. During sexual arousal a 
history of conventional RHL was associated with a signifi cantly lower vaginal blood fl ow response 
compared to healthy controls (10). The results of the current study are partly in line with this; we also 
found that the conventional group had signifi cantly lower VPA mean scores than the control group. 
The VPA mean scores of the conventional group tended also to be lower than the VPA mean scores of 
the nerve-sparing group. These differences in VPA were critically dependent on baseline differences 
between the three groups, and occurred despite the fact that these three groups felt an equally strong 
















Figure 2. Postmenopausal versus premenopausal; change in logarithmically transformed mean vaginal pulse 
amplitude (log10VPA) during experimental session: Neutral stimulus 1 (Baseline assessment) (1-5 min), Erotic 
stimulus 1 (6-10 min), Neutral stimulus 2 (11-15 min), Erotic stimulus 2 (16-21 min).
 – – =Conventional RHL, postmenopausal (n=10), – –=Conventional RHL, premenopausal (n=13), – –=Controls, 
postmenopausal (n=12),  –––=Controls, premenopausal (n=14) RHL, radical hysterectomy with pelvic 
lymphadenectomy. See colour fi gure page 153.
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patients with a history of conventional RHL probably have a lower vaginal blood fl ow than healthy 
controls and patients after a nerve-sparing RHL. Consequently, the vaginal blood fl ow during sexual 
stimulation does not reach the same high level in women with a history of conventional RHL.
The strength of the current study is the fact that all patients were treated by the same group of gyneco-
logic oncologists, which ensures a uniform surgical technique.
The most ideal design would have been a pre-operative versus post-operative vaginal pulse amplitude 
assessment within subjects. We did not carry out such a study because we felt it was unethical to ask 
women in the period leading up to major cancer surgery to take part in an emotionally confronting 
psychophysiological sexual assessment.
In general, it has proven to be diffi cult to recruit women after they have had their treatment because of 
the intrusive nature of this experiment. For this reason it will take at least 3 years before we will have 
recruited a suffi cient number of subjects for each group.
In interpreting the results of this preliminary analysis, the limits of the design and its size should be 
taken into account. The sample used was small. The fact that we did not fi nd a signifi cant difference 
between the conventional RHL group and the nerve-sparing RHL group could possibly be a conse-
quence of relatively small power (39%) of the study so far (26).
Previous studies have shown that participants in sexuality studies tend to be more sexually liberal and 
permissive, and more sexually active than non-participants (29) which might infl uence the representa-
tivity of our sample. In the current study the control group showed mean FSFI total scores comparable 
with women without sexual problems (22). The two patients groups did not differ signifi cantly from 
our control group. This could imply that women with more severe dysfunctions refrained from par-
ticipating and that the difference in vaginal blood fl ow between the nerve-sparing RHL group and 
conventional RHL group might be an under-estimate.
The similarity of the VPA response curve of the women with a history of a conventional RHL and 
postmenopausal women is striking. In line with our fi ndings, Laan et al.(27;30) also reported that 
postmenopausal women displayed signifi cantly lower VPA responses than premenopausal women 
in the basal (unstimulated) state. They also found that the changes in VPA responses during erotic 
stimulation were similar in both premenopausal and postmenopausal women.
We suggest that a common pathophysiologic mechanism explaining the low basal vaginal blood fl ow 
in postmenopausal women and women with a history of conventional RHL could be an altered vascular 
smooth muscle contraction state in the vaginal blood vessels. We postulate that the observed altered 
vaginal blood fl ow in women with a history of a conventional RHL and postmenopausal women is in 
both cases the result of a reduced number of autonomic nerve fi bres in the vascular smooth muscle 
cells in the vagina. Recent studies have shown both in animal models as well as in human tissue that 
the autonomic nerves which innervate the reproductive organs have been found to be responsive to 
circulating steroids such as oestrogen. These nerves express oestrogen receptor α (ER α) and oestro-
gen receptor β (ER β) (31-34). A changed number of autonomic nerve fi bres in the vascular wall of 
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the vagina mediated by either direct nerve disruption (conventional RHL) or low oestrogen levels which 
modulate nerve density through oestrogen receptors in the vaginal wall (postmenopausal women) causes 
a changed contraction state of the vaginal arteries.
Chronic oestrogen exposure reduces the density of sympathetic nerves, but increases the density of 
parasympathetic nerves (31;32). Regarding vaginal blood fl ow, an increase of parasympathetic nerves 
would lead to vascular smooth muscle relaxation resulting in an increased VPA. This explains the higher 
baseline VPA in premenopausal women. Alternatively, a hypoestrogen status leads to a sympathetic 
hyperinnervation, causing vascular smooth muscle contraction resulting in a lower baseline VPA in post-
menopausal women.
Interestingly, the typical sexual complaints reported by women with a history of conventional RHL (2-4) 
are similar to postmenopause-related sexual problems (35-37). These sexual complaints include dys-
pareunia, a dry vagina, reduced vaginal lubrication and a decline in sexual interest.
ER β, the receptor which is associated with human vaginal vascular smooth muscle has been documented 
to be expressed in the uterosacral ligaments (38). The critical modifi cation of the conventional RHL into a 
nerve-sparing technique is the alternative surgical dissection of the uterosacral ligaments which contain 
essential parts of the pelvic autonomic nerves (6). Sparing the autonomic nerves expressing ER β could 
explain the higher baseline VPA in the premenopausal women with a history of nerve-sparing RHL.
 The physiological model behind the subsequent ‘normal’ increase in VPA once the subject (after con-
ventional RHL or in postmenopausal state) is erotically stimulated, i.e. after a low baseline, the vaginal 
blood fl ow increases to the same extent as in healthy controls but never reaches the high fl ow of controls, 
is the endothelin/ Nitric oxide (NO) system. Vessel walls react to sheer stress caused by blood pressure 
changes. Endothelin release results in vasoconstriction, while NO induces vasodilatation. This ability of 
the arteries to adapt to changes in the circulation is not regulated by the autonomic nervous system. This 
explains why a partly denervated vagina does show a relatively normal vaginal blood fl ow response.
In conclusion, the preliminary data from the present study show that women with a history of nerve-
sparing surgery seem to have an overall better vaginal blood fl ow. Further research of the functional 
results of nerve-sparing modifi cations of RHL should therefore be performed, to prove without any doubt 
that nerve-sparing techniques lead to lower sexual morbidity with similar treatment results.
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Summary
Improving the quality of cancer care will lead to a better survival rate and less morbidity and, therewith, 
to a better quality of life for cancer patients. To achieve this goal, treatment-related information, like 
clinical data regarding treatment, survival items and the postoperative morbidity, is needed. This could 
be acquired by registries. A regular audit of this information will result in more awareness of individual 
differences, gain more insight into the existence of risk factors and comorbidity and could lead to 
other treatment modalities.
Furthermore, improving the quality of life is important when results of cancer treatment in terms of 
survival are good, because cancer treatment has its adverse effects. For cervical cancer patients these 
adverse side effects may include loss of fertility, bladder dysfunction, colorectal motility disorders and 
sexual dysfunction (1-10). It has been shown that for women with gynaecological cancer, the maintance 
of a positive self-image and feelings of sexuality is an issue of central importance in the provision of 
quality of their daily life (11). Because sexual function and satisfaction are based on both physical and 
psychological components, the treatment of gynaecological cancer can affect both of these aspects; 
particularly because of the anatomical nature of the cancer (12).
This thesis focused on the sequelae of treatment acquired by registries of women with early stage 
cervical cancer in order to improve the quality of treatment procedures and the quality of life. The 
results of these studies are summarized and discussed in this chapter.
A general introduction is presented in chapter 1. In this introduction aspects are reviewed about the 
quality control of cancer care, quality of life, morbidity after radical hysterectomy for the treatment of 
cervical cancer and different ways of monitoring morbidity. Finally, the role of the pelvic autonomous 
nerves in radical hysterectomy is described.
When radical hysterectomy with pelvic lymphadenectomy (RHL) is performed for women with early 
stage cervical cancer and adverse risk factors, such as lymph node involvement, parametrial invasion 
or positive surgical margins are present, postoperative radiotherapy is indicated (13-23). Several stud-
ies have suggested that patients with disease confi ned to the cervix but with certain other primary 
tumour related risk factors might also benefi t from postoperative radiotherapy (13-28). In a study 
performed by the Gynecologic Oncology Group (GOG), Delgado et al. identifi ed capillary lymphatic 
space involvement (CLS), clinical tumour size and depth of tumour invasion into the cervical stroma 
(DI) as predictors of prognosis and proposed a scoring system that identifi es three separate risk 
groups for recurrence (14). Since 1997, patients with at least 2 of the following 3 risk factors also 
received postoperative radiotherapy in our centre (Leiden University Medical Centre, LUMC): tumour 
size ≥40mm, depth of invasion ≥ 15 mm and CLS. In chapter 2, the outcome of patients who received 
adjuvant radiotherapy on the basis of tumour related risk factors mentioned above was compared to 
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the outcome of patients with a similar risk profi le treated before 1997 who did not receive radiotherapy. 
Furthermore, the prognosis of patients using our criteria for giving adjuvant radiotherapy (LUMC risk 
profi le) was compared to those of the GOG prognostic scoring system (GOG risk score) (14). For this 
study prospectively collected data of 643 patients with stage I-IIa cervical carcinoma was used.
In line with the literature (14;21;22;29;30) the current study indicated that the high risk group accord-
ing to the LUMC risk profi le signifi cantly benefi ted from postoperative radiotherapy. We found that a 
signifi cantly larger percentage (41 vs 12%, p=0.02) of the high risk group who did not receive radio-
therapy, had recurrence of disease. This occurred in the knowledge that apart from the number of deep 
infi ltrating tumours (more frequent in the irradiated group), the other clinical important risk factors 
of the 2 groups were similar. The differences in the cancer specifi c survival (CSS) and the disease free 
survival (DFS) between the high risk group with adjuvant radiotherapy (86% and 85%, respectively) 
and high risk group without adjuvant radiotherapy (57% and 43%, respectively) were statistically 
signifi cant (p=0.013 and p=0.006, respectively). Finally, this study showed that the LUMC modifi cation 
of the GOG prognostic scoring system did not signifi cantly differ from the GOG prognostic scoring 
system itself, with regard to risk of recurrence, CSS and DFS. It was concluded that the LUMC risk 
profi le is simpler and more straightforward in use, has a slightly higher threshold to defi ne patients as 
candidates for adjuvant radiotherapy as compared to the GOG prognostic scoring system, but without 
compromising their prognosis.
The goal of lymphadenectomy as part of the treatment of patient with early stage cervical cancer is 
to remove and diagnose cancer cells that have been transported to the lymphatic system draining the 
uterine cervix and the upper vagina. A systematic lymphadenectomy can reliably establish the presence 
or absence of lymph node involvement, with the attendant consequences for prognosis and treatment 
(31). For the treatment of early stage cervical cancer, the therapeutic value of lymphadenectomy is 
still a matter of debate, although some authors emphasized the possible benefi cial effect of removing 
metastatic lymph nodes (31-38). Yet, it has never been proven that the removal of nodes itself leads 
to better survival fi gures (32). The aim of the study in chapter 3 was to determine if the number of 
removed pelvic lymph nodes in RHL infl uences survival of patients with early stage cervical cancer. 
Furthermore the relation of patient, tumour and treatment factors on one hand and the number of 
nodes examined in node-negative early stage cervical cancer patients on the other hand was analyzed. 
For the fi rst part of the study a group of 331 patients with negative nodes and without adjuvant therapy 
(group A) and a group of 136 patients with positive nodes (group B) were used. For the second part only 
group A was used. Lymphadenectomy consisted of removal of all the fatty tissue from 6 different pelvic 
stations. Parametrial nodes were not included in the counting of number of nodes. In the current study 
there were no para aortic lymph nodes removed in patients of group A and B.
The current study indicated that when all regional lymph nodes are pathologically negative, there is no 
relation between the number of nodes removed and CSS or DFS. However, the number of examined 
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lymph nodes effects DFS fi gures for patients with positive lymph nodes. Patients with early stage cervi-
cal cancer with positive lymph nodes consequently benefi t from a suffi cient number of removed lymph 
nodes. As such, the most important clinical consequence of this study is that one should complete 
the lymphadenectomy when frozen section reveals lymph node involvement during RHL. Finally, this 
study showed that the number of removed lymph nodes was not infl uenced by age, referral from Suri-
nam, postmenopausal status, conisation before surgery, tumour size, infi ltration depth and capillary 
lymphatic space involvement.
When a patient confronts the physician with questions about the exact risk of recurrence or death 
in their individual case by time, it can be diffi cult and sometimes even impossible to answer this 
adequately. Standard survival data measure the time span from some time origin until the occurrence 
of one type of event. If several types of events (like recurrence or death) occur, a model describing 
progression to each of these competing events is needed.
Multi-state models may be considered as a generalization of the basic framework for dealing with 
survival data to the case where several (possibly competing) events occur successively over time. The 
occurrence of successive events constitutes the transitions from an initial state to a fi nal state. Here, 
the states of the cervical cancer patients are recurrence and death. Furthermore, these models allow 
the incorporation of prognostic factors in order to study the infl uence of these factors on each of the 
transition rates. Multi-state models can be used to predict the likelihood to reach a specifi c future state 
(e.g. recurrence) on the basis of their present state at various time intervals following initial treatment.
The aim of chapter 4 was to evaluate the possibility to give a prediction of the future (disease free) 
survival, given the fact that a patient with a history of early stage cervical cancer has been disease free 
for a specifi c period after treatment. For this means the prospectively collected data were used of 615 
patients with stage I-IIa cervical carcinoma who were treated with a RHL with or without adjuvant 
radiotherapy. Statistical analysis was done with multi-state risk models specifi cally designed for this 
purpose. The multi-state risk models estimate the infl uence of covariates and generate predicted 
survival curves by simulation. The covariates that have been taken into consideration in the analysis of 
individual patient survival were; lymph nodes involvement, tumour size, depth of invasion, capillary 
lymphatic space involvement, parametrial invasion, adenosquamous carcinoma and positive surgical 
margins. The simulations were done for patients with positive lymph nodes (n=492), patients with 
negative lymph nodes (n=123) and four hypothetical patients. The predicted probability of death of 
these 2 groups and the 4 hypothetical patients were demonstrated in predicted cumulative probability 
plots.
Until the results of other trials are known, the outcome of the present study shows the possibility to 
give a prediction of the future (disease free) survival, given the fact that a patient has been disease free 
for a specifi c period after treatment. This could provide information to individualise the treatment 
management and the (length of ) programs of surveillance and this obviously will benefi t cost and 
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time implications. Furthermore, improving the quality of cancer care will undoubtedly lead to a better 
quality of life for cancer patients. Therefore, it can be concluded that this possibility is an important 
step forward to improve the quality of cancer care.
To become aware of the morbidity that exists after a treatment and to obtain an impression of the 
impact of it on a patient’s quality of life, self-report questionnaires may give more informative answers 
(39;40). Besides, self-report questionnaires might also give more comprehension of the patient’s 
perception of symptom severity. We developed a Dutch self-report questionnaire, the Qynaecologic 
Leiden Questionnaire (LQ), which is the fi rst developed Dutch list consisting of the items for sexual 
function, voiding- and bowel problems for women with cancer. The Gynaecologic LQ has one item for 
weariness, one item for lymphedema, 11 items for sexual functioning, 6 items for voiding and 2 items 
for bowel problems. The aim of chapter 5 was to investigate the psychometric properties of the items 
concerning sexual functioning of the Gynaecologic LQ. The total study sample consisted of 198 sub-
jects: 66 patients treated for cervical cancer, 66 patients with sexual complaints and 66 subjects from 
the general population. The patients treated with RHL for cervical cancer by a RHL were asked to com-
plete the Gynaecologic LQ before, 3, 12 and 24 months after treatment. For the internal validation we 
used the Gynaecologic LQ that was completed 12 months after the operation. The patients with sexual 
problems, who solicited for therapy at an out-patient clinic for sexology, completed the questionnaire 
at the end of the fi rst visit. The convergent and divergent construct validity of the Gynaecologic LQ was 
investigated using other validated instruments (questionnaires) measuring sexual functioning, sexual 
dissatisfaction, marital distress, general life distress and psychological distress.
By means of factor analysis three subscales were derived: Female Sexual Complaints, Female Sexual 
Function and Female Orgasm. The reliability of the subscales appeared to be satisfactory. The scores 
on the three subscales differentiated well between the patients treated for cervical cancer, patients 
with sexual complaints and the subjects from the general population. Furthermore, the subscales 
were sensitive to change within the patients treated for cervical cancer, since the score changed in 
the theoretically proposed direction following the treatment. The convergent and divergent validity of 
the Gynaecologic LQ was good, since the 3 subscales corresponded with subscales measuring similar 
complaints and discriminated from subscales measuring other (psychological) problems.
In conclusion, the results of the current study support the reliability and psychometric validity of Gy-
naecologic LQ in the assessment of sexual functioning and vaginal changes in gynaecological cancer 
patients.
The effects of the treatment for cervical carcinoma on the women’s sexuality and the resulting distress, 
have received more attention in recent years (8;41-48). In chapter 6 the results are described of the fi rst 
longitudinal study of self-reported bladder, defecation, sexual and vaginal problems with a baseline 
score before the RHL with or without adjuvant radiotherapy. Women with early stage cervical cancer 
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who had to undergo RHL were enrolled in the study. For this study only 14 out of the 21 items of the 
self-report Gynaecologic LQ were used. The 14 items asked for lymphedema, sexual function, voiding 
and bowel problems and were completed before operation and at 3, 12, and 24 month after operation. 
We compared this group of patients with a group of age-matched controlled women from the general 
population. The control group was asked to complete the questionnaire once. Seventy-three patients 
fi lled in all the questionnaires. The control group consisted of 224 women.
Up to 1 year after the treatment the patients complained signifi cantly more often of little or no urge 
to urinate and diarrhoea as compared to the controls. However, after 2 years follow-up, we found no 
signifi cant difference anymore concerning bladder dysfunction and colorectal dysfunction compared 
to the control group and compared to the situation before surgery. Retrospective studies of frequency 
of late postoperative micturition and colorectal problems show various fi gures (2;4;9;49;50). The fact 
that in this study no signifi cant difference was found after 2 years of follow-up might be a refl ec-
tion of post-surgical recovery or an indication that perception of quality of life may be independent 
of objective measures. The relief resulting from the completion of potentially curative treatment may 
also have contributed to the subjective improvement despite changes in bowel and bladder function. 
And fi nally, most studies of colorectal and micturial dysfunction offer data collected from the medical 
fi les (4;9;49;50). This study used questionnaires and has a longitudinal design that makes a direct 
comparison with literature data problematic.
The patients showed signifi cantly more negative effects on sexual function compared both to the 
controls as well as compared to their situation before the treatment throughout 2 years of follow-up. 
The problems included less lubrication, a narrow and short vagina, numb areas around the labia, dys-
pareunia, and sexual dissatisfaction. In agreement with the literature (1;3;44;51) it can be concluded 
that up to 2 years after the RHL, women with early stage cervical cancer experience negative effects 
mainly on sexual function. Adjuvant radiotherapy did not signifi cantly increase the risk of bladder 
dysfunction, colorectal motility disorders and sexual functions.
It is known from several anatomical and clinical studies (52-55) that RHL for cervical cancer causes 
surgical damage to the pelvic autonomic nerves which are responsible for the increased vaginal blood 
fl ow during sexual arousal (56;57). It is conceivable that surgical damage to these autonomic nerves 
plays a crucial role in the aetiology of the postoperative morbidity that exist after RHL (52;58-62). 
Photoplethysmographic assessment of vaginal pulse amplitude has been proven to be reliable and 
reproducible to measure objectively the vaginal blood fl ow during sexual arousal (63;64).
Chapter 7 reports preliminary data of a study with the aim to determine whether the nerve-sparing 
technique indeed leads to an objectively less disturbed vaginal blood fl ow response during sexual 
stimulation. Photoplethysmographic assessment of vaginal pulse amplitude (VPA) during sexual 
stimulation by erotic fi lms was performed. Sexual and psychological functioning of the participating 
women was assessed by four self-report questionnaires: Gynaecologic LQ (65); FSFI (66;67) ; HADS 
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(68); EORTC-C30 (69). Subjective sexual arousal was assessed after each stimulus. Thirteen women 
with a history of a conventional RHL, 10 women with a history of a nerve-sparing RHL and 14 healthy 
controls participated.
The mean VPA differed between the three groups (p=0.014): the conventional group had overall a 
signifi cantly lower vaginal blood fl ow response than the control group (p=0.016), and tended also to 
be lower than the nerve-sparing group (p=0.079). These differences in VPA were critically dependent 
on baseline differences between the three groups; the vaginal blood fl ow during the fi rst 5 minutes 
lasting neutral stimuli, preceding the sexual stimuli, was already signifi cant lower for the conventional 
RHL group compared to the control group. Furthermore, a trend was found between the conventional 
RHL group and nerve-sparing RHL group; the conventional RHL group had a lower baseline vaginal 
blood fl ow compared to the nerve-sparing RHL group. These differences occurred despite the fact 
that these three groups felt an equally strong subjective sexual arousal after erotic stimulus condition. 
Therefore, it seems that women with a history of nerve-sparing surgery have an overall better vaginal 
blood fl ow response. It is probably due to the low power of the study that differences with the women 
after conventional RHL were not statistically signifi cant.
Furthermore, visual inspection of the data indicates that the conventional group follows a vaginal 
blood fl ow response pattern which is comparable to the vaginal blood fl ow pattern of postmenopausal 
women. This similarity could be explained by a changed number of autonomic nerve fi bres in the 
vascular wall of the vagina mediated by either direct nerve disruption (after conventional RHL) or by 
low estrogen levels which modulate nerve density through estrogen receptors in the vaginal wall (in 
postmenopausal women).
This is the fi rst study in which vaginal photoplethysmography was used to compare the functional 
results of the nerve-sparing modifi cation of the RHL with the conventional RHL. However, a defi nite 
conclusion concerning the benefi t of nerve-sparing surgery can only be made after inclusion of more 
subjects. Further research of the functional results of nerve-sparing modifi cations of RHL should 
therefore be performed, to prove without any doubt that nerve-sparing techniques lead to lower sexual 
morbidity.
Discussion, recommendations and future perspectives
Summarizing from our studies it can be concluded fi rst that treatment-related information from 
registries is a prerequisite to improve the quality of cancer care. Illustrative is the fact that UK studies 
reporting on the wide variety in outcomes in breast and colorectal cancer have had major consequences 
(70). The results of our studies, achieved by the use of our prospective clinical database, can also have 
consequences for the treatment of patients with early stage cervical cancer.
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First of all the results of our study and data from the literature (14;24-28) may be used as argument to 
give adjuvant radiotherapy to patients with tumour related risk factors, without lymph node involve-
ment, parametrial invasion or positive surgical margins, since these high-risk patients seem to benefi t 
from adjuvant radiotherapy.
Another recommendation is that one should complete the lymphadenectomy when frozen section 
reveals lymph node involvement during RHL, because a greater number of examined lymph nodes 
leads to better disease free survival fi gures for patients with positive lymph nodes. Although in the 
literature the therapeutic value of lymphadenectomy is still a matter of debate, the results of our study 
confi rm similar fi ndings of a previous analysis (32).
Furthermore, we found a possibility to give an accurate prediction of the future (disease free) survival 
of an individual patient. This could provide information to individualise the treatment management 
and the (length of ) programs of surveillance and this will also benefi t cost and time implications. The 
future perspective could be that every gynaecologic-oncologist will have a program on his or her com-
puter by which it will be possible to predict the future (disease free) survival for an individual patient. In 
the future these kinds of programs will become even more accurate because of the growing availability 
of new software for multi-state models. But also because the number of patients treated for early stage 
cervical cancer will increase in the database in which all clinical and pathological parameters of these 
patients are prospectively collected. Not only for this last purpose but also to maintain the possibility to 
be able to give recommendations like the other 2 mentioned above, it is necessary to collect treatment-
related information in a registry. The Dutch Comprehensive Cancer Centres (IKC) only register new 
cases of cancer and do not collect other treatment-related data from these new patients apart from 
some study wise activities. Moreover, there are still hospitals and even several European countries that 
do not have (reliable) cancer registries (71;72). We therefore strongly recommend hospitals and also 
the IKC’s to set up such registries, because they can provide valuable information on differences in 
treatment modalities, risk factors, morbidity or outcome and therefore form the basis of a strategy for 
monitoring, audit and improving of cancer care.
Secondly, it can be concluded from our studies that with the right tools it is possible to become aware 
of and to gain insight into the existence of morbidity after RHL for the treatment of cervical cancer. We 
validated the questions concerning sexual function of the self-report questionnaire, the Gynaecologic 
LQ, which is the fi rst developed Dutch list consisting of the items for sexual function, voiding- and bowel 
problems for women with cancer. This questionnaire will help us to measure in a subjective way the 
complaints of patients after their treatment, and therefore might give insight in the necessity to develop 
other treatment modalities. Furthermore, this tool can be used to compare conventional therapy with 
new developed modalities.
Since we become more aware of the side effects of the treatment of cervical cancer and since the quality of 
life is nowadays an important issue, the number of studies about self-reported sexual function and vagi-
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nal changes will undoubtedly increase in the future. It is however essential that these studies assessing 
sexual function use data of patients with the same diagnosis, treatment, stage, and follow-up periods. A 
longitudinal design, validated questionnaires and a baseline score are also important.
Photoplethysmographic assessment of vaginal pulse amplitude has been proven to be reliable and repro-
ducible to measure objectively the vaginal blood fl ow during sexual arousal (63;73;74). RHL for cervical 
cancer causes damage to the autonomic nerves which are responsible for the increased vaginal blood 
fl ow during sexual arousal (1;52;75;76). Since this is known, several authors have proposed different 
nerve-sparing surgical approaches to avoid pelvic disruption during RHL (54;58;61;62;77-81). Vaginal 
photoplethysmography is therefore an important tool in the investigation of the functional results of 
these new developments.
In the LUMC we have also developed a nerve-sparing technique in an attempt to reduce the nerve damage 
during RHL without sacrifi cing oncological principles of radicality (59). The nerve-sparing modifi cation 
of the RHL is performed since 2000. Recently we have started a multicentre observational study to assess 
the results of treatment in terms of DFS and the incidence of urinary, colorectal and sexual dysfunction 
after nerve sparing surgery in RHL for cervical carcinoma stage Ib1/IIa. The results of this study are to be 
expected in the coming years. The Gynaecologic LQ and the vaginal photoplethysmography are used in 
this study to investigate on a subjective and objective way the results of this new technique.
We made a start with the photplethysmographic assessments. For this part of the study a number of 
minimal 26 women with a history of conventional RHL and 26 women after nerve-sparing RHL is needed 
(82). We did not yet succeed to recruit this number of subjects. It has proven to be diffi cult to recruit 
women after they have had their treatment because of the intrusive nature of the experiment. For this 
reason it will take at least 3 years before a suffi cient number of subjects for each group will be recruited. 
However, the preliminary data from the study show that a conventional RHL is associated with an overall 
disturbed vaginal blood fl ow response compared to healthy controls. Since it was not observed to the 
same extent after nerve-sparing RHL, it seems that the nerve-sparing technique leads to better overall 
vaginal blood fl ow caused by less denervation of the vagina.
The next years the recruitment of subjects for the multicentre observational study will be continued, to 
prove that the Leiden nerve-sparing modifi cation of the RHL leads to lower morbidity with similar treat-
ment results. This might lead to an improvement of the quality of life of women undergoing live-saving 
surgery for early stage cervical cancer.
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Samenvatting
Verbetering in de kwaliteit van kanker zorg zal leiden tot betere overleving en minder morbiditeit, met 
als gevolg een betere kwaliteit van leven voor deze patiënten. Om dit doel te kunnen bereiken is infor-
matie nodig over de behandeling. Dit kan worden verkregen uit databanken. Deze informatie bestaat 
onder andere uit klinische gegevens met betrekking tot de behandeling, gegevens ten aanzien van de 
overleving en postoperatieve morbiditeit. Het regelmatig nazien of controleren van deze informatie 
zal leiden tot meer bewustwording van individuele verschillen, zal meer inzicht geven in het mogelijke 
bestaan van risicofactoren en morbiditeit en kan resulteren in andere behandelingsmodifi caties.
Wanneer op basis van overlevingscijfers kan worden gesteld dat de resultaten van de behandeling voor 
kanker goed zijn, wordt vervolgens de verbetering van de kwaliteit van leven belangrijk, dit omdat 
de behandeling van kanker ook zijn prijs heeft. Voor patiënten met baarmoederhalskanker betekent 
dit het verlies van vruchtbaarheid, disfunctioneren van de blaas, colorectale motiliteitstoornissen en 
problematiek op het gebied van de seksualiteit.
Het is aangetoond dat voor vrouwen met een gynaecologische vorm van kanker het behoud van een 
positief zelfbeeld en gevoelens van seksualiteit zeer belangrijk zijn voor de kwaliteit van leven. Om-
dat de seksuele functie en seksuele bevrediging gebaseerd zijn op zowel lichamelijke als psychische 
componenten, kan een behandeling voor een gynaecologische vorm van kanker deze beide aspecten 
aantasten, vooral vanwege de anatomische aard van de kanker.
Dit proefschrift bevat een aantal studies naar de gevolgen en de resultaten van de behandeling voor 
vrouwen met een vroeg stadium van baarmoederhalskanker (FIGO I-IIa) met als doel de kwaliteit van 
behandelingsprocedures en de kwaliteit van leven te verbeteren. De gegevens voor deze studies zijn 
onder meer verkregen uit een databank. In deze databank wordt sinds januari 1984 op prospectieve 
wijze meer dan 200 relevante klinische en pathologische parameters verzameld van vrouwen die in het 
Leids Universitair Medisch Centrum (LUMC) zijn behandeld voor baarmoederhalskanker.
In hoofdstuk 1 worden aspecten zoals de kwaliteitscontrole op behandelingsprocedures en de kwaliteit 
van leven besproken. In dit inleidende hoofdstuk komen ook de verschillende vormen van morbiditeit 
na een radicale hysterectomie, de mogelijkheden om deze morbiditeit te meten en de rol van de auto-
nome zenuwen aan bod.
Wanneer bij vrouwen met een vroeg stadium van baarmoederhalskanker blijkt dat er na de radicale 
hysterectomie met pelviene lymphadenectomie (RHL) ongunstige risico factoren aanwezig zijn, zoals 
positieve lymfeklieren, positieve snijranden en infi ltratie in het parametrium, dan is postoperatieve 
radiotherapie geïndiceerd. Er zijn studies die hebben gesuggereerd dat patiënten ook baat hebben wan-
neer zij postoperatieve radiotherapie krijgen als de ziekte beperkt blijft tot de baarmoederhals, maar 
er wel bepaalde tumour gerelateerde risicofactoren aanwezig zijn. De Amerikaanse Gynaecologische 
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Oncologie Groep (GOG) toonde in hun studie aan dat vasoinvasie, tumor grootte en infi ltratie diepte 
factoren zijn die een voorspellende waarde hebben voor de prognose. Zij ontwikkelde een scorings-
systeem aan de hand van deze 3 factoren en vormde hiermee 3 risicogroepen voor het krijgen van 
een recidief. Sinds 1997 gebruikt het LUMC ook een scoringssysteem; patiënten met tenminste 2 van 
de volgende 3 tumor gerelateerde risico factoren krijgen postoperatieve radiotherapie: tumor grootte 
≥40mm, infi ltratiediepte ≥15mm en vasoinvasie. In hoofdstuk 2 worden de resultaten vergeleken van 
de patiënten die op basis van bovengenoemde tumor gerelateerde risico factoren radiotherapie hebben 
gekregen met de groep patiënten met hetzelfde risico profi el, maar die voor 1997 zijn behandeld en 
dus geen radiotherapie hebben gekregen. Daarnaast is de overleving van patiënten die zijn behandeld 
volgens de criteria van het LUMC (LUMC risico profi el) vergeleken met de overleving van patiënten die 
zijn behandeld volgens het GOG prognostische scoringssysteem (GOG risico score). Voor deze studie 
zijn prospectief verzamelde data van 643 patiënten met baarmoederhalskanker stadium I-IIa gebruikt. 
In overeenstemming met de literatuur laat deze studie zien dat de hoge risico groep volgens het LUMC 
risico profi el signifi cant baat heeft bij het krijgen van postoperatieve radiotherapie. Een signifi cant 
hoger percentage ( 41 vs 12%, p=0.02) van de patiënten in deze hoge risico groep zonder radiotherapie, 
kreeg een recidief van de ziekte. Dit gebeurde ondanks het feit dat het aantal diep infi ltrerende tumoren, 
een belangrijke risicofactor, meer voorkwam in de bestraalde groep. De overige klinisch prognostische 
factoren waren gelijk tussen de groepen. De verschillen in de kanker specifi eke overleving en de ziekte 
vrije overleving tussen de hoge risico groep met adjuvante radiotherapie (86% en 85%, respectievelijk) 
en de hoge risico groep zonder adjuvante radiotherapie (57% en 43%, respectievelijk) waren statistisch 
signifi cant (p=0.013 en p=0.006, respectievelijk). Tenslotte toonde deze studie aan dat de LUMC modi-
fi catie van het GOG prognostische scoringssysteem niet signifi cant verschilde van dit laatste systeem 
ten aanzien van het risico op een recidief, de kanker specifi eke overleving en de ziektevrije overleving. 
Geconcludeerd is dat het LUMC risico profi el eenvoudiger is in het gebruik. Het heeft wel een iets 
hogere drempel voordat het beslist om adjuvante radiotherapie te geven aan patiënten vergeleken met 
het GOG prognostische scoringssysteem, maar dit levert geen verschil op voor de resultaten.
Het doel van een lymfadenectomie als onderdeel van de behandeling van patiënten met het vroege 
stadium van baarmoederhalskanker is om kankercellen die zijn getransporteerd naar het lymfatische 
systeem dat baarmoederhals en het bovenste deel van de vagina draineert, te diagnostiseren en te 
verwijderen. Een systematisch uitgevoerde lymfadenectomie kan betrouwbaar de aan- of afwezigheid 
vaststellen van positieve lymfeklieren, wat consequenties heeft voor de prognose en de behandeling. 
De therapeutische waarde van de lymfadenectomie voor de behandeling van het vroege stadium van 
baarmoederhalskanker is nog steeds niet duidelijk, hoewel sommige auteurs het mogelijk gunstige 
effect van de verwijdering van gemetastaseerde lymfeklieren benadrukken. Toch is het nooit bewezen 
dat het verwijderen van klieren op zichzelf leidt tot betere overlevingscijfers. Het doel van hoofdstuk 3 
was om te kijken in hoeverre het aantal verwijderde pelviene lymfeklieren bij een RHL invloed heeft op 
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de overleving van patiënten met het vroege stadium van baarmoederhalskanker. Verder werd de relatie 
tussen patiënt, tumor en behandelingsfactoren aan de ene kant en het aantal onderzochte klieren 
van patiënten met negatieve klieren aan de andere kant vergeleken. Voor het eerste gedeelte van het 
onderzoek werd gebruik gemaakt van een groep van 331 patiënten met negatieve klieren en zonder 
adjuvante therapie (groep A) en een groep van 136 patiënten met positieve klieren (groep B). Voor het 
tweede gedeelte werd alleen groep A gebuikt.
Lymfadenectomie bestond uit het verwijderen van al het vetweefsel van 6 verschillende pelviene lymfe-
klierstations. Parametriale klieren werden niet bij het totale aantal verwijderde klieren geteld. Zowel in 
groep A als in groep B waren para-aortale klieren verwijderd.
Deze studie indiceert dat wanneer alle regionale lymfeklieren pathologisch negatief zijn, er geen 
relatie bestaat tussen het aantal verwijderde klieren en de kanker specifi eke overleving of ziektevrije 
overleving. Echter, het aantal verwijderde klieren heeft wel invloed op de ziektevrije overleving van 
patiënten met positieve klieren. Patiënten met het vroege stadium van baarmoederhalskanker met 
positieve klieren hebben dus profi jt wanneer een voldoende aantal klieren is verwijderd. Als zodanig, 
is de meest belangrijke klinische consequentie van deze studie dat men een volledige lymfadenectomie 
zou moeten verrichten wanneer tijdens de RHL uit de vriescoupe blijkt dat er sprake is van positieve 
lymfeklieren. Tot slot liet deze studie zien dat het aantal verwijderde klieren niet werd beïnvloed door 
leeftijd, Surinaamse afkomst, postmenopauzale status, conisatie in de voorgeschiedenis, tumor grootte, 
infi ltratiediepte en vasoinvasie.
Wanneer een patiënt de dokter confronteert met vragen over haar exacte risico op een recidief of 
de kans op overlijden op een bepaald moment, kan het moeilijk zijn en zelfs onmogelijk om deze 
vragen adequaat te beantwoorden. Standaard overlevings data meten de tijdspanne van een beginpunt 
tot het moment van een gebeurtenis. Als meerdere type gebeurtenissen (zoals recidief of dood) zich 
voordoen, is een model nodig dat de progressie beschrijft van elk van deze concurrende gebeurtenis-
sen. Multi-state modellen kunnen worden beschouwd als een algemeen basaal raamwerk dat zich 
bezighoudt met overlevingsdata waarbij meerdere (mogelijk concurrerende) gebeurtenissen zich ach-
tereenvolgens kunnen voordoen in de tijd. Het zich voordoen van achtereenvolgende gebeurtenissen 
vormt de overgang van een begin toestand naar een eind toestand. Voor patiënten die een behandeling 
voor baarmoederhalskanker hebben ondergaan zijn dit respectivelijk het krijgen van een recidief en 
de dood. Daarnaast nemen deze modellen prognostische factoren mee in de analyse om de invloed 
van deze factoren op de snelheid van de overgang van de ene naar de andere gebeurtenis te kunnen 
bestuderen. Multi-state modellen kunnen worden gebruikt om de waarschijnlijkheid te voorspellen 
dat iemand een specifi eke toestand (b.v. een recidief ) in de toekomst bereikt, op basis van zijn of haar 
aanwezige toestand op verschillende tijdsintervallen die volgen op het moment van de initiële behan-
deling. Het doel van hoofdstuk 4 was te onderzoeken of er een mogelijkheid bestaat een voorspelling 
van de toekomstige (ziektevrije) overleving te geven, gegeven het feit dat een patiënte met een vroeg 
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stadium van baarmoederhalskanker in de voorgeschiedenis, ziektevrij is geweest voor een specifi eke 
periode na de behandeling. Gebruik is gemaakt van de prospectief verzamelde data van 615 patiënten 
met baarmoederhalskanker stadium I-IIa die zijn behandeld met een RHL met pelviene lymfadenecto-
mie met of zonder adjuvante radiotherapie. Statistische analyses werden gedaan met multi-state risico 
modellen die speciaal voor dit doel zijn ontwikkeld. De multi-state modellen schatten de invloed van 
covariaten en maken voorspelde overlevingscurven door middel van simulatie. In de analyse van de 
overleving van de individuele patiënte is rekening gehouden met de volgende covarianten; positieve lym-
feklieren, tumor grootte, infi ltratiediepte, vasoinvasie, infi ltratie in het parametrium, adenosquameus 
carcinoom en positieve snijranden. De simulaties zijn gedaan voor patiënten met positieve klieren 
(n=492), patiënten met negatieve klieren (n=123) en vier hypothetische patiënten. De voorspelde kans 
op overlijden van deze 2 groepen en de 4 hypothetische patiënten zijn gedemonstreerd in voorspelde 
cumulatieve waarschijnlijkheidsgrafi eken. Totdat resultaten van andere studies bekend zijn, laat de 
huidige studie zien dat er een mogelijkheid bestaat om een meer gedetailleerde voorspelling van de 
toekomstige (ziektevrije) overleving te geven, gegeven het feit dat een patiënt ziektevrij is geweest voor 
een specifi eke periode na de behandeling. Deze mogelijkheid zou informatie kunnen verschaffen om 
het behandelplan en (de duur van) het follow-up beleid te individualiseren. Dit zal duidelijk voordelige 
gevolgen kunnen hebben voor kosten en tijd. Daarnaast zal een verbetering in de kwaliteit van kanker 
zorg ongetwijfeld leiden tot een betere kwaliteit van leven voor kanker patiënten. Daarom kan worden 
geconcludeerd dat deze mogelijkheid een belangrijke stap vooruit is om de kwaliteit van kanker zorg 
te verbeteren.
Om bewust te worden van de morbiditeit die is ontstaan na de behandeling en om een indruk te krijgen 
van de impact hiervan op het leven van de patiënte, kunnen vragenlijsten informatieve antwoorden ge-
ven. Daarnaast kunnen deze vragenlijsten ook een beter begrip geven van de perceptie van de patiënte 
ten aanzien van de ernst van de symptomen. Wij ontwikkelden een Nederlandse vragenlijst, de Gynae-
cologische Leidse Vragenlijst (LV). Dit is de eerst ontwikkelde Nederlandse vragenlijst die items bevat 
over seksueel functioneren, mictie- en darmproblemen voor vrouwen met kanker. De Gynaecologische 
LV bevat 1 item over moeheid, 1 item over lymfoedeem, 11 items over het seksueel functioneren, 6 items 
over blaas- en 2 items over darmproblemen. Het doel van hoofdstuk 5 was om de psychometrische ei-
genschappen van de items over het seksueel functioneren van de Gynaecologische LV te onderzoeken. 
De totale studie populatie bestond uit 198 vrouwen: 66 patiënten behandeld voor baarmoederhalskan-
ker, 66 patiënten met seksuele klachten en 66 vrouwen uit de algemene bevolking.
De patiënten die een RHL hadden ondergaan voor de behandeling van baarmoederhalskanker werden 
gevraagd de Gynaecologische LV vóór, 3, 12 en 24 maanden na de operatie in te vullen. Voor de interne 
validatie werd alleen de Gynaecologische LV gebruikt die 12 maanden na de operatie was ingevuld. De 
patiënten met seksuele klachten gingen voor deze klachten naar een polikliniek seksuologie en vulde 
de vragenlijst in aan het einde van hun eerste bezoek. De convergente en divergente construct validiteit 
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werd onderzocht door gebruik te maken van andere gevalideerde vragenlijsten die de seksuele functie, 
seksuele ontevredenheid, relatie problemen, ontevredenheid over het algemene leven en psychologi-
sche problemen meten.
Door middel van factor analyse werden drie subschalen gevonden: Vrouwelijke Seksuele Klachten, 
Vrouwelijk Seksueel Functioneren en Vrouwelijk Orgasme. De betrouwbaarheid van de subschalen 
was voldoende. De score op de drie subschalen laat een goed onderscheid zien tussen de patiënten 
behandeld voor baarmoederhalskanker, de patiënten met seksuele problemen en de vrouwen uit de al-
gemene bevolking. Daarnaast waren de subschalen gevoelig voor verandering binnen de groep patiën-
ten behandeld voor baarmoederhalskanker, omdat de score veranderde in de theoretische verwachtte 
richting volgend op de behandeling. De convergente en divergente validiteit was goed, omdat de drie 
subschalen overeenkwamen met subschalen die dezelfde klachten meten en zich onderscheidde van 
subschalen die andere (psychologische) problemen meten. Kortom, de resultaten van deze studie steu-
nen de betrouwbaarheid en de psychometrische validiteit van de Gynaecologische LV in de beoordeling 
van het seksueel functioneren en van vaginale veranderingen in gynaecologische kanker patiënten.
De effecten van de behandeling voor baarmoederhalskanker op de seksualiteit van de vrouw en de 
daaruit voortvloeiende droefheid en pijn, krijgt de laatste jaren steeds meer aandacht. In hoofdstuk 
6 worden de resultaten beschreven van de eerste longitudinale studie over zelfgerapporteerde blaas, 
darm, seksuele en vaginale problemen met een uitgangswaarde voor de RHL met of zonder adjuvante 
radiotherapie. Vrouwen met een vroeg stadium van baarmoederhalskanker die een RHL zouden on-
dergaan werden geincludeerd in de studie. Voor dit onderzoek werden 14 items van 21 items tellende 
Gynaecologische Leidse Vragenlijst (LV) gebruikt. De 14 items vragen naar lymfoedeem, seksueel 
functioneren, mictie- en darmproblemen. De Gynaecologische LV werd vóór de operatie en 3, 12, en 24 
maanden na de operatie ingevuld. Drieënzeventig patiënten vulden alle vragenlijsten in. We vergeleken 
deze groep patiënten met een op leeftijd gesorteerde groep vrouwen uit de samenleving. De controle 
groep vulde de Gynaecologische LV eenmalig in. De controle groep bestond uit 224 vrouwen.
Patiënten klaagden tot 1 jaar na de behandeling signifi cant vaker over weinig of geen aandrang om 
te urineren en diarree in vergelijking met de controle groep. Echter na 2 jaar follow-up werd er ten 
aanzien van blaas- en darmdisfunctie geen signifi cant verschil meer gezien vergeleken met de controle 
groep en vergeleken met de situatie voor de operatie. Retrospectieve studies over de frequentie van 
voorkomen van mictie en darm problematiek, laten verschillende cijfers zien. Onze studie liet geen 
signifi cant verschil zien na 2 jaar follow-up. Dit zou kunnen komen door postoperatief herstel of het 
zou kunnen wijzen op het feit dat de perceptie van kwaliteit van leven onafhankelijk is van objectieve 
metingen. De opluchting na een potentieel curatieve behandeling zou ook kunnen bijdragen aan de 
subjectieve verbetering ondanks veranderingen in darm- en blaasfunctie. Tot slot gebruiken veel 
studies over colorectale- en blaasdisfunctie verzamelde data uit medische statussen. Deze studie ge-
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bruikte vragenlijsten en heeft een longitudinale opzet, zodat een direkte vergelijking met de literatuur 
hierdoor niet goed mogelijk is.
De patiënten hadden na 2 jaar follow-up wel signifi cant meer seksuele problematiek, zowel in verge-
lijking met de controle groep als met hun situatie vóór de behandeling. De problemen waren minder 
lubricatie, een nauwe en korte vagina, gevoelloosheid rondom de labia, dyspareunie en ontevreden-
heid over hun seksleven. In overeenstemming met de literatuur kan worden geconcludeerd dat tot 
tenminste 2 jaar na de RHL, vrouwen met een vroeg stadium van baarmoederhalskanker negatieve 
gevolgen ondervinden vooral op het gebied van het seksueel functioneren. Adjuvante radiotherapie liet 
geen signifi cante toename zien van het risico op blaasproblematiek, colorectale motiliteitsstoornissen 
en seksueel functioneren.
Uit verschillende anatomische en klinische studies is gebleken dat de RHL voor de behandeling van 
baarmoederhalskanker chirurgische schade veroorzaakt aan de pelviene autonome zenuwen. Deze 
zenuwen zijn verantwoordelijk voor de toename van de vaginale doorbloeding tijdens seksuele opwin-
ding. Het is denkbaar dat chirurgische schade aan deze autonome zenuwen een cruciale rol spelen in 
de etiologie van de postoperatieve morbiditeit die ontstaat na RHL. Met behulp vant photoplethysmo-
grafi e kan de vaginale doorbloeding tijdens seksuele opwinding betrouwbaar en objectief beoordeeld 
worden.
Hoofdstuk 7 laat de voorlopige resultaten zien van een studie waarin wordt onderzocht of de zenuw-
sparende techniek inderdaad leidt tot een objectief minder verstoorde vaginale doorbloeding tijdens 
seksuele stimulatie. Photoplethysmografi sche beoordeling van de vaginale doorbloeding werd uitge-
voerd tijdens seksuele stimulatie door erotische fi lmpjes. Het seksueel en psychologisch functioneren 
van de deelnemende vrouwen werd beoordeeld door vier vragenlijsten: Gynaecologische LV; FSFI; 
HADS; EORTC-C30. De subjectieve seksuele opwinding werd na iedere stimulus vastgesteld. Dertien 
vrouwen met een conventionele RHL in de voorgeschiedenis, 10 vrouwen met een zenuwsparende RHL 
in de voorgeschiedenis en 14 gezonde controles namen deel aan de studie.
De gemiddelde vaginale doorbloeding verschilde tussen de groepen (p=0.014): de conventionele 
RHL groep had over het geheel, een signifi cant lagere vaginale doorbloeding dan de controle groep 
(p=0.016), en neigde ook lager te zijn dan de zenuwsparende RHL groep (p=0.079). Deze verschillen 
in vaginale doorbloeding werden veroorzaakt door verschillen in de baseline tussen de drie groepen; 
de vaginale doorbloeding tijdens de eerste 5 minuten durende neutrale stimuli, voorafgaand aan de 
seksuele stimuli, was al signifi cant lager voor de conventionele RHL groep vergeleken met de controle 
groep. Verder werd een trendverschil gevonden tussen de conventionele RHL groep en de zenuwspa-
rende RHL groep waarbij de conventionele groep een lagere vaginale baseline doorbloeding had in 
vergelijking met de zenuwsparende groep. Deze verschillen bestonden ondanks het feit dat deze 3 
groepen dezelfde mate van subjectieve seksuele opwinding voelde na een erotische stimulus conditie. 
Het lijkt dus dat vrouwen na een zenuwsparende operatie een algeheel (basaal) betere vaginale door-
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bloeding hebben. Dat het verschil met vrouwen na een conventionele RHL niet statistisch signifi cant 
is, komt waarschijnlijk door de lage power van de studie.
Verder indiceerde het visuele beeld van de data dat de conventionele RHL groep een vaginaal doorbloe-
dingspatroon heeft dat gelijkenis toont met die van postmenopauzale vrouwen. Deze gelijkenis zou 
verklaard kunnen worden door een veranderd aantal autonome zenuwvezels in de vaatwand van de 
vagina door enerzijds directe zenuwschade (na conventionele RHL) of anderzijds door een lage oestro-
geen concentratie (bij postmenopauzale vrouwen). De oestrogeenconcentratie reguleert namelijk de 
zenuwdichtheid door middel van oestrogeen receptoren in de vagina wand.
Dit is de eerste studie die vaginale plethysmografi e als meetinstrument gebruikt om de functionele 
resultaten van de conventionele RHL met de zenuwsparende RHL te vergelijken. Echter, een defi nitieve 
conclusie omtrent het nut van zenuwsparend opereren kan alleen worden gemaakt wanneer meer 
mensen worden geïncludeerd. Verder onderzoek naar de functionele resultaten van de zenuwsparende 
modifi catie van de RHL moet daarom worden uitgevoerd, om zonder enige twijfel te bewijzen dat de 
zenuwsparende techniek leidt tot minder seksuele morbiditeit.
Discussie, aanbevelingen en toekomst perspectieven
Samenvattend kan als eerste uit onze studies worden geconcludeerd dat informatie gerelateerd aan 
de behandeling, afkomstig uit databanken, een eerste vereiste is om de kwaliteit van kanker zorg te 
verbeteren. Illustratief is het feit dat de rapportage van Engelse studies over de grote variabiliteit in 
behandelingsresultaten van borst en colorectaal kanker grote consequenties heeft gehad. Evenzo 
kunnen de resultaten van onze studies, waarbij we gebruik hebben gemaakt van onze prospectieve 
klinische databank, consequenties hebben voor de behandeling van patiënten met een vroeg stadium 
van baarmoederhalskanker. Allereerst kunnen de resultaten van onze studie en gegevens uit de litera-
tuur worden gebruikt als argument om radiotherapie te geven aan patiënten met tumor gerelateerde 
risico factoren, zonder positieve klieren, infi ltratie in het parametrium of positieve snijranden. Dit 
wordt aanbevolen omdat deze hoog risico patiënten baat hebben bij adjuvante radiotherapie.
Een andere aanbeveling is dat men een volledige lymfadenectomie zou moeten doen wanneer uit 
de vriescoupe tijdens de RHL blijkt dat er positieve klieren aanwezig zijn, omdat een groter aantal 
onderzochte (verwijderde) klieren leidt tot een betere ziektevrije overleving voor patiënten met po-
sitieve klieren. In de literatuur wordt nog steeds gedebatteerd over de therapeutische waarde van de 
lymfadenectomie. De resultaten van onze studie bevestigen echter dezelfde soort bevindingen van een 
eerder door ons uitgevoerde studie.
Daarnaast hebben we een mogelijkheid gevonden om een accurate voorspelling te geven van de toe-
komstige (ziektevrije) overleving van een individuele patiënt. Dit zou informatie kunnen geven om het 
behandelplan en (de duur van) het follow-up beleid te individualiseren. Hierdoor kan de follow-up 
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kosteneffectiever worden. Het toekomst perspectief zou kunnen zijn dat elke gynaecoloog-oncoloog 
een programma op zijn of haar computer heeft staan, waarmee het mogelijk zal zijn om een gedetail-
leerde toekomstige (ziektevrije) overleving voor een individuele patiënt te voorspellen. Dit soort pro-
gramma’s zullen in de toekomst nog nauwkeuriger worden vanwege de toenemende beschikbaarheid 
van nieuwe software voor multi-state modellen. Maar ook omdat het aantal behandelde patiënten voor 
baarmoederhalskanker zal toenemen in de database, waarin alle klinische en pathologische parame-
ters van deze patiënten prospectief worden verzameld. Het is niet alleen hiervoor noodzakelijk om 
behandelingsgerelateerde informatie te verzamelen in een databank. De databank is ook essentieel om 
in staat te zijn aanvullende aanbevelingen te kunnen geven, zoals de andere 2 aanbevelingen hierboven 
genoemd. De Nederlandse Integrale Kanker Centra (IKC) registreren alleen nieuwe gevallen van kanker 
en verzamelen gegevens voor enkele onderzoeksgerichte activiteiten, maar geen behandelingsgerela-
teerde data van deze nieuwe patiënten. Bovendien zijn er nog steeds ziekenhuizen en verscheidene 
Europese landen die geen (betrouwbare) databanken hebben om gegevens van kankerpatiënten in te 
kunnen verzamelen. Daarom willen wij ziekenhuizen en ook de IKC’s ten zeerste aanbevelen zulke 
databanken op te zetten, omdat ze waardevolle informatie kunnen geven over verschillen tussen be-
handelingsbenaderingen, risicofactoren, morbiditeit en overleving. Het vormt daarom de basis om de 
kanker zorg te bewaken, te controleren en te verbeteren.
Ten tweede kan uit onze studies worden geconcludeerd dat, door gebruik te maken van de juiste mid-
delen, het mogelijk is om bewust te worden van en inzicht te krijgen in de mate van morbiditeit na 
een RHL voor de behandeling van het vroege stadium van baarmoederhalskanker. Wij valideerden de 
vragen betreffende het seksueel functioneren van de zelfrapporterende vragenlijst, de Gynaecologi-
sche LV. Dit is de eerst ontwikkelde Nederlandse vragenlijst die bestaat uit onderwerpen over seksueel 
functioneren, blaas- en darmproblematiek voor vrouwen met kanker. Deze vragenlijst zal ons helpen 
om op een subjectieve manier de klachten van patiënten na hun behandeling te meten en kan daardoor 
inzicht geven in de noodzaak om andere behandelingsmodifi caties te ontwikkelen. Bovendien kan de 
vragenlijst worden gebruikt om de conventionele therapie met de nieuw ontwikkelde modifi caties te 
vergelijken.
Omdat we ons steeds meer bewust worden van de neveneffecten van de behandeling voor baarmoe-
derhalskanker en omdat de kwaliteit van leven vandaag de dag een belangrijk onderwerp is, zullen 
het aantal studies met behulp van zelfrapporterende vragenlijsten over de seksuele functie en vaginale 
veranderingen ongetwijfeld in de toekomst toenemen. Het is echter essentieel dat deze studies die 
de seksuele functie beoordelen, gebruik maken van gegevens van patiënten met dezelfde diagnose, 
behandeling, stadium en follow-up periodes. Een longitudinale opzet, gevalideerde vragenlijsten en 
een uitgaanswaarde zijn ook belangrijk.
Het is bewezen dat photoplethysmografi sche beoordeling van de vaginale doorbloedingsamplitude 
betrouwbaar en reproduceerbaar is om op een objectieve manier de vaginale doorbloeding tijdens sek-
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suele opwinding te meten. RHL voor de behandeling van baarmoederhalskanker veroorzaakt schade 
aan de autonome zenuwen die zorgen voor een toename van de vaginale doorbloeding tijdens seksuele 
opwinding. Sinds dit bekend is, hebben meerdere auteurs verschillende zenuwsparende chirurgische 
benaderingen voorgesteld. Vaginale plethysmografi e is daarom een belangrijk hulpmiddel voor het 
onderzoek naar de functionele resultaten van deze nieuwe chirurgische technieken.
In het LUMC hebben wij ook een zenuwsparende techniek ontwikkeld in een poging de zenuwschade 
tijdens RHL te verminderen zonder dat de oncologische principes van de radicaliteit worden opgeof-
ferd. Deze zenuwsparende modifi catie van de RHL wordt sinds 2000 uitgevoerd.
Onlangs zijn wij begonnen met een multicentrum observationele studie ter evaluatie van de ziektevrije 
overleving en de incidentie van blaas, colorectale en seksueel disfunctioneren na een zenuwsparende 
RHL voor de behandeling van baarmoederhalskanker stadium I-IIa. De resultaten van deze studie 
zullen in de komende jaren worden verwacht. De Gynaecologische LV en de photoplethysmografi e 
worden hiervoor gebruikt om op een subjectieve en objectieve wijze de resultaten van deze nieuwe 
techniek te onderzoeken.
We hebben een begin gemaakt met de photoplethysmografi sche metingen. Voor dit deel van de studie 
zijn minimaal 26 vrouwen met een voorgeschiedenis van een conventionele RHL en 26 vrouwen na 
een zenuwsparende RHL nodig. Op dit moment is het ons nog niet gelukt om voldoende vrouwen te 
werven. Het blijkt erg moeilijk te zijn vrouwen te includeren nadat ze zijn behandeld vanwege het in-
dringende karakter van het onderzoek. Om die reden zal het zeker nog 3 jaar duren voordat voldoende 
mensen zijn verzameld in iedere groep. Echter, de voorlopige resultaten van de studie laten zien dat 
de conventionele RHL geassocieerd lijkt te zijn met een algeheel lagere basale vaginale doorbloeding. 
En omdat het niet in dezelfde mate werd gezien na een zenuwsparende RHL, lijkt het dat de zenuw-
sparende techniek leidt tot een algeheel betere vaginale doorbloeding door minder denervatie van de 
vagina. De komende jaren zal de werving van patiënten voor de multicentrum observationele studie 
worden voortgezet, om aan te tonen dat de Leidse zenuwsparende modifi catie van de RHL leidt tot 
minder morbiditeit met overeenkomstige behandelingsresultaten. Dit zou voor een verbetering van de 
kwaliteit van leven kunnen zorgen van patiënten die een levensreddende operatie ondergaan voor het 





CLS capillary lymphatic space involvement
CSS cancer specifi c survival
DFS disease free survival
DI depth of tumour invasion
GOG Gynecologic Oncology Group
HR high risk
LQ Leiden Questionnaire
RHL radical hysterectomy with pelvic lymphadenectomy
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Figure 1. Cancer specifi c survival of the entire group (n=615), the patients with positive lymph nodes 
(n=123) and the patients with negative lymph nodes (n=492). Legend: Total, entire group; LN+, positive 
lymph nodes; LN-, negative lymph nodes. ( page 59 )































































Figure 2. Predicted cumulative probability plots of patients with early stage cervical cancer with negative lymph nodes 
(LN negative) and with positive lymph nodes (LN positive).
Legend: T0=0 months, T12= 12 months, T24=24 months, T36=36 months, T48=48 months and T60=60 months. 
( page 60)























































































































































Figure 3. Predicted cumulative probability plots of patient A, B, C and D (Table 3).  Legend: T0=0 months, T12= 12 
months, T24=24 months, T36=36 months, T48=48 months and T60=60 months. ( page 61 )
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Figure 1. Change in logarithmically transformed mean vaginal pulse amplitude (log10VPA) during experimental 
session: Neutral stimulus 1 (Baseline assessment) (1-5 min), Erotic stimulus 1 (6-10 min), Neutral stimulus 2 (11-15 
min), Erotic stimulus 2 (16-21 min).
 – –=Conventional RHL (n=13), – –=Nerve-sparing RHL (n=10), – –=Controls (n=14). RHL, radical hysterectomy 































Figure 2. Postmenopausal versus premenopausal; change in logarithmically transformed mean vaginal pulse 
amplitude (log10VPA) during experimental session: Neutral stimulus 1 (Baseline assessment) (1-5 min), Erotic 
stimulus 1 (6-10 min), Neutral stimulus 2 (11-15 min), Erotic stimulus 2 (16-21 min).
 – – =Conventional RHL, postmenopausal (n=10), – –=Conventional RHL, premenopausal (n=13), – –=Controls, 
postmenopausal (n=12),  –––=Controls, premenopausal (n=14) RHL, radical hysterectomy with pelvic 
lymphadenectomy. ( page 112 )
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Curriculum vitae
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1996 behaalde zij cum laude haar propedeuse. Haar wetenschappelijke stage deed zij op de afdeling 
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kind. Na het cum laude behalen van haar doctoraal examen in 2000, heeft zij in de wachttijd voor haar 
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Bosch Medisch Centrum te Den Bosch. In december 1999 begon zij aan haar co-schappen. Tijdens 
haar co-schappen deed zij wetenschappelijk onderzoek op de afdeling Gynaecologie en Verloskunde 
in het AMC, onder leiding van Dr. J. van der Velden, naar de overleving van het klinisch stadium II 
endometriumcarcinoom waarbij een radicale uterusextirpatie werd verricht.
Na het behalen van het artsexamen in maart 2002 was zij een jaar werkzaam als AGNIO op de afde-
ling Gynaecologie en Verloskunde in het Medisch Centrum Alkmaar te Alkmaar (opleider Dr. J.B. 
Maathuis) en daarna anderhalf jaar in het Leyenburg Ziekenhuis, thans Haga Ziekenhuis, te Den haag 
(opleider Dr. P.A. de Jong). Tijdens haar werkzaamheden als AGNIO in het Haga Ziekenhuis deed zij 
wetenschappelijk onderzoek naar morbiditeit en kwaliteit van leven na een radicale uterusextirpatie 
voor de behandeling van het cervixcarcinoom onder leiding van Prof. Dr. G.G. Kenter op de afdeling 
Gynaecologie en Verloskunde in het LUMC. Deze studie was de aanleiding om in januari 2005 te 
starten als AGIKO voor full-time wetenschappelijk onderzoek. Dit onderzoek, dat plaatsvond op de 
afdeling Gynaecologie in het LUMC (Prof. Dr. G.G. Kenter en Prof. Dr. J.B.M.Z. Trimbos) leidde tot 
dit proefschrift.
Vanaf 1 april 2007 is zij in opleiding tot gynaecoloog in het Haga Ziekenhuis (opleider: Dr. E. van 





Dit proefschrift is mede tot stand gekomen door de steun en deskundigheid van een team van mensen 
om mij heen. De basisopstelling wil ik hier graag persoonlijk bedanken.
Allereerst de voorhoede, bestaande uit alle mensen op de werkvloer die mij hebben geholpen tijdens 
het onderzoekstraject. Kees, van je uitleg, je inzicht, je hulp, je anatomieles, je inzet en je altijd positieve 
instelling heb ik onbeschrijfelijk veel geleerd, heel veel dank daarvoor. Snap je? Paul, dat ik ooit in staat 
zou zijn om statistiek te bedrijven en het ook nog een heel klein beetje leuk ben gaan vinden, heb ik 
mede aan jou te danken. Heleen, dank voor je hulp met computers, je luisterend oor en al het geklets. Je 
bent een geweldige kamergenoot en collega! Lot, dank voor alles wat je me hebt geleerd over het praten 
over seks (poli) en het onder de knie krijgen van het sekslab. Philomeen, jij was altijd op de hoogte 
van de vorderingen van mijn onderzoek, bedankt voor al je belangstelling. Alle medewerkers van de 
poli seksuologie, dank voor al jullie medewerking. Pauline en Irma, met jullie eeuwige enthousiasme 
en hulp bij het werven van controles is het includeren zeker een stuk sneller gegaan! Jessica, Fleur 
en Karijn, het was altijd gezellig op de grootste kamer van J8. Wendela, al je adviezen en informatie 
hebben me veel geholpen. Edgar en Sabine, ik vond het echt fantastisch jullie als mijn paranimphen te 
hebben! Alle collega-assistenten, klinisch verloskundigen, verpleging en gynaecologen uit het LUMC 
en het Haga Ziekenhuis; bedankt voor al jullie adviezen, steun en collegialiteit. Margriet en Anneke, 
het was fi jn met jullie samen te werken. Al jullie invoerwerk is de basis geweest van alle studies. Bea, 
Wil en Ineke, jullie kletspraat was heerlijk en jullie secretariële ondersteuning onmisbaar! Jullie zijn 
goud waard. En tot slot alle vrouwen die hebben deelgenomen aan mijn onderzoek. Zonder hen was 
het niet gelukt. Dank jullie wel!
Echter, een sterke voorhoede functioneert niet zonder een goed middenveld. Het zijn de mensen 
die naast mijn werk en familie een belangrijke rol spelen in mijn leven. Lieve Nicole, dank voor je 
grenzeloze vriendschap! Dames 2 van HDM; echt t allerleukste team van Den Haag! Oud dames 1 van 
Gooische; we blijven een team! Urbian, Inge, Didi, Titia, Juliette, Roos, Karin, Leonie, Valérie, en 
allen die ik ben vergeten, dank voor jullie vriendschap, steun en aanmoediging. Familie Schoenaker, 
ik geniet van jullie enthousiasme en warmte. Jort alias doctor Phil, je bent onvervangbaar. En tot slot 
Delfi en, dank je wel voor het geven van inzicht.
Dan komen we bij de achterhoede, mijn achtergrond en basis. Justin, Kevin en Rogier, betere broers 
kan ik me niet wensen! Jocelyne, onze ‘zusmomenten’ zijn onvervangbaar! Lieve mam, thanx for all!
Eén speler in het team heb ik nog niet genoemd. Dat is de ‘midden midden’; de belangrijkste speler 
in het veld, de spelverdeler, het middelpunt, het hart. Deze positie wordt ingenomen door mijn grote 
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